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Extracts of honeybush (Cyclopia genistoides) containing glycosylated xanthones, mangiferin (1) and 
isomangiferin (2), and benzophenones, 3-β-D-glucopyranosyliriflophenone (3) and 3-β-D-glucopyranosyl-4-
O-β-D-glucopyranosyliriflophenone (4) inhibit α-glucosidase (AG), a key digestive enzyme and treatment 
target for postprandial hyperglycaemia associated with type 2 diabetes. Ultrafiltered green C. genistoides 
extract served as the starting material for the development of an optimised production protocol for xanthone- 
and benzophenone-enriched fractions (XEFs and BEFs) by macroporous adsorbent resin chromatography. 
Inter-batch variation in the phenolic content of the raw material manifested as variation in the composition and 
degree of enrichment of target compounds in XEFs and BEFs. The in vitro AG inhibitory effects of 
C. genistoides phenolics, extract, XEF and BEF, combined with the commercial AG inhibitor (AGI), acarbose, 
were investigated using the combination index. The single-compound AGIs demonstrated potency in the 
descending order: acarbose (IC50 = 44.3 µM) > 1 (102.2 µM) > 2 (119.8 µM) > 3 (237.5 µM) > 4 (299.4 µM). 
Potency of the extract and fractions was strongly linked to their xanthone content. XEFs (xanthone 
content = 22.3–48.1 g/100 g) were produced using ten different batches of plant material and tested at a fixed 
concentration (160 µg/mL), achieving 63 to 72% enzyme inhibition. BEFs (benzophenone content = 11.4–
21.7 g/100 g) achieved enzyme inhibition of 26 to 34%. There was a weak linear correlation (R2 < 0.43) 
between the target compound content of the fractions and their AG inhibition potency. Synergistic AG 
inhibition at > 50% effect levels was observed for all combinations of acarbose with fractions (XEFs, BEFs) 
or target compounds (1–4). Combinations of acarbose with 1 and 2 gave the highest theoretical in vitro 
acarbose dose reduction (> six-fold) across all effect levels. XEFs showed greater theoretical acarbose dose 
reduction (≈ four-fold at 50% inhibition) than BEFs, demonstrating the potential of XEFs as a supplement to 
acarbose. In a subsequent in vivo oral sucrose tolerance test in normal and diabetic Wistar rats, XEF (single 
orally administered dose of 300 mg/kg body weight) did not result in significantly lowered postprandial blood 
glucose or in an improved effect in combination with acarbose (5 mg/kg body weight). The suitability of 
C. genistoides phenolics as non-toxic active pharmaceutical ingredients (APIs) was confirmed in a liver cell 
model, which indicated no cytotoxicity following acute or chronic exposure. Ex vivo intestinal transport studies 
using porcine jejenum showed that the target compounds (1–4) are poorly absorbed, confirming their suitability 
as APIs aimed at an intestinal target, and re-emphasising the low risk of systemic toxicity. XEF and BEF were 
subsequently incorporated (alone and combined) in a non-effervescent gastroretentive tablet formulation 
containing low-density styrene-divinylbenzene co-polymer as floating agent. The tablets floated in an in vitro 
medium (0.1 N HCl) for at least 8 h and released APIs through a diffusion-based process, described by the 
Weibull model (  > 0.99). API degradation during storage under adverse conditions (12 weeks at 40 °C) 





Ekstrakte van heuningbos (Cyclopia genistoides) met ‘n hoë inhoud van die geglikosileerde xantone, 
mangiferien (1) en isomangiferien (2), en die bensofenone, 3-β-D-glukopiranosieliriflofenoon (3) en 3-β-D-
glukopiranosiel-4-O-β-D-glukopiranosieliriflofenoon (4), inhibeer α-glukosidase (AG), ‘n belangrike 
spysverteringsensiem en behandelingsteiken vir postprandiale hiperglukemie geassosieer met tipe 2 diabetes. 
Ultrafiltreerde groen C. genistoides ekstrak het gedien as beginmateriaal vir die ontwikkeling van ‘n 
geoptimiseerde produksieprotokol vir xantoon- en bensofenoon-verrykte fraksies (XVFs en BVFs) d.m.v. 
makroporeuse adsorberende hars chromatografie. Variasie in fenoliese inhoud tussen verskillende 
produksielotte van die roumateriaal het gemanifesteer as variasie in die samestelling en mate van 
teikenverbindingverryking in XVFs en BVFs. Die in vitro AG inhiberingsvermoë van C. genistoides fenole, 
ekstrak, XVF en BVF, gekombineer met akarbose, ‘n kommersiële AG inhibeerder (AGI), is ondersoek d.m.v. 
die kombinasie indeks. Die rang-orde van die AGIs se potensie was as volg: akarbose (IC50 = 44.3 µM) > 
1 (102.2 µM) > 2 (119.8 µM) > 3 (237.5 µM) > 4 (299.4 µM). Die potensie van die ekstrak en fraksies was 
sterk verwant aan hul xantooninhoud. XVFs, met xantooninhoud tussen 22.3 en 48.1 g/100 g, is geproduseer 
van tien verskillende produksielotte van plantmateriaal, en getoets teen ‘n vaste konsentrasie (160 µg/mL), met 
resulterende ensieminhibering van 63–72%. Die BVFs, met bensofenooninhoud tussen 11.4 en 21.7 g/100 g, 
het ensieminhibering van 26–34% bewerkstellig by dieselfde konsentrasie. Daar was ‘n swak lineêre korrelasie 
(R2 < 0.43) tussen die teikenverbindinginhoud van fraksies en hul AG inhiberingspotensie. Sinergistiese 
inhibering van AG by > 50% effektiwiteitsvlakke is waargeneem vir alle kombinasies van akarbose met 
fraksies (XVFs, BVFs) of teikenverbindings (1–4). Kombinasies van akarbose met 1 en 2 het die hoogste 
teoretiese in vitro akarbose dosisverlaging (> sesvoudig) bewerkstellig by alle effektiwiteitsvlakke. XVFs het 
beter akarbose dosisverlaging (≈ viervoudig by 50% effektiwiteitsvlak) bewerkstellig as BVFs, wat dui op die 
potensiaal van XVFs as aanvuller tot akarbose. In ‘n daaropvolgende in vivo orale sukrose toleransie toets in 
normale en diabetiese Wistar rotte, het XVF (enkele orale dosis van 300 mg/kg liggaamsgewig) nie die 
postprandiale bloedglukose noemenswaardig verlaag nie, en ook nie ‘n verbeterde effek in kombinasie met 
akarbose (5 mg/kg liggaamsgewig) bewerkstellig nie. Die geskiktheid van C. genistoides fenole as potensiële 
nie-toksiese aktiewe farmaseutiese bestanddele (AFBs) is bevestig d.m.v. ‘n lewer-sel model, waarin geen 
sitotoksiteit waargeneem is na akute of chroniese blootstelling nie. Ex vivo intestinale transportstudies met 
varkderm het aangedui dat die teikenverbindings (1–4) swak geabsorbeer word, wat hul geskiktheid as AFBs 
met ‘n intestinale teiken bevestig, asook die lae risiko vir sistemiese toksisiteit herbeklemtoon. XVF en BVF 
is geïnkorporeer (alleen en gekombineerd) in ‘n nie-bruisende gastro-retentiewe afleweringsisteem met 
laedigtheid stireen-divinielbenseen ko-polimeer as die dryfagent. Die tablette het in ‘n in vitro medium (0.1 N 
HCl) vir minstens 8 h gedryf, en die AFBs is vrygestel d.m.v. ‘n diffusie-gebaseerde proses wat met die 
wiskundige model van Weibull beskryf is (R2 > 0.99). Afbreking van AFBs gedurende opberging onder 
nadelige toestande (12 weke teen 40 °C) het eerste-orde reaksiekinetika gevolg met ‘n chemiese 
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Diabetes mellitus refers to a disorder of glucose homeostasis that remains one of the major causes of disease 
and death worldwide. The name is derived from a term traditionally used by ancient Greek physicians to 
describe the typical “honey-like” urine of the afflicted—a result of failure of the kidneys to process the 
pathologically elevated levels of blood glucose (hyperglycaemia) (Lakhtakia, 2013). It may present in different 
forms, e.g. pregnancy-related diabetes, drug-induced diabetes or immune-mediated (type 1) diabetes, but the 
most common form, representing ca. 80–90% of all cases, is type 2 diabetes (T2D), which is strongly linked 
to a sedentary lifestyle, obesity and a high-calorie diet (Bird & Hawley, 2012; Baynest, 2015; Yamaoka et al., 
2019). The primary goal of any anti-diabetic treatment is the prevention or reduction of persistent 
hyperglycaemia, which could eventually result in glucotoxicity, i.e. the various harmful effects of excessive 
glucose concentrations throughout the body (Kaiser et al., 2003; Bailey, 2015). These harmful effects include 
oxidative stress damage to the retina, kidneys, nervous system and blood vessels, which increases the risk of 
cardiovascular disease and strokes (Pitocco et al., 2013). Lifestyle interventions and reduced caloric intake 
through dietary modification are the preferred first-line approaches for treating T2D, before the introduction 
of pharmacological treatment. Apart from its anti-diabetic benefits, recent research in gerontology suggests 
that calorie restriction is also the most robust intervention for slowing down the ageing process and increasing 
lifespan (Most et al., 2017). Simply put, this means dieting—eating less, reducing energy intake and assuming 
a state of relative starvation, which activates stress response pathways in the body that result in improved 
health (Mercken et al., 2012).  
In truth, not many would willingly undertake such drastic dietary modifications, and this has prompted 
the search for calorie restriction mimetics (CRMs), i.e. treatments that simulate starvation even in the presence 
of food consumption, essentially “fooling” the body into thinking it has not just eaten a large meal (Testa et 
al., 2014). Ingram and Roth (2015) referred to this as “having your cake and eating it too”. One of the proposed 
CRMs is acarbose, a pharmaceutical inhibitor of α-glucosidase (AG) and α-amylase, i.e. digestive enzymes 
that break down dietary carbohydrates in the small intestine (Ingram et al., 2004; Harrison et al., 2014). 
Currently, digestive enzyme inhibitors are used mainly as prescription medications by sufferers of metabolic 
disorders such as obesity and diabetes. Considering the close link between these two disorders, as well as their 
common co-occurrence, some have suggested adopting the term diabesity to refer to this phenomenon (Astrup 
& Finer, 2000; Farag & Gaballa, 2011). 
The use of digestive enzyme inhibitors such as acarbose is possibly the earliest and most “upstream” 
level at which a pharmacological target can be identified for the treatment of diabesity, as this mechanism does 
not rely upon the intestinal absorption and systemic distribution of the active pharmaceutical ingredient (API). 
This stands in contrast to most other anti-diabetic treatment approaches, where the API, e.g. metformin or 
glibenclamide, requires intestinal absorption and uptake into the systemic circulation (Bailey, 2015). Ingram 
and Roth (2015) put forth the argument that inhibiting energy utilisation as far upstream as possible would 
elicit a broader spectrum of CRM effects as compared with targeting a single downstream molecular target, 
e.g. sirtuin-1 or growth hormone receptors.  
Various studies have shown that a diet high in polyphenol content could prevent obesity and reduce 




(Riccardi et al., 2005). Therefore, many commonly consumed plant foods and extracts could hold considerable 
health-promoting benefits waiting to be unlocked and utilised. Recently published reviews have noted that the 
South African herbal teas, rooibos and honeybush, could be utilised as sources of bioactive polyphenols, 
specifically aimed at the treatment of diabesity (Ajuwon et al., 2018; Johnson et al., 2018; Muller et al., 2018; 
Joubert et al., 2019). Honeybush (Cyclopia spp.) is recognised as one of the few indigenous South African 
plant species to make the successful transition from an obscure, wild-growing local resource to a commercially 
viable product in the last century (Joubert et al., 2011). Established in the late 1990s following a meeting of 
various key stakeholders, the formal honeybush tea industry recently reached its 20-year milestone (Joubert et 
al., 2019). Honeybush tea is prepared from “unfermented” (green, unoxidised) or “fermented” (oxidised) plant 
material of different Cyclopia species, but mostly from C. genistoides, C. subternata, C. intermedia and C. 
longifolia. The majority of the annual production is exported to global markets, including the United States of 
America, Netherlands, Germany, Japan and United Kingdom (SAHTA, 2017; Joubert et al., 2019). 
The honeybush industry currently revolves mainly around agriculture and agro-processing, but 
product-orientated research conducted in recent years has presented new opportunities for nutraceutical and 
cosmetic applications. Prompted by the flourishing export market, the Agricultural Research Council (ARC) 
initially intensified its research efforts into the cultivation and processing of honeybush tea, with the aim of 
improving the product quality. It was only later on, once more became known about its phytochemical 
composition, that potential health-promoting attributes of honeybush also fell under the research spotlight, as 
summarised in previous review articles (Joubert et al., 2008, 2019). Much of the focus over the past decade 
has been directed towards elucidating the health-promoting potential of honeybush, which can largely be 
attributed to its polyphenol content. Reviews published since 2009 have focused on the bioactive properties of 
honeybush, including anti-mutagenicity (Kokotkiewicz & Luczkiewicz, 2009; Marnewick, 2010), 
phytoestrogenicity (Louw et al., 2013) and anti-diabetic activity (Ajuwon et al., 2018; Jack et al., 2019).  
Honeybush is a natural source of the xanthone, mangiferin, which occurs in particularly high amounts 
in unfermented C. genistoides (Beelders et al., 2015) and is well-documented as a natural bioactive with a 
range of therapeutic applications, including anti-diabetic (Masibo & He, 2008; Vyas et al., 2012). Mangiferin 
is also known as a potent antioxidant (Sekar, 2015) and, consequently, mangiferin-containing supplements 
have been developed and brought to market, including Vimang®, a Cuban mango bark extract that is promoted 
specifically for its antioxidant effect (Núñez-Sellés et al., 2002). Products that carry more specific anti-diabetic 
claims have also recently emerged. Salaretin®, a standardised extract of Salacia reticulata containing 1% 
mangiferin, is sold by the Sabinsa Corporation, based in New Jersey, USA. It is specifically marketed as an 
anti-diabetic phytonutrient for blood glucose control, based on its traditional use in Ayurvedic medicine 
(Anonymous, 2018). Honeybush extract containing mangiferin is also being used as an active ingredient in a 
variety of patented products, including an anti-diabetic nutraceutical, CycloferinTM (Joubert et al., 2019).  
Inhibition of intestinal AG is one of the likely mechanisms underlying the anti-diabetic effects of 
mangiferin and isomangiferin, its regio-isomer (Bosman et al., 2017). Polyphenols belonging to the other 
major chemical subclass in C. genistoides, the benzophenones, have also demonstrated in vitro AG inhibition 




enzyme inhibitors (Raaths, 2016). This bioactivity could be enhanced even more by formulating a modified 
oral delivery system that prolongs the release of the API in the gastrointestinal tract (GIT). Cyclopia 
genistoides could represent a sustainable natural source of APIs because of the successful cultivation of this 
species. 
No animal or human studies have been conducted to confirm whether polyphenol-enriched extracts or 
fractions of C. genistoides exert a significant in vivo hypoglycaemic effect, whereas acarbose has been the 
subject of extensive clinical trials and scientific review that confirm its efficacy, but also highlight its potential 
for dose-related side effects (bloating, flatulence and diarrhoea) (Van de Laar et al., 2005; Rosak & Mertes, 
2012). Many different types of plant or food extracts have been proposed as alternatives to acarbose (Yin et 
al., 2014). Furthermore, a number of studies have reported synergistic interaction between acarbose and other 
AG inhibitors (Adisakwattana et al., 2009; Akkarachiyasit et al., 2010; Boath et al., 2012; Satoh et al., 2015; 
Zhang et al., 2017). Synergism in drug combinations is attracting a great deal of attention in the medical 
research community because of the potential benefits of dose reduction and improved side effect profiles 
(Bijnsdorp et al., 2011; García-Fuente et al., 2018; Zhu et al., 2019). This suggests that the effective therapeutic 
dose of acarbose could be reduced by combining it with other AG inhibitors such as mangiferin. To date, no 
published studies have investigated the potential synergistic AG inhibitory effects of the major C. genistoides 
phenolics in combination with acarbose, either in vitro or in vivo. However, the evaluation of synergistic effects 
remains a contentious issue, and many dubious claims of synergism can be found in literature, as highlighted 
in several papers (Caudle & Williams, 1993; Chou, 2010; Geary, 2012; Ocana et al., 2012; Berthoud, 2013; 
Tang et al., 2015). This topic is covered in more detail in the literature review (Chapter 2).  
Even though optimised solvent extraction protocols are available for maximum recovery of bioactive 
compounds from C. genistoides plant material for the production of nutraceutical products (Bosman et al., 
2017), the use of organic solvents also results in co-extraction of plant matrix components, i.e. “crude” 
extraction in terms of target compound purity. Membrane separation technologies such as ultrafiltration can 
be used for semi-purification of crude extracts by the selective enrichment of target compounds based on 
physical properties, e.g. molecular weight. Membrane-based filtration has been increasingly applied in the 
food industry ever since technological advances in the early 1990s greatly improved their efficiency, ease of 
operation and energy consumption (Li & Chase, 2010; Kelly et al., 2019). 
Adsorption chromatography is also recognised as an efficient method for the recovery of plant 
phenolics from extracts or industrial waste streams (Kammerer et al., 2018). The development of synthetic 
macroporous resins resulted in major advances in the field of adsorption chromatography, as their chemical 
stability, limited toxicity, high adsorption capacity, and ease of regeneration at low or moderate temperatures 
have made them popular industrial adsorbents (Soto et al., 2011). The same resins that are used in commercial 
food processing to remove unwanted phenolic compounds, which cause bitterness, astringency or browning, 
can be used to recover valuable bioactive phenolic compounds from extracts or waste streams (Pérez-Larrán 
et al., 2018). Membrane filtration and adsorption chromatography provide “green”, energy-efficient 
alternatives to traditional separation techniques because of their physical separation mechanisms and 




Kelly et al., 2019). Therefore, these methods are particularly appealing for the recovery of heat-sensitive APIs 
from plants. 
Another important element in the development of bioactive natural extracts is the selection of 
appropriate experimental methods that are relevant to the intended application. As the literature review will 
demonstrate, the use of inappropriate methods, in either data analysis or in data generation, could produce 
misleading results and conclusions, which only serves to perpetuate the confusion regarding the actual health 
benefits of natural products. Early epidemiological studies suggested that dietary polyphenol intake could 
protect against some chronic and degenerative diseases, resulting in a heavy focus on in vitro elucidation of 
the potential underlying mechanisms (Bohn et al., 2015). However, a recent commentary by Ávila-Gálvez et 
al. (2018) highlighted the vast discrepancy between the high number of in vitro studies reporting “potential 
health benefits” for polyphenols and the number of studies that present any sort of actual in vivo evidence of 
these purported benefits. Only a small number of in vitro models are able to mimic in vivo conditions 
successfully, but the more closely related the in vitro conditions are to the in vivo application, the more relevant 
and useful the resulting data should be (Ávila-Gálvez et al., 2018).  
The aim of the present study was to develop a gastroretentive delivery system for an anti-diabetic 
nutraceutical incorporating fractions enriched in xanthones or benzophenones from C. genistoides. The first 
main objective (Chapter 3) was to develop a scalable, multi-step enrichment protocol using membrane filtration 
and adsorption chromatography for the production of the enriched fractions. This included an investigation 
into the effect of plant material inter-batch variation on the enrichment protocol and the degree of target 
compound enrichment achieved. The second main objective (Chapter 4) was the identification of the most 
active enriched fraction of C. genistoides in terms of the inhibitory effect against mammalian AG, for further 
development as a potential alternative or supplement to acarbose. Combinations of acarbose with the active 
AG inhibitors were also evaluated for potential in vitro synergistic interaction. The in vivo hypoglycaemic 
effect of acarbose and of a xanthone-enriched fraction of C. genistoides, as well as a combination of the two, 
was also investigated in normal and diabetic rats given an oral sucrose loading. The third main objective 
(Chapter 5) was the production of the gastroretentive delivery system. This included pre-formulation 
investigations entailing in vitro cytotoxicity screening of the extract and phenolic fractions, determination of 
their physicochemical properties (hygroscopicity, moisture sorption isotherms, thermal behaviour) and storage 
stability, as well as ex vivo transport studies to investigate the absorption of the major compounds in the small 
intestine. Subsequently, the basic physicochemical characteristics of a gastroretentive tablet containing the 
active AG inhibitors of C. genistoides are described—a first step towards the development of an effective and 
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The growing interest in South African honeybush tea during the 1990s coincided with greater consumer 
demand for health-promoting foods in an era when the links between diet, lifestyle and disease were becoming 
more apparent. Nowadays, these links are becoming even more ingrained in the minds of some consumers, 
who are showing unprecedented levels of interest in the health effects of their consumption habits (Aschemann-
Witzel, 2015). Anecdotal health-promoting properties of honeybush were first reviewed by Du Toit et al. 
(1998), but relatively little scientific data were available at this stage. Subsequently, the chemical composition 
of honeybush was investigated more comprehensively to augment contemporaneous research into its bioactive 
properties, and to gain more insight into possible value-addition and commercialisation opportunities (Joubert 
et al., 2008a, 2011, 2019). Traditional herbal teas such as honeybush—with a long-established history of 
regular use as home-brewed infusions with no reported ill effects—can be the ideal raw material for the 
production of nutraceuticals with health-promoting phytochemical content. 
Nutraceuticals refer to products, derived from food sources, which offer additional health benefits 
above and beyond the basic nutrition provided by conventional food products (Cory et al., 2018). They are 
often taken as dietary supplements, similar to mineral or multivitamin tablets, and may be targeted towards 
specific conditions with health-promoting claims (depending on the local labelling laws) (Siró et al., 2008). 
Functional foods are different from nutraceuticals in that they resemble conventional food products, e.g. milk 
or cereal, but also contain bioactive compounds within that food matrix, either naturally or through deliberate 
addition (enrichment/fortification) (Gul et al., 2016). Nutraceuticals or functional food products should not be 
used as the exclusive means to treat disease or serious medical conditions, nor are they intended for these 
purposes. Instead, they are to be taken for disease prevention or to obtain nutrients that are lacking in the 
normal diet (Khedkar et al., 2017). At best, they may serve as a supplement to enhance the effect of legitimate 
pharmaceuticals with proven therapeutic value, as prescribed by a physician or pharmacist (Das et al., 2012). 
The strong link between the diet and diabetes underpins the development of nutraceuticals or functional 
food ingredients with specific anti-diabetic bioactivity, particularly blood glucose-lowering effects (Riccardi 
et al., 2005; Zhu et al., 2019). Diabetes and impaired glucose tolerance, along with the associated rise in obesity 
and the metabolic syndrome, have become global health concerns of overwhelming proportions. The 
International Diabetes Federation has estimated that, as of 2017, approximately 425 million adults (aged 20–
79) were living with diabetes (IDF, 2017). This number was projected to increase to 629 million by 2045. 
Furthermore, the majority of diabetic adults (79%) are living in low- to middle-income countries, with the 
prevalence of lifestyle-related type 2 diabetes (T2D) steadily increasing. The number of diagnosed diabetics 
amongst South African adults in 2017 was 1 826 100, which amounts to 5.4% of the adult population (IDF, 
2019). 
Abnormally high blood glucose concentrations (hyperglycaemia) can eventually lead to diabetic 
complications of the skin, eyes, blood vessels, heart, kidneys and peripheral nervous system (Chaturvedi, 2007; 
Pitocco et al., 2013). As diabetes is becoming more prevalent amongst the economically active adult 




economy and put a strain on the healthcare infrastructure of developing countries (Herman, 2011). Pre-
diabetes—an intermediate state of impaired glucose tolerance with above-normal blood glucose levels, but 
below the diagnostic levels of diabetes—is also increasingly being acknowledged as an important metabolic 
state due to the high risk of progression to overt diabetes (Hostalek, 2019).  
The following literature review will present and discuss some of the aforementioned topics in more 
detail and greater scope, with the aim of laying down a solid foundation of background knowledge for the 
research activities to follow in subsequent chapters. 
 
2.2. The role of α-glucosidase inhibitors in diabetes treatment 
 
The inhibition of enzymes—proteins that catalyse and regulate critical metabolic pathways in the body—has 
been the basis for many widely used pharmaceuticals, including essential medicines such as penicillin, 
allopurinol and neostigmine (WHO, 2019). Indeed, most medicines are inhibitors of some kind that either 
block specific metabolic pathways/receptors or suppress enzyme activities to exert their effects (Chou, 2006). 
Therefore, the multitude of enzymes involved in sustaining life and maintaining good health creates many 
opportunities for developing novel pharmaceutical agents or condition-specific nutraceuticals based on the 
inhibition of a specific enzyme or enzyme class. 
The mammalian digestive tract is equipped with a variety of luminal and brush border enzymes that 
break down ingested foods to smaller, absorbable molecules. The breakdown of dietary carbohydrates (CHOs) 
begins in the mouth, where salivary α-amylase initiates the hydrolytic digestion of starch. Once the food bolus 
reaches the proximal small intestine (duodenum and jejenum) and undergoes further hydrolysis by pancreatic 
α-amylase, the resultant oligo- and disaccharides are made available for further breakdown to their 
monosaccharide constituents (Tucci et al., 2010). The small intestine can only absorb CHOs in the form of 
simple monosaccharides, i.e. glucose or fructose, and any partially digested and unabsorbed CHOs will be 
transported to the large intestine, where it undergoes bacterial fermentation by intestinal flora (Grabitske & 
Slavin, 2009). While amylases are secreted into the small intestine by specialised glands, α-glucosidases (AGs) 
occur primarily in the jejunum as brush border enzymes (Bischoff, 1994).  
Because of their crucial role in the absorption of glucose, the targeted inhibition of digestive enzymes 
has been identified as an important strategy in the development of blood glucose-controlling treatments against 
pre-diabetes, diabetes and obesity (Asano, 2003; Van de Laar et al., 2005; Ali Asgar, 2013). AG can be 
classified as an “exo-enzyme”, which liberates a D-glucose monomer from the non-reducing end of the 
substrate (Borges de Melo et al., 2006). Inhibition of this action of AG results in a decreased rate of glucose 
absorption from the small intestine because of the lower amount of glucose molecules available for uptake by 
mucosal transporters (Hirsh et al., 1997). This results in an attenuation of the spike in blood glucose typically 
observed after a meal, i.e. it prevents postprandial hyperglycaemia, a hallmark of established diabetes and 
indicator of impaired glucose tolerance and pre-diabetes (Van de Laar et al., 2005). 
When lifestyle interventions alone do not provide adequate blood glucose control, pharmacological 




2002; Nathan et al., 2009; Kumar & Sinha, 2012; Ghani, 2015). Effective blood glucose control is usually 
achieved with a combination of two or more oral anti-diabetic agents (Prabhakar et al., 2014). Various 
scientific publications have described α-glucosidase inhibitors (AGIs) as the most effective of all the available 
classes of oral anti-diabetic drugs in terms of achieving long-term blood glucose control (Oki et al., 1999; Hu 
et al., 2011; Derosa & Maffioli, 2012; DiNicolantonio et al., 2015; Proença et al., 2017). A systematic review 
of 41 studies (Van de Laar et al., 2005) concluded that pharmaceutical-grade AGIs show “clear beneficial 
effects” in reducing fasting and postprandial hyperglycaemia, and in the long-term maintenance of insulin 
homeostasis. As an added benefit, the AGIs, unlike sulfonylureas and biguanides, are not associated with 
episodes of reactive hypoglycaemia, i.e. abnormally low blood glucose following over-secretion of insulin 
(Yee & Fong, 1996; Kumar & Sinha, 2012). 
 
2.2.1. Commercial α-glucosidase inhibitors 
 
One of the strongly advocated treatment modalities for long-term maintenance of normal blood 
glucose levels (normoglycaemia or euglycaemia) is the use of pharmaceutical-grade AGIs. The currently 
available drugs have a potent effect against AG but are not well tolerated by some individuals, who experience 
significant gastrointestinal side effects. Not only do the side effects of commercial AGIs limit their more 
widespread use, especially in Western countries (Rosak & Mertes, 2012), but they also negatively affect patient 
adherence to treatment regimens that include these AGIs (Norris et al., 2005; Lahiri, 2012).  
In recent years, a great number of AGIs have been synthesised in laboratories or discovered in natural 
sources, but only a few have been successfully brought to market after undergoing successful clinical trials. 
They are typically used as part of a treatment regimen that includes other anti-diabetic agents with different 
modes of action, e.g. sulfonylureas or biguanides, which then work together on different levels to prevent 
hyperglycaemia (Kumar & Sinha, 2012). Because of their structural resemblance to the dietary 
oligosaccharides, the commercially available synthetic AGIs have been described as “pseudocarbohydrates”, 
which inhibit AG by competing with dietary oligosaccharides for the active binding site (Van de Laar et al., 
2005; DiNicolantonio et al., 2015). Acarbose (Glucobay®, Prandase®, Precose®)—originally developed by 
Bayer AG (Schmidt et al., 1977) and currently the most widely used commercial AGI—is produced on an 
industrial scale by the fermentation of developed strains of Actinobacteria (Ghani, 2015). As a 
“pseudotetrasaccharide” with a nitrogen bond between the first and second glucose moieties (Fig. 2.1), it is 
poorly absorbed from the gastrointestinal tract (GIT) (< 2%) (Puls et al., 1977; Kumar & Sinha, 2012; 
Williamson, 2013) and has a much higher affinity than the dietary oligosaccharides for the active center of AG 
(Dodane et al., 1991; Van de Laar et al., 2005). In addition to its hypoglycaemic effect, acarbose treatment has 
been shown to improve the blood lipid profile in non-diabetics with severe hypertriglyceridaemia 






Figure 2.1 Comparison of molecular structures of acarbose (a “pseudotetrasaccharide”) and oligosaccharides 
from dietary starch, with an arrow indicating the location of the nitrogen bond, and a schematic depicting 
competitive inhibition of intestinal α-glucosidase by acarbose (Rosak & Mertes, 2012). 
 
 
The elimination half-life of acarbose is approximately 2 h (Kumar & Sinha, 2012) and it is 
recommended that acarbose should be taken orally with the first bite of a meal for maximum efficacy, with a 
typical starting regimen of 25 mg three times a day (assuming three substantial meals). The dose may be 
increased to 50 or 100 mg depending on the observed response, but a dose higher than 100 mg has not been 
shown to provide significantly better outcomes (Tucci et al., 2010). Indeed, higher doses have been associated 
with dose-related side effects of intestinal malabsorption (bloating, diarrhoea and nausea) because of the higher 
amount of partially digested CHOs entering the colon and undergoing bacterial fermentation (Grabitske & 
Slavin, 2009; Rosak & Mertes, 2012). 
The efficacy of acarbose, as well as its potential to cause unpleasant side effects, depends largely on 
the composition of the diet and on the natural variation in the complex gastrointestinal environments of 
different individuals (Chiasson et al., 2002). Severe side effects are reportedly more common in Western 
countries, e.g. the UK, USA and Germany, than in Asian countries (Rosak & Mertes, 2012). This could be 
attributed to the relatively fiber-rich diet of Asian populations (Yang & Read, 1996), which is thought to result 
in upregulated digestive enzyme activity in the distal small intestine that increases the breakdown of 
oligosaccharides and reduces bacterial fermentation in the colon (Creutzfeldt et al., 1985; Dodane et al., 1991). 
Furthermore, the severity of the symptoms tends to improve over time with sustained use of acarbose (Neuser 
et al., 2005; Rosak & Mertes, 2012). Avoidance of particular types of foods, e.g. beer, sweets or refined sugars, 
could also reduce incidences of severe gastrointestinal side effects during AGI therapy (Toeller, 1992). 
 Citing the reported side effects of acarbose as motivation for the search for natural alternatives, 




to acarbose and other commercial AGIs (Yin et al., 2014; Ghani, 2015). Acarbose, which is highly soluble in 
water (Kumar & Sinha, 2012), frequently serves as the reference standard (positive control) in experiments 
testing the AG inhibitory activity of new candidate AGIs. An important point to note is that the term “α-
glucosidase” (Enzyme Commission no.: 3.2.1.20) does not refer to one specific enzyme complex with a fixed 
molecular structure, but it can refer to different molecules occurring in different species, genera or phyla, which 
all perform the same function, i.e. hydrolysing terminal non-reducing (1→4)-linked α-D-glucose residues. 
Included amongst the different types of enzyme with this AG function are acid maltase, glucoinvertase, 
glucosidosucrase, lysosomal α-glucosidase, maltase and maltase-glucoamylase (Chiba, 1997). Therefore, the 
inhibitory effect of a particular candidate AGI against different types of AG, e.g. sucrase vs. maltase, could 
indeed differ considerably (Jones et al., 2011; Zhang et al., 2017a). Despite the structural differences between 
various types of AG, they all carry out the same enzyme activity. For example, maltase in single-celled 
Saccharomyces cerevisiae (baker’s yeast) and maltase-glucoamylase in the human GIT may both correctly be 
referred to as “α-glucosidase” despite their different structures, origins and responses to a particular inhibitor. 
This topic is explored in more detail in Section 2.7.1, particularly within the context of identifying potent AGIs 
relevant to humans. 
 
2.2.2. Natural α-glucosidase inhibitors  
 
There is growing consumer interest in deriving additional health benefits from plant-based foods in 
the form of enriched functional foods or nutraceuticals (Egert & Rimbach, 2011), particularly in the 
management of chronic metabolic and lifestyle-related diseases, e.g. T2D and obesity (Bahadoran et al., 2013). 
Consequently, a number of studies have investigated the inhibition of AG by plant extracts or purified 
phytochemicals (Kumar et al., 2011; Yin et al., 2014; Ghani, 2015; Di Stefano et al., 2018), including phenolic 
compounds isolated from South African honeybush tea (Beelders et al., 2014a). Phenolics, the most widely 
distributed class of secondary plant metabolites, are marked by the presence of an aromatic ring bearing a 
single hydroxyl group (phenol) or multiple hydroxyl groups (polyphenol). In general, plant phenolics refers to 
(monomeric or polymeric) secondary plant metabolites that are derived from either the shikimate pathway or 
the malonate pathway (Cheynier et al., 2013).  
Plant polyphenols of various chemical subclasses have been reported as AGIs, including chalcones, 
stilbenes, tannins, proanthocyanidins, flavanones and flavanols (Xiao et al., 2013a). The reported inhibitory 
effects of these natural AGIs are generally less potent than those of the commercial AGIs, which are often 
included in experiments as positive controls. Of particular interest is that some of these studies have reported 
that combinations of commercial AGIs with natural AGIs may enhance the overall inhibitory effect through 
apparent synergistic interactions. Crude botanical extracts may contain more organic acids or complex sugars 
than polyphenols, and these “impurities” may interact with the enzyme and enhance (or reduce) the bioactivity. 
Tan et al. (2017) used column chromatography with macroporous adsorbent resin to remove sugars and organic 
acids from crude extracts of black legumes, and the resultant fractions of purified and semi-purified 




been the result of concentrating the active compounds in the extract, or of removing antagonists and non-
inhibitors from the sample matrix with macroporous resin chromatography. 
 
2.2.3. The ileal brake 
 
Digestive enzyme inhibitors could play another significant role in diabesity management on a different 
level than simply inhibiting nutrient digestion and delaying absorption. Since the 1980s, researchers have 
demonstrated that undigested nutrients can reach the distal small intestine and induce activation of the so-
called ileal brake, a combination of effects influencing ingestive behaviour and digestive processes (Spiller et 
al., 1984). Activation of the ileal brake increases satiety and reduces food intake, mainly mediated by L-cells, 
a type of enteroendocrine cell found in the distal small intestine and colon, which secretes peptide YY and 
glucagon-like peptide 1 (GLP-1) in response to dietary CHOs and fats (Maljaars et al., 2008). Nutrient-specific 
studies on dietary CHOs in humans have shown that the presence of undigested starch and maltose in the distal 
small intestine decreased intestinal motility, delayed gastric emptying and  reduced the secretion of gastric 
acid and pancreatic enzymes (Layer et al., 1990, 1993, 1995; Gröger et al., 1997). Ranganath et al. (1998) 
reported that 100 mg acarbose (2 × 50 mg tablets) extended the gastric residence time and delayed absorption 
of paracetamol that was orally co-administered with a 500 mL sucrose solution (200 mg/mL). In another study, 
acarbose (100 mg tablet dissolved in 200 mL tea) was shown to delay gastric emptying of solid meals and 
augment the release of cholecystokinin (CCK), GLP-1 and peptide YY by inhibiting CHO absorption (Enç et 
al., 2001). This suggests that AGIs could also exert anti-diabetic effects through stimulation of the intestinal 
neurohormonal sensing mechanism, which regulates GIT motility and the secretion of digestive enzymes. 
 
2.2.4. Synergistic α-glucosidase inhibition 
 
In recent years, the study of synergism has become a major activity in phytomedicine and traditional 
herbal medicine, since combinations or complex mixtures of natural extracts are commonly encountered in 
these fields (Wagner & Ulrich-Merzenich, 2009). Some recent studies have reported synergistic AG inhibitory 
effects for combinations of acarbose with phyto-extracts or isolated plant phenolics, e.g. Sun et al. (2017) 
reported that combining acarbose with Oroxylym indicum seed extract enhanced the blood glucose-lowering 
effect of acarbose in the treatment of pre-diabetic mice over eight weeks. Synergistic inhibition of rat intestinal 
AG has also been claimed for combinations of acarbose with Camellia sinensis extracts (Satoh et al., 2015), 
blackcurrant (Ribes nigrum) extracts (Boath et al., 2012) and cyanidin-3-galactoside, a natural anthocyanin 
found in cranberries (Vaccinium macrocarpon) (Adisakwattana et al., 2009; Akkarachiyasit et al., 2010). The 
informed evaluation of such claims and the reasoning behind them requires a closer look at the fundamentals 






2.2.4.1. General overview of synergism 
 
Combinations of different pharmaceutical agents have proven effective for the treatment of a number 
of diseases, e.g. AIDS, malaria, pulmonary tuberculosis, hypertension and diabetes (Bijnsdorp et al., 2011; 
Prabhakar et al., 2014; Foucquier & Guedj, 2015). Combination therapy also remains the cornerstone of 
traditional Chinese herbal medicine practices, where complex blends of multiple herbal extracts are commonly 
used (Zhou et al., 2016). One of the potential benefits of combined pharmacotherapy is synergism between 
two or more agents, i.e. a combined effect that is greater than that achieved by the individual agents at the 
same concentration. Antagonism (essentially “negative synergism”) refers to a combined effect that is less than 
that achieved by the individual agents at the same concentration (Berenbaum, 1989). 
Until relatively recently there was no clear consensus on the definition of synergism or its scientific 
assessment, with some authors accusing others of “misuse” of methods or of making misleading claims 
(Caudle & Williams, 1993; Geary, 2012; Ocana et al., 2012; Berthoud, 2013; Tang et al., 2015). Goldin and 
Mantel (1957) discussed seven different previously proposed definitions for synergism, and a later review 
(Greco et al., 1995) explored 13 different methods for testing synergism, none of which supported the others 
(Chou, 2010). The term synergism is sometimes used interchangeably with augmentation, enhancement or 
potentiation, but a synergistic interaction is “mutual”, whereas the latter three terms refer to a “one-sided” 
phenomenon (Chou, 2008). For true synergistic interaction to take place between two pharmaceutical agents, 
it is a prerequisite that each agent individually acts as an agonist with a clear dose-dependent effect (Chou, 
2010).  
At the most basic level, synergism refers to a combined effect that is more than additive. Therefore, 
its definition hinges upon first establishing what exactly represents an additive effect. Chou (2010) referred to 
the older concept of the fractional product, i.e.. if X and Y each inhibit 50%, then their additive effect equals 
75% [= 100% − (50% ×  50%)] (Webb, 1963). It was noted that this approach would only be valid if the effects 
of both agents were mutually non-exclusive with hyperbolic dose-response curves, i.e. if they adhered to first 
order Michaelis-Menten kinetics (Michaelis & Menten, 1913). However, Chou and Talalay (1984) previously 
indicated that dose-response curves in cellular or animal models are more likely sigmoidal or flat sigmoidal in 
shape.  
An important point to note is that a combined effect greater than that of each individual agent alone 
does not necessarily confirm synergism, and may be the result of a simple additive effect or even slight 
antagonism (Chou, 2010). Crucially, it should also be noted that the additive effect of two agents cannot be 
determined simply by finding the arithmetic sum of their individual effects (Berenbaum, 1977, 1989; Chou, 
2010; Zhou et al., 2016). For instance, if enzyme inhibitors X and Y exert effects of 30% and 30%, 
respectively, the additive effect of X and Y is not equal to 60%, because if they both had exerted 60%, the 
additive effect could not be equal to 120% (Chou, 2006).  
The degree of synergism or antagonism can be classified using the Chou-Talalay method (as discussed 
in the following section), but an augmentation, enhancement or potentiation effect can only be expressed in 




exerts no effect on its own, but enhances the effect of another agent that does exert an individual effect (Chou, 
2010). Where two ineffective single agents prove to be effective when used in combination, it is referred to as 
coalism (Foucquier & Guedj, 2015). A major benefit of combination therapy and synergism is the potential to 
reduce the dose of one or more of the agents and still maintain the same effect level, which may reduce the 
risk of toxicity, side effects and the development of drug resistance over time (Bijnsdorp et al., 2011; García-
Fuente et al., 2018; Zhu et al., 2019). 
 
2.2.4.2. Combination Index theorem of Chou-Talalay 
 
Professor Ting-Chao Chou, reviewing the basic principles of synergism in drug combinations (Chou, 
2006), stated that “the meaning of synergism has become an individual’s preference, agenda, or wishes”, also 
remarking later that “faulty or unsubstantiated synergy claims are pervasive” (Chou, 2010). Prompted by long-
standing disparity in scientific literature regarding the definition and assessment of synergism, Chou, working 
alongside Professor Paul Talalay, introduced the concept of the combination index (CI), which provided a 
quantitative definition for synergism (CI < 1), antagonism (CI > 1) and additive effect (CI = 1) in combination 
therapy (Chou & Talalay, 1983, 1984). The resulting Chou-Talalay or CI method for determining synergism 
is based on the median effect equation (MEE), which is derived from the law of mass action. Most active 
pharmaceutical ingredients (APIs) are inhibitors of some kind that block pathways, receptors or suppress 
enzyme activity, and the principles of the mass action law will apply irrespective of the type of inhibition 
(competitive, uncompetitive, non-competitive) or the number of reactants (inhibitors, substrates, products) 
(Chou, 2006). The underlying principle of mass action law-based theory is that the median represents the 
common link between single and multiple entities, and between first-order and higher-order dynamics (Chou, 
2010). The MEE provides a simple explanation of dose-effect relationships in biological systems, including 
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  (Eq. 2.1) 
 
where D represents the dose (concentration) of an inhibitor, Dm represents the median effect dose that results 
in 50% inhibition of the same system (i.e. the IC50 value), the variable fa refers to the fraction affected by D, 
i.e. percentage inhibition ÷ 100, and fu represents the remaining unaffected fraction, i.e. fu = (1− fa). The 
coefficient m denotes the shape of the dose-response curve, where m = 1, < 1, and > 1 indicate hyperbolic, flat 
sigmoidal and sigmoidal curves, respectively. Notably, both sides of this generalised equation represent 
dimensionless ratios, which is crucial for its broad applicability and flexibility. Synergism or antagonism may 
thus be determined even if the doses (D) for individual agents are given in different units (e.g. µM vs. mg/L), 
provided that there is good conformity to the mass action law principle (r > 0.95). The MEE for a single agent 
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where D1 and D2 represent the doses of agents 1 and 2 that result in a given effect level in the combination 
system, and (Dx)1 and (Dx)2 represent the doses of agents 1 and 2 that produce the same effect when used alone. 
The dose reduction index (DRI), also derived from this equation, is discussed in the next section. 
The MEE is the unified form of the mass action law principle that also underlies the equations of Hill, 
Henderson-Hasselbach, Scatchard and Michaelis-Menten, all of which are major concepts in the field of 
biomedical science (Chou, 2010). Because mass action law-based assessment of synergism is mechanism-
independent, exact knowledge of the biochemical mechanisms causing the synergistic effects is not an absolute 
requirement for applying the Chou-Talalay method. Indeed, even an ubiquitous pharmaceutical agent such as 
aspirin has yet to be fully elucidated in terms of its various mechanisms, despite decades of use (Chou, 2006). 
Some agents may also have multiple modes of action, and determining which one contributes to the synergistic 
effects may prove challenging (Chou, 2010). 
One article, which first presented the application of the CI method (Chou & Talalay, 1984), has been 
cited nearly 5000 times as of November 2019 according to Scopus statistics. The underlying theory was 
subsequently used to develop algorithms for automated computer simulation of synergism at any dose or effect 
level (Chou & Martin, 2005). Benefits of the CI method include its simplicity, flexibility (mechanism- and 
unit-independence), economy (requires small number of data points) and the ability to make numerically 
indexed conclusions, i.e. quantify degrees of synergism using the CI (Chou, 2010). In contrast, response 
surface modelling, another approach to evaluating synergism, requires substantial statistical background 
knowledge due to its complexities (Bijnsdorp et al., 2011).  
The assertion is that synergism is fundamentally a matter of physicochemical mass action laws, and 
not a statistical parameter, and should be determined by CI values and not P values (Chou, 2010). In the 
conventional statistical approach to dose-response analysis, empirical curves are drawn to fit the data points, 
but the Chou-Talalay method instead uses scattered data points to fit the MEE. Purely statistical approaches 
may prove problematic when dealing with more complex systems containing multiple enzyme inhibitors 
(Chou, 2006). The most recently updated software for applying the Chou-Talalay method is CompuSyn (Chou 
& Martin, 2005), which is freely available (http://www.combosyn.com/register.html) and enables processing 
of large data sets whilst providing detailed, print-ready statistical and graphical output. CompuSyn analyses 
simply require the input of “dose and effect” data for each individual agent, as well as for their combinations 
(Fig. 2.2). Having a dose-response curve for each agent is a basic requirement for synergism testing, because 
each will have a unique shape (m value) and potency (Dm). The combination of two agents (e.g. enzyme 
inhibitors X and Y), subjected to serial dilutions, essentially represents a third agent (enzyme inhibitor XY) 
with its own dose-response relationship. The mass action law parameters (r, Dm and m) for this new, third entity 
can then be derived from the automated median effect plot. Once these parameters have been determined, the 
CI equation (Eq. 2.2) can be used to detect synergism. This is theoretically possible even if only one data point 




the potential biological and technical variability one may encounter in such experiments (García-Fuente et al., 
2018). 
Ideally, mass action law parameters should be determined for a drug combination before assessing 
synergism, i.e. the dose-response curve for the combination should first be generated from multiple data points. 
However, the CI can still be calculated from just a single data point using the CI equation (Chou & Talalay, 
1984). This means that the minimum theoretical number of data points that is required for a CompuSyn analysis 
of a two-agent combination is just five—two for each individual agent and one for the combination. Chou 
(2006) proposed a tiered classification system for describing degrees of synergism and antagonism using the 
CI (Table 2.1).  
 
Figure 2.2 User interface of CompuSyn software (http://www.combosyn.com/register.html), developed for 
synergism testing in drug combinations based on the combination index method (Chou & Talalay, 1984). 
 
 
Table 2.1 Classification system for synergistic and antagonistic 
interactions according to combination index values calculated using the 
Chou-Talalay method (Chou, 2006). 
Range of combination index (CI) Description 
> 10 Very strong antagonism 
3.3–10 Strong antagonism 
1.45–3.3 Antagonism 
1.20–1.45 Moderate antagonism 
1.10–1.20 Slight antagonism 
0.90–1.10 Near additive 
0.85–0.90 Slight synergism 
0.70–0.85 Moderate synergism 
0.3–0.7 Synergism 
0.1–0.3 Strong synergism 





In addition to median effect plots and dose-response curves, CompuSyn can also generate Fa-CI plots 
(combination index or Chou-Talalay plots), Fa-DRI plots (dose-reduction index or Chou-Martin plots), and 
traditional isobolograms, all of which provide simple graphical representations of synergistic or antagonistic 
interactions (Fig. 2.3). For example, Wing-Shing Cheung et al. (2012) used Fa-CI plots to depict synergism 
and antagonism in a traditional Chinese herbal combination (Salvia miltiorrhiza and Pueraria lobata) against 
atherogenic enzymes. The isobologram, first introduced by Loewe (1928), is a graph constructed on a 
coordinate system consisting of the concentrations of the individual agents, and depicts a straight line (or 
isobole) of additivity that is used to differentiate between synergistic and antagonistic interactions (Foucquier 
& Guedj, 2015). Traditional isobologram analyses assume a constant relative potency, and cannot be used to 
quantify the extent of synergism nor to determine confidence intervals (Greco et al., 1995; Tallarida, 2006). 
 
 
Figure 2.3 Examples of two-drug combination plots with their interpretations based on the Chou-Talalay 
combination index (CI) theorem: (a) Fa-CI plot, (b) classic isobolograms, (c) normalised isobologram for non-
constant combination ratios and (d) Fa-DRI plot (Chou, 2006). (DRI = dose reduction index; Fa = effect level; 
ED = effective dose; Dx = dose of drug x). 
 
 
The Chou-Talalay method has been widely adopted in pharmaceutical development, especially for 
anti-cancer and anti-viral combination therapy, where increased drug efficacy and decreased toxicity is of 




extensively—in the development of traditional Chinese herbal medicine preparations, where multi-component 
mixtures are frequently encountered (Yi & Wetzstein, 2011; Zhou et al., 2016). Such mixtures hold even 
greater potential for synergistic interactions between the various components (Wagner & Ulrich-Merzenich, 
2009).  
Zhang et al. (2017a) used the Chou-Talalay method with CompuSyn software to investigate potential 
synergism between 16 common dietary flavonoids (as pure standards) and acarbose in the inhibition of 
mammalian AG and porcine pancreatic α-amylase. Although the individual in vitro inhibitory effects of most 
of the flavonoids under study were relatively weak (> 400 µM; acarbose IC50 = 0.4 µM), luteolin 
(IC50 = 339.4 µM), quercetin (IC50 = 281.2 µM), (+)-catechin (IC50 = 175.1 µM) and baicalein 
(IC50 = 74.1 µM) showed greater potency. The combination of acarbose with luteolin, quercetin or baicalein 
showed in vitro synergistic AG inhibition, with all CI values falling below 0.9 (Fig. 2.4a–c). Different dose 
combinations of acarbose with baicalein, the most potent of the tested compounds, resulted in CI values < 0.41. 
Acarbose combined with (+)-catechin at high doses showed slightly antagonistic AG inhibition (CI = 1.17) 
(Fig. 2.4d). The combination of apigenin or baicalein with acarbose had an additive effect on α-amylase 
inhibition at lower concentrations, and an antagonistic effect at higher concentrations. In a subsequent in vivo 
experiment, a combination of 1 mg/kg acarbose with 80 mg/kg baicalein synergistically reduced blood glucose 
levels in Kunming mice. A hypoglycaemic effect roughly equal to that of 8 mg/kg acarbose, i.e. a dose 
reduction index of 8 (8/1), was observed with the combination (Zhang et al., 2017a).  
 
Figure 2.4 Assessment of α-glucosidase inhibition by combinations of acarbose with baicalein (A), quercetin 
(B), luteolin (C) and (+)-catechin (D) at different dose concentrations. Combination index (CI) values, 




Gao et al. (2013), applying the Chou-Talalay method through the use of CompuSyn software, 
investigated the combined in vitro AG inhibitory effect of green tea extract (GTE) or epigallocatechin gallate 
(EGCG) with acarbose. Based on CI values and visual inspection of Fa-CI plots (Fig. 2.5), they concluded that 
all of their samples exhibited synergism with acarbose at low concentrations, and antagonism with acarbose at 
higher concentrations. The Fa-CI plot for the GTE-acarbose combination (Fig. 2.5a) clearly shows that 
antagonism was present above ca. 50% inhibition, whereas antagonism was only detected above ca. 70% 
inhibition for the EGCG-acarbose combination (Fig. 2.5b). Lower minimum CI values for the latter 
combination also indicate that it displayed stronger synergism than the GTE-acarbose combination. This kind 
of information is useful for the identification of suitable extracts, fractions or lead compounds from plant 
sources for further development as alternative AGIs. 
 
 
Figure 2.5 Fa-CI (effect level-combination index) plots showing antagonism and synergism in combinations 
of acarbose with (a) green tea extract (GTE) and (b) epigallocatechin gallate (EGCG) (Gao et al., 2013). 
 
 
2.2.4.3. Practical considerations in synergy testing using the Chou-Talalay method 
 
Despite greater flexibility in the concentration ranges that can be tested for in vitro drug combination 
studies, it should be considered whether these in vitro concentration ranges would be achievable in vivo, or 
whether they would fall within the allowable limits for toxicity. As a rule of thumb, data points in the middle 
of the dose-response should not be omitted, except where known experimental errors occurred (Bijnsdorp et 
al., 2011). With data points at very high or very low dose concentrations, accurate analyses are not always 
possible, i.e. data points are outside of the detection limits of the assay. CompuSyn software regards every data 
point equally, and inaccurately determined values could, therefore, result in erroneous conclusions (Chou, 
2006). Entering Fa (effect level) values of 0 or 1 into a computer running CompuSyn could result in a software 
crash because log 0 is undefined and log 1 = 0. Ideally, the data points should be evenly distributed around the 
half-maximal inhibitory concentration (IC50) for more accurate analyses, but the Chou-Talalay method can 
readily handle skewed data sets because of the unified theory of the MEE (providing that r > 0.95) (Chou, 





In theory, the isobologram and Fa-CI plot (plots effect level against CI) should provide the same 
conclusions regarding the presence of synergism because both are ultimately based on the same CI equation 
(Chou, 2006). Isobolograms depicted at no more than three effect levels (e.g. Fa = 0.5, 0.75, and 0.9), will 
typically be readable by inspection, but may become unreadable at > four effect levels because of overlapping 
or congestion of data points (Tallarida, 2011). This is not an issue in Fa-CI plots, where the entire range of Fa 
(0–1) can be displayed on the x-axis with no crowding of data points (Fig. 2.3a).  
Another important consideration is that synergistic or antagonistic effects may differ depending on the 
dose concentrations, as alluded to previously in the case of Zhang et al. (2017a) (Fig. 2.4). For example, a 
given combination of agents may display synergism at a 90% effect level, while displaying antagonistic 
interactions at lower effect levels. For acute diseases requiring aggressive pharmacotherapy, e.g. 
immunosuppressants, anti-cancer chemotherapy or antiviral “cocktails” for AIDS, there is greater therapeutic 
relevance to achieving synergism at high effect levels (Fa > 0.9), especially where this would allow for dose 
reduction of one or more agents to prevent toxicity or side effects. Synergism at lower effect levels (Fa < 0.5) 
might be more relevant in the context of treating chronic illness or in the field of nutritional supplements and 
other adjuvants to intensive pharmacotherapy.  
The default CompuSyn output includes the dose reduction index (DRI), which is derived from the CI 
equation (Eq. 2.2). DRI is another quantitative measure of the degree of synergism, representing the x-fold 
dose reduction of each agent in a synergistic combination that may be achieved at a given effect level relative 
to the dose of that agent when used alone. An additive or slightly antagonistic interaction may sometimes result 
in DRI > 1, and the interpretation of this value should, therefore, take into consideration the accompanying CI 
value, which is a more reliable indicator of synergism (Chou, 2006). CompuSyn automatically plots DRI 
values against effect levels (Fa-DRI plot) (Fig. 2.3d), but some DRI values may be very high and out-of-scale 
in cases where strong synergism exists. Therefore, CompuSyn also generates a Fa-log(DRI) plot by default to 
condense the scale. 
While it is possible to apply the Chou-Talalay method even with a low number of data points (as few 
as five), this advantage of the method is more relevant to in vivo experiments, where the number of animal or 
human models may be limited. In vitro testing will usually allow for more experimental replicates and data 
points. The diagonal constant ratio combination design was proposed by Chou and Talalay (1984) to reduce 
the number of data points and still obtain reliable information. The simple serial dilution scheme with a small 
number of data points (15 for a two-agent combination) allows for computer simulation of DRI and CI values 
across all effect levels. In this way, basic in vitro testing for the quantitative determination of synergism can 
be completed within a matter of days or weeks, but establishing exactly which mechanisms are responsible for 
the synergistic effects may take months to years, and often with only tentative results. These are, essentially, 
separate issues (Chou, 2006). 
Ideally, experiments for the individual agents and their combination(s) should be conducted 
simultaneously to minimise any technical variability. While this practical consideration might limit the 
manageable experimental size, the use of in vitro multi-well microplate assays with high throughput would 




dose-response curves each consisting of five to eight data points for the individual agent and their combinations 
(Chou, 2006). 
The ratio in which multiple agents are combined (dose ratio) may have an effect on the degree of 
synergism (Tallarida, 2011). Different dose ratios can be investigated in order to find the one that optimises 
the synergistic interaction in terms of the specific requirements or limitations of the study. It has been 
recommended that at least one of the tested combination ratios should represent an equipotency ratio, i.e. 
(IC50)1/(IC50)2, so that the contribution of each agent to the total effect is roughly the same (Chou & Talalay, 
1984). This is not an absolute requirement, however, as particular agents may need to be emphasised or de-
emphasised, because of limited availability, dose-dependent toxicity/side effects or solubility constraints, 
amongst others (Conidi et al., 2014; Foucquier & Guedj, 2015). In practice, one can decide on a particular 
arbitrary combination ratio and simply observe the results, which can then guide in the selection of additional 
ratios for testing, if necessary.  
 
2.3. Honeybush (Cyclopia spp.) 
 
The Western Cape Province of South Africa is home to a wealth of endemic flora known as the “fynbos” 
biome, which represents a major part of the Cape Floristic Region, one of six globally recognised floral 
kingdoms, and a “biodiversity hotspot” with great economic potential and inherent eco-biological value 
(Cowling et al., 2003). The genus Cyclopia Vent. (family Fabaceae; tribe Podalyrieae), colloquially referred 
to as honeybush or “heuningbos” in Afrikaans, contains more than 20 species and has been used by the local 
people to prepare herbal teas for more than a century (Greenish, 1881; Marloth, 1913, 1925; Watt & Breyer-
Brandwijk, 1962). Van Wyk and Gorelik (2017), in a review of the history and ethnobotany of Cape herbal 
teas, stated that “the tradition of drinking tea (and coffee), introduced by early European settlers in the 17th 
century, appears to have stimulated the use of numerous indigenous plants as tea and coffee substitutes”. Since 
the 1990s, honeybush has gone from strength to strength as a commercial commodity following intensified 
research activities and concerted efforts towards establishing a formal industry (Du Toit et al., 1998; Joubert 
et al., 2011), which has recently reached its 20-year milestone (Joubert et al., 2019).  
Honeybush tea is available in an “unfermented” (green or unoxidised) and “fermented” (oxidised) 
form, with the latter the traditionally preferred form of the product. The fermented herbal tea has a 
characteristic sweet taste and honey-like aroma and flavour (Joubert et al., 2011), as opposed to the prominent 
vegetal (“green grass”, “hay/dried grass”) aroma notes of the unfermented product (Alexander et al., 2017, 
2018). Only a small number of documented Cyclopia species, including C. genistoides, are utilised for 
commercial honeybush tea production. Cyclopia genistoides grows naturally in sandy soils along the Cape 
Peninsula, the western coastal area (Malmesbury, Darling), Overberg region (Hermanus, Grabouw, 
Bredasdorp, Caledon, Swellendam) and Garden Route district (Albertinia, Plettenberg Bay) (Schutte, 1997; 
Joubert et al., 2011). This species tends to produce slightly bitter-tasting infusions, even when “fermented”.  




2019) presents a challenge to plant breeders. Other commercially important species include C. maculata, 
C. intermedia, C. subternata and C. longifolia (Fig. 2.6).  
 
 
Figure 2.6 Geographical distribution of major species of honeybush (Cyclopia spp.) endemic to the Western 




The local herbal tea market in South Africa is dominated by two product categories: rooibos 
(Aspalathus linearis) and honeybush. Rooibos, with a longer history of large-scale cultivation and 
commercialisation, holds a substantially larger share in the local and export market, but recent years have seen 
the honeybush industry showing appreciable growth, with local production capacity often falling short of 
global demands (Joubert et al., 2011). Emerging from its humble beginnings as a localised cottage industry 
(Du Toit et al., 1998), by 2011 the majority of honeybush tea and its derived products were being exported to 
more than 20 different countries (most notably the UK, USA, Netherlands and Germany) (Joubert et al., 2011). 
Honeybush extracts are also being used as ingredients in a variety of patented products, including an anti-
diabetic nutraceutical, CycloferinTM and an anti-wrinkle skin-care product (Joubert et al., 2019). Prompted by 
the flourishing export market, the Agricultural Research Council (ARC) initially intensified its research efforts 
into the cultivation and processing of honeybush tea, with the aim of improving the product quality to maintain 
export standards. It was only later, when more became known about its phytochemical composition, that the 
potential health-promoting attributes of honeybush also fell under the research spotlight, as summarised in the 
review article by Joubert et al. (2019).  
The bulk of freshly harvested honeybush plant material (Fig. 2.7) undergoes an oxidative 
“fermentation” process, during which comminuted plant material is moistened and exposed to temperatures 
above 60 °C, in order to obtain the typical honey-like flavour, sweet taste and reddish-brown colour 




reduction in polyphenol content and radical scavenging capacity, i.e. antioxidant activity (Joubert et al., 2008a; 
Beelders et al., 2015; Erasmus et al., 2017). Therefore, unfermented honeybush, which is not exposed to this 
high-temperature oxidation process, is the preferred raw material for the production of extracts or tea products 
with specific health-promoting claims, e.g. antioxidant or anti-diabetic properties. 
    
Figure 2.7 Hand-harvesting of Cyclopia genistoides (left) and drying (right) of traditional fermented 
honeybush tea (Image credits: Agulhas Honeybush Tea Company; http://www.agulhashoneybushtea.co.za). 
 
 
2.3.1. Major phenolic compounds 
 
The potential health-promoting benefits of honeybush, and in particular C. genistoides, have been 
attributed to the presence of specific subclasses of polyphenolic compounds, namely the xanthones, mangiferin 
(1,3,6,7-tetrahydroxyxanthone-2-β-D-glucoside) and isomangiferin, and the benzophenones, 3-β-D-
glucopyranosyliriflophenone (I3G), 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone (IDG) and 
3-β-D-glucopyranosylmaclurin (M3G) (Table 2.2). De Nysschen et al. (1996) reported the presence of 
mangiferin, a bioactive xanthone with well-documented health benefits (Masibo & He, 2008; Vyas et al., 
2012), in 19 out of 22 different Cyclopia species, but the first report of a benzophenone derivative in honeybush 
was made by Kokotkiewicz et al. (2012), who isolated and identified I3G from an extract of C. subternata. In 
a subsequent study, I3G and M3G were isolated from unfermented C. genistoides extract by semi-preparative 
high performance liquid chromatography (HPLC) (Kokotkiewicz et al., 2013). This was the first 
documentation of M3G, a benzophenone with a close structural relation to mangiferin, in the genus Cyclopia. 
Beelders et al. (2014b) tentatively identified a hitherto unknown iriflophenone-di-C-hexoside in aqueous 




Analysis of hot water infusions at ‘cup-of-tea’ strength of a large number of samples of fermented plant 
material of C. subternata, C. maculata, C. longifolia and C. genistoides, also demonstrated the presence of 
IDG in C. subternata and C. longifolia (Schulze et al., 2015). Considering the xanthones and benzophenones 
of interest, IDG is the least susceptible to thermal degradation (Beelders et al., 2015, 2017). 
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Mango tree bark (Mangifera indica) remains the principal source of mangiferin for commercial extract 
production, but mango peels and seeds (Dorta et al., 2012, 2013, 2014; Irondi et al., 2014; Gondi & Prasada 
Rao, 2015) and leaves (Ling et al., 2009; Zhang et al., 2011; Fernández-Ponce et al., 2012; Zhang et al., 2013a; 
Zou et al., 2013; Salomon et al., 2014; Vo et al., 2017) have also been utilised as raw materials. Other reported 
plant sources of mangiferin include Salacia spp. (Yoshikawa et al., 2001; Li et al., 2004), the rhizomes of 
Anemarrhena asphodeloides, a traditional Chinese medicinal plant (Miura et al., 2001), the leaves of a variety 
of coffee species (Coffea spp.) (Talamond et al., 2011; Campa et al., 2012) and Chinese agarwood (Aquilaria 
sinensis) (Ito et al., 2012). The mangiferin content of mango leaf extract has been reported as ca. 3.6% (Zou 
et al., 2013), and given that similar mangiferin content has been reported for unfermented C. genistoides 
(Joubert et al., 2003), this species of honeybush could serve as another renewable natural source of mangiferin. 
Even higher levels of mangiferin (> 7%) have been measured in C. genistoides extracts that were produced 
using only leaf material (Joubert et al., 2014). 
Efforts to improve the health-promoting potential of plant-based foods and their extracts also extend 




produce crops with the highest possible content of bioactive phytochemicals (Martin, 2013). Accordingly, 
researchers have explored new ways to optimise the major bioactive content in honeybush extracts, either at a 
pre-harvest or post-harvest level. The content of xanthones and benzophenones in honeybush extracts depends 
on the species used for extract production, as substantial variation in the phenolic profiles of different Cyclopia 
species has been demonstrated (De Beer & Joubert, 2010; De Beer et al., 2012; Schulze et al., 2015). The 
mangiferin content of aqueous honeybush extracts could range from as low as 1–3% (g/100 g dried extract) 
for C. subternata to 12% for C. genistoides (Beelders et al., 2015). The latter species has been identified as 
the preferred raw material for the production of xanthone and benzophenone-enriched extracts intended for 
nutraceutical or food ingredient applications (Bosman et al., 2017). The comparatively high xanthone content 
of C. genistoides (4.1%) vs. that of three other species (C. intermedia, C. sessiflora and C. maculata—all 
below 2%) was reported in a paper by Joubert et al. (2003). In a subsequent study aimed at the development 
of a near-infrared spectroscopy (NIRS) calibration model for predicting the mangiferin content of dried, green 
C. genistoides, the mangiferin content of 240 samples, determined by HPLC, ranged between 0.7 and 7.2% 
(mean = 3.7%) (Joubert et al., 2006). Much of this variation in C. genistoides extracts could be attributed to 
the inherent genetic variation between seedlings of the same plant species. 
Two studies investigated the effect of the harvesting date on the phenolic content of C. genistoides so 
that an optimal harvesting time could be identified. In the first study (Joubert et al., 2003) the harvesting period 
commenced at the end of March 2001 and ran to mid-July with 5-week intervals between harvesting dates. 
The mangiferin content steadily decreased over the 15-week period, although the isomangiferin content did 
not change. This indicates that harvesting in late March/early April would result in higher total xanthone 
content. The same study also demonstrated significantly higher total xanthone content for the Overberg-type 
vs. West Coast-type C. genistoides. Seeds were sourced from natural plantations in these areas, but the 
seedlings were all planted at one location (Pearly Beach area, Overberg) (E. Joubert, ARC Infruitec-
Nietvoorbij, personal communication). This theme was explored further in a more comprehensive study 
(Joubert et al., 2014) that investigated the impact of the seed source, as well as harvesting times and intervals 
(over a longer period), on the phenolic contents of three types of C. genistoides from the same plantation. Only 
a few shoots/plants were harvested at a time, and only the leaves were analysed to eliminate the potentially 
confounding effect of different leaf-to-stem ratios in the processed plant material. In a single year of sampling, 
mangiferin content decreased from March to July, mirroring the previously reported results (Joubert et al., 
2003). Summer harvesting, when environmental stressors such as water deficits and solar radiation are at a 
peak, was associated with higher xanthone and benzophenone content in C. genistoides leaves. Furthermore, 
plants derived from the GK (Cape Peninsula) seed source had higher xanthone and benzophenone content 
compared with the GD (Western Seaboard) and GP (Southern Seaboard) seed sources, despite being cultivated 
at the same plantation, near Pearly Beach. Harvesting intervals also affected the xanthone content of 
C. genistoides leaves. Although the isomangiferin content remained unchanged, significantly lower mangiferin 
content (P < 0.05) was measured in leaves from 19-month-old shoots compared with leaves from 12-month-
old shoots. It should be noted that C. genistoides is a resprouter, i.e. new growth sprouts from a thickened 




harvesting interval (Joubert et al., 2014). Subsequently, North et al. (2017) investigated the effect of harvest 
date on the tea quality of non-irrigated commercial C. genistoides plantations, and found that the mangiferin 





After harvesting, the high-temperature oxidation process that Cyclopia plant material undergoes to 
produce the traditionally “fermented” form of honeybush tea results in decreased total polyphenol and 
individual phenolic contents of the plant material, as well as a reduction in the total extractable soluble solids 
content (Joubert et al., 2008b; De Beer & Joubert, 2010; Schulze et al., 2014). Thermal processing of 
honeybush induces a number of chemical reactions, including the cleavage of O-linked sugar moieties, 
isomerisation, dimerisation and the conversion of benzophenones to xanthones as demonstrated specifically 
for the conversion of M3G to mangiferin, and to lesser extent, isomangiferin (Beelders et al., 2017). 
Simulated industrial fermentation conditions (80 °C/24 h and 90 °C/16 h) were applied to investigate 
the degradation of phenolic compounds in C. genistoides plant material (Beelders et al., 2015). The data 
confirmed first order degradation kinetics, with thermal stability of the major compounds decreasing in the 
order IDG > isomangiferin > I3G > mangiferin. The benzophenones became more thermally stable with the 
addition of a glucosyl moiety (IDG > I3G), whereas glucosylation of the basic dibenzo-γ-pyrone structure at 
C-4 instead of C-2 resulted in greater thermal stability for the xanthones (isomangiferin > mangiferin) in the 
plant matrix. The same phenomenon was observed for the individual compounds (mangiferin, isomangiferin, 
I3G, IDG and M3G) in aqueous model solutions at a pH of 5 (Beelders et al., 2017). A greater degree of B-
ring hydroxylation in the benzophenones was associated with increased degradation rate constants. The 
oxidative coupling of M3G that results in the formation of the xanthone regio-isomers was associated with a 
substantial increase in thermal stability. Higher temperature was associated with increased degradation rates 
for all compounds in the model solutions, as well as in the plant matrix. The thermal stability of mangiferin 
was investigated over a pH range of 3–7, and degradation rates were markedly increased at a higher pH 
(Beelders et al., 2018a). 
Pauck et al. (2017) determined that spray-drying (inlet temperature of 180 °C and outlet temperature 
of 90–100 °C) had no detrimental effect on the antioxidant activity or the mangiferin, isomangiferin and I3G 
content of C. subternata extract, whether a carrier (inulin or corn syrup solids) was added or not. In a 
subsequent related study (De Beer et al., 2018), small losses of mangiferin, isomangiferin and I3G were 
observed when powdered C. subternata honeybush iced-tea formulations were subjected to six months of 
storage at 25 °C/60% relative humidity (RH). Mangiferin had higher degradation rates than isomangiferin, 
another confirmation of the relative stability as demonstrated by Beelders et al. (2017) in a model solution. 
They also noted that the presence of an ascorbic acid-citric acid mixture in the powdered iced tea formulations 
drastically increased the degradation rate of phenolic compounds under accelerated storage conditions 






Many phytochemicals have gained attention because of in vitro bioactivity, but the question often 
remains whether those same effects could be replicated in vivo, following absorption, distribution and 
metabolism of the bioactive compounds (Bohn et al., 2015). Even though many phytochemicals may exert 
potent bioactive effects in vitro, they may not be suitable candidates for nutraceutical development because of 
low systemic bioavailability, i.e. failure to reach and maintain therapeutic blood plasma concentrations. Hou 
et al. (2012) reported 40 ng/mL as the maximum blood plasma concentration that was measured one hour after 
oral administration of 0.9 g mangiferin to humans. No increase in the blood plasma concentration was seen 
when the mangiferin dose was increased, with poor intestinal absorption and the hepatic first-pass effect being 
suggested as possible reasons.  
A recent study measured the phenolic content and antioxidant activities of four varieties of mango 
bark extract, as well as the intestinal permeability of their major phenolic compounds, including mangiferin 
(Vazquez-Olivo et al., 2019). In a Caco-2 cell assay, considered to be a good model for assessing in vitro 
intestinal permeability (Balimane et al., 2006; Bernardi et al., 2019), mangiferin showed higher intestinal 
permeability (3- to 4.8-fold) as part of the mango bark extract than as a pure standard (Vazquez-Olivo et al., 
2019). This suggests that the absorption of mangiferin could be enhanced by the presence of other constituents 
in the extract. Similarly, Tian et al. (2016b) determined that mangiferin absorption was higher as a constituent 
of Rhizoma Anemarrhenae extract than as a pure standard. A related study (Tian et al., 2016a) reported that 
hepatic first-pass metabolism only slightly contributed to the low bioavailability of mangiferin, with limited 
accumulation of mangiferin and norathyriol, the aglycone of mangiferin, measured in the liver. In a study on 
the regulation of lipid and glucose homeostasis (Zhang et al., 2013b), a methanolic extract of mango leaves 
was administered to mice for eight weeks at 200 or 500 mg/kg body weight (BW). The accumulation of 
mangiferin in soleus muscle was less than I3G in both administration groups, suggesting that the systemic anti-
lipogenic effects of the extract were less attributable to mangiferin than had previously been proposed. 
Bock et al. (2008) fed a mangiferin-enriched C. genistoides extract to pigs at 74 mg mangiferin/kg BW 
for 11 days, and subsequently collected blood plasma, urine and faeces samples at various time intervals. Only 
8.2% of the initial mangiferin intake was detected in the faecal samples. Urine samples contained two 
metabolites of mangiferin, methyl mangiferin and norathyriol, whereas the plasma samples contained only 
norathyriol. Similarly, Geodakyan et al. (1992) had failed to detect mangiferin in rat blood plasma after the 
oral administration of a single dose at 50–500 mg/kg BW. The results suggest that the in vivo deglycosylation 
of mangiferin to norathyriol in the colon is followed by absorption into the systemic circulation. Hattori et al. 
(1989) previously identified norathyriol as a product of in vitro anaerobic fermentation of mangiferin by a 
mixture of human intestinal bacteria. 
The low systemic bioavailability of mangiferin can also be related to its violation of Lipinski’s ‘‘rule 
of five’’, which enables the prediction of the bioavailability of molecules on the basis of specific molecular 
properties (Clark & Pickett, 2000; Bergström et al., 2014). The relevant physicochemical properties of the 




by Lipinski et al. (1997), refers to a set of physicochemical criteria (involving the number five or multiples of 
five) to which a compound should adhere for acceptable intestinal permeability. According to the rule, an 
orally active drug should violate no more than one of the following criteria: 
• Molar mass < 500 g/mol 
• No more than 10 hydrogen bond acceptors (all nitrogen and oxygen atoms) 
• No more than 5 hydrogen bond donors (all nitrogen-hydrogen and oxygen-hydrogen bonds) 
• Octanol-water partition coefficient (log P) less than 5 
 
The low oral bioavailability of acarbose (< 2%) (Puls et al., 1977; Kumar & Sinha, 2012; Williamson, 
2013) can be related to its “rule of five” violations (Table 2.3), which contributes towards its potency as an 
inhibitor of intestinal enzymes, as it is concentrated at its therapeutic target by efflux mechanisms. In practice, 
there are exceptions to the “rule of five”, and the criteria for predicting oral bioavailability have been expanded 
by Veber et al. (2002), who reported that good oral bioavailability can be predicted by the following additional 
criteria: 
• No more than 10 rotatable bonds 
• Polar surface area of 140 Å2 or less 
 
 
Table 2.3 Physicochemical properties of acarbose and major Cyclopia genistoides phenolics relevant to the 



















Rule of 5 
violations 
Mangiferin 422 11 8 0.13 2 197 2 
Isomangiferin 422 11 8 0.13 2 197 2 
I3Ga 408 10 8 2.35 4 188 2 
IDGb 570 15 11 0.35 7 267 3 
M3Gc 424 11 9 2.05 4 208 2 
Acarbose 646 19 14 –4.16 9 321 3 
All values were predicted by ACD/Labs Percepta software and obtained from the Royal Society of Chemistry online 
database (http://www.chemspider.com); a 3-β-D-glucopyranosyliriflophenone; b 3-β-D-glucopyranosyl-4-O-β-D-
glucopyranosyliriflophenone; c 3-β-D-glucopyranosylmaclurin 
 
 
Mortimer (2014) investigated the transport of polyphenols across porcine small and large intestine, 
using a flow-through diffusion system with a methanolic extract of C. subternata. The data indicated 
concentration-dependent diffusion across the small intestine, with 8.0% of the benzophenones and 7.1% of the 
xanthones moving across the barrier. No transport of any target analytes was detected across the large intestine. 
Furthermore, an absorptive apparent permeability coefficient ( ) was calculated for mangiferin (2.23 × 10−6 
cm/s), isomangiferin (1.91 × 10−6 cm/s) and I3G (2.64 × 10−6 cm/s). There is no clear consensus in literature 




as part of a general screening process in drug absorption studies. The  is defined as the initial flux of 
compound through the membrane, normalised by the donor sample concentration and membrane surface area. 
It is typically determined by fitting a straight line to the initial portion of the recorded amounts in the receiver 
compartment (possibly disregarding the first few data points where there is obvious lagging of the transfer 
process) (Palumbo et al., 2008). Various authors have attempted to establish a relationship between in vitro 
permeability of Caco-2 monolayers and human absorption in vivo, but the reported threshold  values above 
which 100% absorption can be predicted have varied between 1 × 10−6  cm/s (Hidalgo et al., 1989) and 
6 × 10−5 cm/s (Rubas et al., 1993). Such differences could be attributed to varying experimental conditions, 
cell characteristics or cell culture conditions (Grès et al., 1998). 
Raaths (2016) conducted ex vivo transport studies, using a Sweetana-Grass diffusion apparatus, of the 
major xanthones and benzophenones in crude extracts and enriched fractions of C. genistoides across porcine 
small intestinal sections. Efflux ratios were calculated using  for the apical-to-basolateral (AB) and 
basolateral-to-apical (BA) directions (Table 2.4). Efflux ratios > 1 were calculated for IDG, I3G, mangiferin 
and isomangiferin, indicating that the rate of efflux exceeded the trans-epithelial absorption rate, which was 
attributed to active efflux by P-glycoprotein transporters (Ashford, 2013). Sanugul et al. (2005) isolated the 
bacterial species involved in the metabolism of mangiferin from a mixture of human faecal bacteria. They 
reported that an anaerobic Bacteroides species transformed mangiferin to the aglycone norathyriol by cleavage 
of the C-glucosyl bond, and that the enzyme responsible for this action is (1) induced by mangiferin and (2) 
demonstrably different from the enzyme that cleaves O-glucosyl bonds. Mangiferin also did not affect bacterial 
α- and β-glucosidase activities (Sanugul et al., 2005).  
 
Table 2.4 Apparent permeability coefficients (Papp) and efflux ratios for major Cyclopia 
genistoides phenolics obtained from ex vivo intestinal transport studies using porcine jejunum 
in a Sweetana-Grass-type diffusion apparatus (Raaths, 2016). 
Compound 
 !""#$  
(× 10−7 cm/s) 
 !""$#  
(× 10−7 cm/s) 
Efflux 
ratio 
 IDGa 4.9 6.7 1.36 
 I3Gb 2.4 4.5 1.90 
 Mangiferin 2.1 3.0 1.43 
Isomangiferin 3.5 4.6 1.30 
AB, apical-to-basolateral direction (absorption); BA, basolateral-to-apical direction (efflux);  a IDG, 
3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone; b 3-β-D-glucopyranosyliriflophenone 
 
 
Various approaches to enhancing the bioavailability of mangiferin have been investigated, e.g. 
complexation with bile salts, muco-adhesive polymers and surfactants (Wang et al., 2013), hydroxypropyl-β-
cyclodextrin (Zhang et al., 2010a) and mesoporous silica (Baán et al., 2014), as well as microencapsulation 
with chitosan (De Souza et al., 2009, 2013). Ma et al. (2014) attempted to enhance the solubility and membrane 




mangiferin was enhanced, as was its intestinal permeability in a rat in situ perfusion model. They concluded 
that the complexation technique increased bioavailability of mangiferin 2.3-fold compared with mangiferin 
alone. Another study (Bhattacharyya et al., 2014) reported that complexation of mangiferin with soy 
phospholipid enhanced its bioavailability 9.75-fold in rat serum compared with mangiferin alone. 
Low oral bioavailability of dietary polyphenols such as mangiferin suggests a low risk for systemic 
toxic effects. Reddeman et al. (2019) conducted a range of toxicological studies on a mango leaf extract 
containing 60% mangiferin and 5% isomangiferin. Data from an in vitro bacterial reverse mutation test 
revealed no evidence of genotoxicity. There was also no evidence of in vivo mutagenicity in mice (as measured 
by micronucleus testing) following administration of the extract in two doses, 24 h apart, at 500, 1000 or 2000 
mg/kg BW. Similarly, no mortality or toxic effects were observed in normal rats administered with the extracts 
at doses of 500, 1000 or 2000 mg/kg BW per day for 90 days. These results support those of previous 
investigators who reported no toxic or mutagenic effects for Vimang®, a commercial M. indica extract 
(mangiferin content 10–20%) (Rodeiro et al., 2006; González et al., 2007; Garrido et al., 2009), purified 





As is the case with other herbal extracts that consist of complex mixtures of various phytochemicals, 
honeybush extracts hold a number of potential health benefits as reviewed by Joubert et al. (2019). Of 
relevance in the context of prevention of the metabolic syndrome, is antioxidant (Hubbe & Joubert, 2000; 
Joubert et al., 2008b), anti-diabetic (Muller et al., 2011; Beelders et al., 2014a; Chellan et al., 2014; Bosman 
et al., 2017) and anti-obesity (Dudhia et al., 2013; Pheiffer et al., 2013; Jack et al., 2017, 2018) effects. 
Honeybush is also naturally caffeine-free (Stander et al., 2019) and has low tannin content, similar to rooibos 
tea (Joubert et al., 2008a). Mangiferin, the predominant phenolic compound in C. genistoides, is also arguably 
its most extensively researched bioactive constituent. The various health-promoting properties reported for 
mangiferin have already been reviewed in detail (Wauthoz & Balde, 2007; Vyas et al., 2012; Benard & Chi, 
2015), as it was the first xanthone to be investigated for potential pharmacological applications (Pinto et al., 
2005). It has even been described as a “natural miracle bioactive” by one particularly enthusiastic group of 
reviewers (Imran et al., 2017). Norathyriol, the aglycone of mangiferin, is not as extensively researched and 
gets few or no mentions in most of the aforementioned review articles that focus on mangiferin, but some 
recent studies have reported anti-diabetic and anti-obesity bioactivity for norathyriol as well (Wilkinson et al., 




The thriving market for nutraceuticals that has emerged in recent years is driven in part by the growing 




oxidant state (Cory et al., 2018). Mangiferin itself is well-documented as a potent antioxidant (Sekar, 2015). 
Consequently, a number of mangiferin-containing nutritional supplements have been developed and brought 
to market, including Vimang®, a Cuban mango bark extract that is promoted specifically for its antioxidant 
effect, which has been scientifically validated (Sánchez et al., 2000; Núñez-Sellés et al., 2002; Pardo-Andreu 
et al., 2008). Human umbilical vein endothelial cells treated with mangiferin showed enhanced in vitro 
resistance to oxidative stress induced by hydrogen peroxide (Luo et al., 2012). Mangiferin was also one of the 
more active antioxidants among honeybush phenolics tested using different assay methods (Hubbe & Joubert, 
2000; Joubert et al., 2008b) and is a major contributor to the antioxidant effect reported for honeybush extracts 
(Joubert et al., 2011). The peroxyl radical scavenging abilities of isomangiferin and I3G were previously 
shown to be similar to and substantially higher than that of mangiferin, respectively (Malherbe et al., 2014). 
On-line HPLC-radical scavenging assays also showed that M3G displayed an antioxidant effect, but the lack 
of an authentic standard precluded quantification of the activity (Malherbe et al., 2014).  
Carvalho et al. (2007) tested the effect of purified mangiferin (> 95%) from mango bark on gastric 
mucosal injury in rodents. Orally administered mangiferin at a dose of 30 mg/kg BW improved mucosal 
damage induced by indomethacin and ethanol by 57% and 63%, respectively, which compared favourably 
with the positive control, lansoprazole (30 mg/kg BW), which attenuated mucosal damage by 76%. They also 
showed that intra-duodenal administration of mangiferin (30 mg/kg BW) in pylorus-ligated rats reduced 





Considering the close link between obesity and T2D, and their common co-occurrence in patients, 
some authors have suggested adopting the term diabesity to refer to this condition (Astrup & Finer, 2000; 
Farag & Gaballa, 2011). The aforementioned antioxidant effects of honeybush are relevant in the context of 
treating diabesity, since the links between oxidative stress and the chronic complications of diabetes, 
compounded by obesity and dyslipidaemia, have been well established (Pitocco et al., 2013; Marseglia et al., 
2015; Ononamadu et al., 2019). Nutraceutical products that present specific anti-diabetic claims have also 
been brought to market in recent years, e.g. Salaretin®, a standardised extract of Salacia reticulata containing 
1% mangiferin, which is sold by the Sabinsa Corporation (New Jersey, USA). This product is specifically 
marketed as an anti-diabetic phytonutrient for blood glucose control, based on its traditional use in Ayurvedic 
medicine (Anonymous, 2018). CycloferinTM, distributed by a US company, Sweet by Nature Inc., is an anti-
diabetic nutraceutical, derived from honeybush, that has been shown to reduce blood glucose in streptozotocin 
(STZ)-induced diabetic rats that received no exogenous insulin treatment (Sathialingam et al., 2019). However, 
no further details are provided regarding the species and processing state of the plant material or the 
standardisation of the product in terms of specific bioactive compounds. Many researchers have attempted to 
elucidate the specific mechanisms underlying the anti-diabetic effect of such extracts. Among the likely 




Girón et al. (2009) suggested that mangiferin-containing Salacia oblonga extracts may exert an anti-
diabetic effect by the up-regulation of GLUT4 glucose transporter expression and translocation in myocytes. 
The authors proposed that this effect of mangiferin was most likely mediated through the induction of 
peroxisome proliferator-activated receptor-γ (PPAR-γ) and an increase in phosphorylation of 5′-adenosine 
monophosphate (AMP)-activated protein kinase. Two studies investigating a hydro-ethanolic extract of mango 
containing 17 different benzophenone-C-glucosides, including I3G and M3G (Zhang et al., 2011, 2013a), 
reported inhibition of triglyceride (TG) accumulation in 3T3-L1 adipocyte cell cultures by the extract. This 
effect was attributed to intracellular activation of AMP kinase gene expression and down-regulation of fatty 
acid synthase, which results in the increased breakdown of adipose tissue. Mangiferin also had beneficial 
effects on the blood TG and lipoprotein profiles of type 2 diabetic rats (Muruganandan et al., 2005; 
Dineshkumar et al., 2010). Significant reductions were noted in the total cholesterol, total TG, low-density 
lipoprotein (LDL) and very low-density lipoprotein (VLDL) concentrations, accompanied by increased high-
density lipoprotein (HDL) concentrations. Another potential anti-diabetic mechanism of mangiferin has been 
reported in mice, namely the inhibition of protein tyrosine phosphatase 1B (PTP1B), which prevents 
dephosphorylation (deactivation) of activated insulin receptors (Hu et al., 2007). Activated insulin receptors 
enhance glucose uptake by cells, which makes this an ideal target for blood glucose-lowering treatment.  
Dudhia et al. (2013) investigated the effect of a hot water extract of unfermented C. maculata on 
markers of adipogenesis in an in vitro 3T3-L1 cell model. Mangiferin was the predominant phenolic in the 
extract, which inhibited the accumulation of intracellular TGs and suppressed the gene expression of PPAR-
γ, emphasising the potential of the extract as an anti-obesity nutraceutical. Another study by the same research 
group reported that hot water extracts of C. maculata stimulated lipolysis in mature 3T3-L1 adipocytes 
(Pheiffer et al., 2013), suggesting that the consumption of honeybush tea may present a practical approach to 
treating the underlying causes of obesity and thereby prevent or delay the onset of obesity-related 
complications such as T2D.  
A crude, polyphenol-enriched fraction of C. intermedia (CPEF), containing 8.6% mangiferin, 
decreased BW gain by 21% over 28 days in obese db/db mice supplemented at 351.5 mg/kg BW, without 
affecting food or water consumption (Jack et al., 2017). Fractionation of CPEF by high-performance counter-
current chromatography in a subsequent study (Jack et al., 2018) produced separate fractions enriched 
predominantly in IDG and mangiferin, respectively. Both fractions inhibited lipid accumulation in 3T3-L1 pre-
adipocytes and decreased lipid content in mature 3T3-L1 adipocytes in a dose-dependent manner. However, 
the enriched fractions had less potent lipolytic effects than CPEF, which highlights the importance of 
considering synergistic effects in phyto-extracts.  
Muller et al. (2011) investigated the efficacy of a hot water extract of C. intermedia in reducing 
hyperglycaemia in two different diabetic Wistar rat models, namely STZ-induced (non-insulin resistant) 
diabetic rats and diet-induced obese insulin resistant (OBIR) rats. The latter model was chosen specifically for 
its well-established similarities to the pathophysiology of human obesity and the metabolic syndrome (Buettner 
et al., 2007). An aqueous extract was chosen because it most closely represents the traditional preparation 




be expected following organic solvent extraction. The extract, which contained 5.8% mangiferin and 1.6% 
isomangiferin, significantly lowered the mean blood glucose concentration compared with the baseline in the 
STZ-induced diabetic model after an acute dose of 50 mg/kg BW. Reductions of 33.5% (P < 0.05), 34.3% (P 
< 0.05) and 35.6% (P < 0.01) were observed after 4, 5 and 6 h, respectively. Lower doses of the extract (5 or 
25 mg/kg BW) did not significantly affect blood glucose levels. Chronic treatment of OBIR rats with the 
extract at various concentrations over three months brought their initial hyperglycaemic fasting blood glucose 
concentrations (control = 12.2 mmol/L) down to within normoglycaemic limits (4.8–5.4 mmol/L). This 
compared favourably with the positive controls, metformin (6.3 mmol/L) and rosiglitazone (5.6 mmol/L). All 
dosage concentrations (77.2–531.3 mg/kg BW per day) of the extract were successful in reducing fasting blood 
glucose. The 3-month treatment with the extract also effectively reduced peak blood glucose levels in an 
intravenous glucose tolerance test, except at the lowest tested daily intake, which, along with metformin and 
rosiglitazone, had no effect in this regard (Muller et al., 2011). Additionally, the chronic treatment of the OBIR 
rats significantly reduced the total plasma cholesterol levels (P < 0.05) by 32–39%, as well as reducing the 
size of pancreatic α-cells and the ratio of α to β-cells compared to untreated rats. The latter two parameters are 
associated with worsening diabetic pathogenesis, marked by a decline in β-cell mass, increase in α-cell number 
and volume, and a consequent increase in the ratio of α to β-cells (Liu et al., 2011c). 
Chellan et al. (2014) investigated the effect of pre-treatment with an aqueous extract of unfermented 
C. maculata on pancreatic β-cell cytotoxicity and STZ-induced diabetes in Wistar rats. The extract contained 
6.2% mangiferin, 2.1% isomangiferin and 1.1% I3G. The ameliorative effect of the extract (300 mg/kg BW 
per day) was observed as a significant reduction in the fasting blood glucose levels (P < 0.05), and a significant 
reduction in peak glucose concentrations in an oral glucose tolerance test (P < 0.01). The extract pre-treatment 
also improved serum TG levels and lowered the glucose-to-insulin ratio, which suggests an increase in glucose 
uptake. Increased pancreatic β-cell proliferation and area were also observed at a higher extract dose 
(300 mg/kg BW/day), but not at a lower dose (30 mg/kg BW/day). The results strongly suggest that 
unfermented C. maculata extract may provide in vivo blood glucose-lowering effects along with protection of 
pancreatic function through a possible antioxidant effect. 
Schulze et al. (2016) investigated the effects of ten different hot water extracts of Cyclopia subternata 
(applied at concentrations of 0.1–100 µg/mL), on glucose uptake in skeletal muscle cells. Although there was 
no clear pattern, all the hot water extracts were effective in enhancing glucose uptake at even at the lowest 
dose. At a dose of 10 µg/mL, the percentage glucose uptake values ranged between 135 and 157%. They gained 
further insight into the role of the xanthones in enhancing glucose uptake in vitro by testing commercial 
standards of mangiferin and isomangiferin under similar conditions as the hot water extracts, and found that 
the xanthones increased glucose uptake significantly (P < 0.01) over the concentration range 10−3 to 10 µM. In 
a subsequent oral glucose tolerance test, a reference active hot water extract was administered in a single dose 
to STZ-induced diabetic Wistar rats at 30, 300 or 600 mg/kg BW. At the highest dose of extract treatment, the 
peak serum glucose levels at 30, 60 and 120 min after administration were significantly lower than the positive 




 Table 2.5 summarises the major findings of additional studies that reported anti-diabetic or anti-
obesity effects for the compounds of interest in the present study, either as purified standards or as constituents 
of plant extracts. It does not cover the most relevant anti-diabetic bioactivity in the context of the present study, 










Selected experimental details Notable findings 
Brito et al. (2019) 
Mangiferin isolated from 
Mangifera indica leaves 
 
Hydro-ethanolic extract of 
M. indica leaves (EMI) 
In vitro: cell viability assay and anti-
inflammatory activity in human macrophage 
THP-1 cell lines  
 
In vivo: non-diabetic Wistar rats; Mangiferin: 
oral administration at 40 mg/kg BW/day for 
16 days; EMI: oral administration at 
250 mg/kg BW/day for 16 days 
• In vitro results indicated a greater anti-inflammatory potential of EMI in 
relation to mangiferin 
• No cytotoxicity was reported for EMI or mangiferin 
• Mangiferin stimulated adipogenesis, and EMI attenuated adipogenesis and 
modulated expression of metabolic risk factors 
• Modulation of endocannabinoid system (CB1) and PPAR-γ receptors are 
likely to be implicated in the anti-obesity effect 
Dineshkumar et al. (2010) 
Mangiferin isolated from 
M. indica stem bark 
In vivo: STZ-induced diabetic rats; intra-
peritoneal administration at 
10 mg/kg BW/day for 30 days 
• Fasting serum glucose was significantly reduced by mangiferin (P < 0.05) in 
type 2 diabetic rats, with an effect comparable to the positive control, 
glibenclamide  
Guo et al. (2011) 
Mangiferin 
(commercial standard) 
In vivo: high-fat-fed hamsters; oral 
administration at 50 or 150 mg/kg BW/day 
for eight weeks 
• Mangiferin significantly reduced body, liver and visceral fat-pad weight, 
hepatic TGs, serum TG and FFA levels, and hepatic and muscle FFA levels 
• Mangiferin upregulated mRNA expression of PPAR-α, fatty acid translocase 
(CD36) and CPT-1 
• Mangiferin downregulated mRNA expression of SREBP-1c, ACC, DGAT-
2 and MTP 
• Amelioration of hypertriglyceridemia likely occurs via 1) downregulation of 
genes involved in lipogenesis in liver and 2) upregulation of genes involved 
in fatty acid β-oxidation in liver and skeletal muscle 
Ichiki et al. (1998) 
Mangiferin and mangiferin-7-
O-β-glucoside isolated from 
Anemarrhena asphodeloides 
rhizome 
In vivo: normal and STZ-induced diabetic 
KK-Ay mice; oral administration at 10, 30 or 
90 mg/kg BW to diabetic mice, and at 
90 mg/kg BW to normal mice; single dose 
• Mangiferin and mangiferin-7-O-β-glucoside lowered serum glucose levels 
and improved hyperinsulinaemia seven hours after oral administration 
in diabetic mice 
• Effect of mangiferin at 90 mg/kg BW was stronger than the positive 
control, tolbutamide, at 50 mg/kg BW 
• Hyperglycaemic and insulin modulation effect were not observed in 
normal (non-diabetic) mice 




Methanolic extract (ME) of 
agarwood (Aquilaria sinensis) 
(3.2% I3G) 
In vitro: glucose uptake in adipocytes from 
normal rats 
 
In vivo: STZ-induced diabetic mice 
ME: oral administration at 0.1 or 
1 g/kg BW/day for 21 days 
I3G: oral administration at 0.047 or 
0.47 g/kg BW/day for 21 days 
• ME (1 mg/mL), I3G (0.25 µM) and the positive control insulin (1.5 nM) 
increased glucose uptake in adipocytes by 152, 153 and 183%, respectively 
• ME (1 g/kg BW), I3G (0.47 g/kg BW) and insulin (8 U/kg BW) lowered 










Selected experimental details Notable findings 




In vitro: glucose uptake in human hepG2 cells 
In vivo: high-fat-fed STZ-induced diabetic 
Sprague-Dawley rats 
Mangiferin: oral administration at 
40 mg/kg BW/day for 28 days 
Combinations: (1) mangiferin 
(40 mg/kg BW/day) + metformin (50 or 
100 mg/kg BW/day); (2) mangiferin 
(40 mg/kg BW/day) + gliclazide (5 or 
10 mg/kg BW/day) for 28 days 
• Glucose uptake in hepG2 cells was enhanced, with positive interaction of 
mangiferin with both metformin and gliclazide (positive controls) observed 
at specific concentrations 
• Treatment with combinations reduced the markers of hyperglycaemia and 
oxidative stress in diabetic rats 
• Combination index analysis using CompuSyn software showed synergistic 
interaction of mangiferin with therapeutic doses of metformin 
(100 mg/kg BW) and gliclazide (10 mg/kg BW) 
Sellamuthu et al. (2013) 
Mangiferin isolated from 
Salacia chinensis 
In vivo: STZ-induced diabetic rats; oral 
administration at 40 mg/kg BW/day for 
30 days 
• Oral administration of mangiferin significantly lowered serum glucose 
and increased insulin levels, and significantly modulated pancreatic 
non-enzymatic antioxidant status (increased serum vitamin C, vitamin 
E and caeruloplasmin, and reduced glutathione content) and other 
oxidative stress biomarkers (TBARS and hydroperoxide) 
• Mangiferin treatment effectively regenerated insulin-secreting 
pancreatic islet cells 
Singh et al. (2018) 
Mangiferin isolated from 
Salacia oblongata leaves 
In vivo: STZ-induced diabetic rats; oral 
administration at 50 or 100 mg/kg BW/day 
for 15 days 
• Mangiferin decreased fasting blood glucose and reduced markers of 
oxidative stress in liver and pancreas 
• Mangiferin improved serum lipid profiles 
• Molecular docking assays suggest dual activation of GLUT4 and PPAR-γ 
pathway as potential mechanism 




In vitro: differentiation-induced human 
mesenchymal stem cells (hMSCs) cultured in 
10, 20 or 40 µM mangiferin for ten days 
• Adipocyte differentiation and lipid accumulation were significantly 
decreased in 40 µM mangiferin-treated groups when compared with the 
reference drugs (quercetin and orlistat) 
• Mangiferin inhibited pre-adipocyte differentiation in hMSCs within the 
first two days of treatment 
• Mangiferin downregulated adipogenic gene expression after hMSCs 
underwent induced adipocyte differentiation 
Xing et al. (2014) 
Mangiferin 
(commercial standard) 
In vivo: fructose-fed spontaneously 
hypertensive rats; oral administration at 5 or 
15 mg/kg BW/day for seven weeks 
• Mangiferin treatment (15 mg/kg BW) reduced the markers of fatty liver 
disease by inhibiting DGAT-2 expression at the mRNA and protein levels in 









Selected experimental details Notable findings 
Yoshikawa et al. (2002) 
Mangiferin isolated from 
Salacia reticulata roots 
 
Hot water extract of 
S. reticulata (SRHW) 
In vivo: female Zucker fatty rats; oral 
administration of SRHW at 
125 mg/kg BW/day for 27 days 
High-fat-fed male Sprague-Dawley rats; oral 
administration of SRHW at 
125 mg/kg BW/day for 31 days 
 
In vitro: tested effects of SRHW and 
mangiferin lipolysis and lipid-metabolising 
enzymes  
• SRHW reduced BW by 14% and peri-uterine fat accumulation in Zucker rats 
• BW and visceral fat in high-fat-fed Sprague-Dawley rats were unaffected by 
SRHW 
• SRHW inhibited porcine pancreatic lipase, rat adipose tissue–derived LPL 
and GPDH activities (IC50 = 264 mg/L, 15 mg/L and 54 mg/L, respectively) 
• Significant lipolytic effects were exerted by mangiferin at 100 mg/L 
• This effect may result from inhibition of insulin receptor phosphorylation 
Zhang et al. (2013b) 
Hydro-ethanolic extract of 
Mangifera indica leaves 
(7.8% mangiferin) (EMI) 
 
Mangiferin and I3G isolated 
from M. indica leaves 
In vitro: protein and gene expression assays 
in murine soleus muscle cells; assessment of 
lipolytic activity in 3T3-L1 pre-adipocytes 
 
In vivo: diabetic KK-Ay mice; oral 
administration of EMI at 200 or 
500 mg/kg BW/day for eight weeks 
• In vitro results suggested that EMI lowers serum glucose by upregulation of 
PI3K, protein kinase B, and glycogen synthase, and downregulation of 
PIP5K 
• EMI’s effect on regulation of lipid homeostasis was possibly exerted through 
the AMPK pathway by upregulation of AMPK and downregulation of ACC, 
HSL, FAS and PPAR-γ  
• Mangiferin and I3G significantly suppressed TG and FFA accumulation in 
mature 3T3-L1 cells at 10 µM compared with 10 µM rosiglitazone (positive 
control) 
• Mesentery fat and mesentery fat-to-BW ratio significantly reduced in 
500 mg/kg BW/day-treated diabetic mice 
• EMI administration significantly reduced serum TG and glucose in a dose-
dependent manner from 2 to 8 weeks 
• Serum FFA levels were reduced from 4 weeks of EMI administration, with 
an effect similar to the positive control, rosiglitazone 
ACC, acetyl-CoA carboxylase; AMPK, adenosine monophosphate kinase; BW, body weight; CPT-1, carnitine palmitoyltransferase 1; DGAT-2, acyl-CoA:diacylglycerol acyltransferase 2; EMI, 
ethanolic extract of Mangifera indica leaves; FAS, fatty acid synthase; FFA, free fatty acid; GLUT4, insulin-regulated glucose transporter; GPDH, glycerophosphate dehydrogenase; hMSC, human 
mesenchymal stem cells; HSL, hormone sensitive lipase; I3G, 3-β-D-glucopyranosyliriflophenone; LPL, lipoprotein lipase; ME, methanolic extract of Aquilaria sinensis; MTP, microsomal 
triglyceride transfer protein; PI3K, phosphoinositide 3-kinases; PIP5K, phosphatidylinositol-4-phosphate 5-kinase; PPAR, peroxisome proliferator-activated receptor; SREBP-1c, sterol regulatory 





2.3.2. Honeybush extracts, xanthones and benzophenones as α-glucosidase inhibitors  
 
A number of studies have investigated the inhibition of AG by xanthones and benzophenones, either 
synthesised (Liu et al., 2006; Li et al., 2011; Liu et al., 2012b) or extracted from plant sources including 
honeybush (Beelders et al., 2014a). In the latter case, rat intestinal AG was used to compare the in vitro 
inhibitory activities of IDG and M3G (isolated from C. genistoides) with standards of acarbose, I3G and 
maclurin (the aglycone of M3G). All the tested compounds inhibited AG in a dose-dependent manner, but 
none matched the efficacy of acarbose (Fig. 2.8). Comparing the inhibitory activities of the benzophenones at 
equimolar concentrations (e.g. 200 µM) revealed possible structure-activity relationships. Maclurin was the 
overall weakest AGI and less potent than M3G, which agrees with previously reported data for iriflophenone 
and I3G against AG of an unstated source (Feng et al., 2011). The additional O-glucopyranosyl group at C-4 
in the structure of IDG resulted in weaker inhibition of rat AG than that reported for I3G, its corresponding 
monoglucoside. Similarly, Feng et al. (2011) reported more potent inhibition of yeast AG by I3G compared 
with the iriflophenone diglucoside, 3-β-D-glucopyranosyl-5-β-D-glucopyranosyliriflophenone (i.e. both sugar 
attached by a C-C bond). Zheng et al. (2014) noted that the inhibitory activity of non-glycosylated xanthones 
against yeast AG was more potent than those of glycosylated xanthone analogues. The reverse was mostly true 
in mammalian α-glucosidases where glycosides of benzophenones were found to be more active than their 
respective aglycones (Beelders et al., 2014a). 
 
 
Figure 2.8 Percentage activity of rat intestinal α-glucosidase challenged with different concentrations of 3-β-
D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone (1), 3-β-D-glucopyranosyliriflophenone, 3-β-D-





The structures of I3G and M3G are closely related, and the significantly higher inhibitory activity (P < 
0.05) of M3G was attributed to its additional 3′-OH group. Li et al. (2009) reported that an additional 3′-OH 
group increased the inhibitory activity of polyhydroxyflavones against yeast AG. Other researchers have also 
shown that the addition of hydroxyl groups to the basic benzophenone (Hu et al., 2011) or xanthone structures 
(Liu et al., 2006) resulted in significantly increased inhibition of baker’s yeast AG. The position of the glucose 
moiety on the dibenzo-γ-pyrone structure of xanthones does not seem to affect the bioactivity, considering that 
Bosman et al. (2017) reported similar inhibitory activity for mangiferin and isomangiferin against rat intestinal 
AG. In another study (Raaths, 2016), benzophenone- and xanthone-enriched fractions of a C. genistoides 
extract and the extract itself were tested for their in vitro inhibitory activity against rat intestinal AG. This 
study is discussed in more detail in Section 2.5.3.3 that describes preparation of such fractions by adsorption 
chromatography. 
The reported AG inhibitory effects of mangiferin in literature, especially considered in the context of 
the source of the enzyme used in testing, are reviewed in Section 2.7.1 (Methodologies).  
 
2.4. Fate of acarbose and dietary polyphenols in the gastrointestinal tract 
 
Ever since polyphenol-enriched supplements were brought to the global market, concerns have been 
raised over the possible harmful effects of high doses of polyphenols in these products, often at levels not 
typical of the average diet (Hooper & Frazier, 2012). For example, green tea extracts are commonly marketed 
as weight-loss supplements, but high doses of green tea catechins have been associated with hepatotoxicity, 
possibly related to oxidative stress induced by EGCG and its systemic metabolites (Mazzanti et al., 2009; 
Lambert et al., 2010; Navarro et al., 2014). Given the poor intestinal absorption and low systemic 
bioavailability of dietary polyphenols (Bernardi et al., 2019), it is perhaps more prudent to consider what type 
of effects these compounds may have on the GIT and vice versa. Some potential adverse effects of excessive 
dietary polyphenol intake include the impaired absorption of other essential nutrients, e.g. thiamine and folic 
acid, due to pre-absorptive interactions, as well as the modulation of transporters or enzymes involved in drug 
metabolism, resulting in increased or reduced bioavailability of these drugs (Cory et al., 2018). The iron-
chelating effect of polyphenols, and the resulting inhibitory effect on iron absorption from the GIT, have also 
been noted (Hurrell & Egli, 2010). Polyphenol supplementation could cause iron deficiency in populations 
whose diets are already rich in iron-sequestering phytates, e.g. from sorghum, beans and millet. 
No regulatory recommendations are currently available for the safe consumption of dietary 
polyphenols (Cory et al., 2018). The drafting of such regulations would be a complicated process due to the 
sheer number of chemical compounds, their variable occurrence in foods, and the limited availability of sound 
scientific evidence from human studies (Williamson & Holst, 2008). The US Food and Drug Administration 
currently allows health claims only for antioxidant nutrients with known Recommended Daily Intake (RDI) 
values, e.g. vitamins A and C (Cory et al., 2018), while the European Food Safety Authority permits health 





The burgeoning consumer market for functional foods requires an efficient system for regulating the 
sale, manufacture and labelling of these products. Apart from ensuring safe and high-quality products, 
regulations regarding health-promoting or therapeutic claims should ensure that consumers are properly 
informed about a product’s intended uses and limitations. Siró et al. (2008) reviewed European, Japanese and 
US legislation and regulations relating to functional foods and nutraceuticals, including the use of health claims 
in marketing, and it is clear that there is no standardised global system to refer to. The Consumer Affairs 
Agency of Japan launched a new food labelling system called “Foods with Function Claims” (FFC) in April 
2015, which enables the food industry to independently evaluate and present scientific evidence for functional 
properties of products without the need for rigorous clinical trials (Kamioka et al., 2017; Maeda-Yamamoto 
& Ohtani, 2018; Iwatani & Yamamoto, 2019). The scientific data is also made available to the public in a 
searchable database that contained more than 1000 FFC entries as of May 2017, allowing consumers to make 
informed choices regarding their diet. In South Africa, guidelines and regulations on functional food health 
claims are still being developed. New regulations were published in 2012 (No. R146 of the Foodstuffs, 
Cosmetics and Disinfectants Act of 1972), which specifically addressed the labelling and advertising of 
foodstuffs with regard to health claims and the type of wording allowed on packaging or promotional material. 
It is clear from these regulations that any claims of therapeutic or curative properties for non-pharmaceutical 
products will be more stringently regulated in the future. More recent draft regulations have been published, 
including a new stipulation that “no person shall…compare a food with a good such as a complementary 
medicine”, which may only serve to “propagate the total confusion that exists in the interface between food, 
medicine and supplements” (Sunley, 2014). 
Diet can be seen as an environmental factor that affects the composition and metabolism of the 
microbial community in the mammalian intestine (Koropatkin et al., 2012; Cockburn & Koropatkin, 2016). 
However, the risks of high doses of polyphenol supplements are difficult to evaluate, as most studies 
investigating these risks have used in vitro assays that may not adequately reflect in vivo conditions (Ávila-
Gálvez et al., 2018; Cory et al., 2018). The safety of dietary polyphenols are often investigated in cellular or 
animal models at much higher concentrations than those found in the typical human diet, and therefore it 
remains unclear at which levels they could be added to food products to ensure a safe and beneficial effect 
(Cory et al., 2018). Many in vitro studies involve the direct exposure of polyphenol-enriched extracts or 
purified phenolic compounds to cell cultures, but this may hold limited physiological relevance as these studies 
do not always consider the bioavailability and tissue distribution of these compounds, nor their interactions 
with intestinal flora (Espín et al., 2017). Only a few in vitro studies have investigated the gut flora-derived 
metabolites or conjugated phase II metabolites of dietary polyphenols that actually reach the systemic 
circulation at sufficiently high levels to exert beneficial effects that could then be properly attributed to dietary 
polyphenol intake (González-Sarrías et al., 2017). 
Unabsorbed dietary polyphenols in the colon may actually provide health benefits by modulating 
specific pathways related to antioxidant and anti-inflammatory activity in the microbial ecosystem (Mosele et 
al., 2015; Bernardi et al., 2019). They may also exert a prebiotic effect by supressing the growth of pathogenic 




Guglielmetti et al., 2013; Boto-Ordóñez et al., 2014). The anaerobic fermentation of polyphenols by intestinal 
flora produces short-chain fatty acids (SCFAs) e.g. butyrate and acetate, as well as phenolic acids e.g. 
protochatecuic acid, that sustain the microbiome (Parkar et al., 2013; Ozdal et al., 2016). Unabsorbed 
polyphenols that reach the large intestine are either deglycosylated by bacterial enzymes, releasing aglycones 
that are broken down to simpler phenolic derivatives by dehydroxylation, demethylation or decarboxylation, 
or they are (to a lesser extent) absorbed from the colon (Dueñas et al., 2015). Some have suggested that the 
beneficial effects of dietary polyphenols could be attributed largely to their metabolites formed in the GIT, 
rather than the original forms contained in food products (Williamson & Clifford, 2010). Hattori et al. (1989) 
demonstrated the deglycosylation of mangiferin by a mixture of human intestinal bacteria, resulting in the 
formation of the aglycone, norathyriol, which is then subjected to further microbial metabolism (Bock et al., 
2008; Bock & Ternes, 2010; Liu et al., 2011a). Mangiferin was one of the major compounds in a traditional 
Chinese herbal medicine preparation (actual content not given) that was shown to enrich beneficial gut bacteria 
(Blautia and Faecalibacterium spp.) in T2D patients treated for 12 weeks (Tong et al., 2018). Baxter et al. 
(2019) reported that acarbose therapy altered the gut microbiota in mice fed on a high-starch diet by promoting 
the growth of Bacteroidaceae and Bifidobacteriaceae, but cessation of treatment resulted in a reversion of the 
microbiota to mirror that of the control group. This suggests that the modulation of intestinal flora by AGIs is 
not irreversible. The same study reported that the content of beneficial SCFAs, particularly butyrate, were 
substantially higher in both high-starch and high-fiber-fed mice that received acarbose therapy (Baxter et al., 
2019). 
The general introduction to this dissertation (Chapter 1) referred to the recent discussion around the 
anti-ageing effects of calorie restriction, i.e. reducing the dietary intake by 20–60% from ad libitum levels 
(Ingram & Roth, 2015), which activates stress response pathways that are associated with increased lifespan 
and improved health (Most et al., 2017). Digestive enzyme inhibitors like acarbose and mangiferin may show 
great potential as means to enhance longevity by acting as calorie restriction mimetics (CRMs), i.e. agents that 
mimic calorie restriction without actually restricting food intake (Ingram et al., 2006). A recent study showed 
that treatment with acarbose increased the median lifespan in male and female mice by 20% and 5%, 
respectively, and altered the composition of the gut microbiome and its fermentation products, the SCFAs, 
acetate, propionate and butyrate (Smith et al., 2019). The authors observed a correlation between faecal SCFAs 
and lifespan in mice, suggesting a role of the microbiome in the anti-ageing potential of digestive enzyme 
inhibitors. High concentrations of acetate, propionate and butyrate are associated with improved host energy 
balance and the prevention of diet-induced obesity (Lin et al., 2012a; Tremaroli & Bäckhed, 2012). Butyrate 
in particular is the preferred energy source of colonocytes and is considered one of the SCFAs with the greatest 
therapeutic potential because of its anti-inflammatory and antimutagenic properties (Hamer et al., 2007). 
Acarbose therapy in humans has also been associated with increased serum and faecal butyrate levels (Holt et 
al., 1996; Weaver et al., 1997; Wolever & Chiasson, 2000), which suggests that some restructuring of the 
microbiome takes place as a result of the increased flow of undigested CHOs to the colon. A study including 
52 prediabetic human volunteers showed that acarbose treatment stimulated the growth of SCFA-producing 




(50 mg taken 3 × day with meals for 4 weeks) also enhanced the growth of beneficial Bifidobacterium longum 
in a cohort study including 95 type 2 diabetics (Su et al., 2015). 
 
2.5. Enrichment of Cyclopia genistoides phenolics for nutraceutical development 
2.5.1. General overview 
 
The development of nutraceuticals derived from botanical extracts could present a number of 
challenges, including natural variation in the bioactive content due to genetic or agronomic factors (Jiang et 
al., 2013; Martin, 2013; Scotti et al., 2019) or the effects of various post-harvest processing steps (Harbourne 
et al., 2013). At the pre-harvest level, the enrichment of xanthone and benzophenone content in C. genistoides 
can start with specific farming practices, e.g. summer harvesting or the cultivation of selected genotypes 
containing higher levels of these compounds (Joubert et al., 2014; Bosman et al., 2017). Unfermented plant 
material should be used for producing a nutraceutical with the greatest potential bioactivity (Joubert et al., 
2003), as it has been shown that the fermentation process results in major losses in phenolic content and a 
reduction in the antioxidant activity of aqueous extracts (Joubert et al., 2008b; Beelders et al., 2015). 
Fermentation of the freshly harvested plant material is essential for the development of desirable sensory 
characteristics in honeybush tea (Joubert et al., 2011), but this is a less important consideration in the 
development of nutraceuticals, especially those intended to be taken as tablets or capsules. 
Bosman et al. (2017) optimised a food-safe, eco-friendly extraction protocol for a xanthone- and 
benzophenone-enriched extract of C. genistoides. Aqueous ethanol (EtOH) was selected as the extraction 
solvent, and the protocol was optimised in terms of EtOH concentration and extraction temperature using a 
central composite experimental design and response surface methodology. The practical optimum extraction 
conditions for a 10:1 (v/m) solvent-to-plant material ratio were identified as 30 min of extraction at 70 °C 
using 40% aqueous EtOH. The application of this optimised protocol to ten different batches of C. genistoides 
resulted in mean extract, xanthone and benzophenone yields of 37.8, 4.1 and 2.0 g/100 g plant material, 
respectively, with mean xanthone content of the extracts 14.8% and that of the benzophenones 7%. In addition, 
the mean in vitro inhibitory effect of the optimised extracts against rat intestinal AG was measured as 39.5%, 
tested at a fixed concentration of 100 µg/mL. This was less potent than acarbose, which inhibited 50% of the 
enzyme activity at 42 µg/mL. An important finding of the study was that extracts containing more or less the 
same xanthone and benzophenone content varied substantially in enzyme inhibitory activity (e.g. 46% for 
extract 1 and 35.5% for extract 3). Given that mangiferin and isomangiferin have the same activity, as 
demonstrated in the same study, this difference between extracts may be related to the difference in I3G and 
IDG content, and their relative activity, demonstrated by Beelders et al. (2014a). The I3G content of extract 1 









Despite the optimisation of extraction parameters for maximum target compound recovery, the use of 
organic solvents results in the co-extraction of plant matrix components, i.e. “crude” extraction in terms of 
target compound purity. Membrane separation technologies can be applied for further purification of crude 
extracts by the selective enrichment of compounds based on physical properties. Membrane-based filtration 
has been increasingly applied in the food industry ever since technological advances in the early 1990s greatly 
improved their efficiency, ease of operation and energy consumption (Li & Chase, 2010a; Kelly et al., 2019). 
It may refer to a number of different separation techniques, e.g. microfiltration, ultrafiltration, nanofiltration 
and reverse osmosis, which are all based on the general principle of selective membrane permeability, allowing 
for the separation of molecules or constituents based on differences in size or molecular weight (Fig. 2.9). The 
driving force behind the separation may be concentration gradients, high pressures or electrical potential 
differences. The basis of all membrane separation techniques is the selective permeability of compounds based 
on size exclusion, i.e. larger compounds are retained by the membrane while smaller compounds pass through 
(Li & Chase, 2010a). The fractions that are retained and that pass through a membrane are referred to as the 
retentate and the permeate, respectively. 
Ultrafiltration refers to a specific type of membrane separation process, based on size exclusion, where 
pore diameters generally range between 20 nm and 0.1 µm, with operating pressures of 2–10 bar (Cuperus & 
Smolders, 1991). It is sometimes used as a primary purification step for polyphenols before a more high 
resolution analysis (Prodanov et al., 2008). Membrane filtration techniques provide a “green” alternative to 
traditional separation techniques because of its pressure-driven separation mechanism and avoidance of harsh 
chemicals or excessively high processing temperatures (Galanakis, 2012). This makes it a particularly 
appealing method for the processing of heat-sensitive bioactive phytochemicals. 
 
 
Figure 2.9 Typical ranges of pore diameters and operating pressures used in four types of size-exclusion 
membrane separation processes, viz. microfiltration (MF), ultrafiltration (UF), nanofiltration (NF) and reverse 





Membrane fouling is an often-encountered problem in industrial ultrafiltration. This can significantly 
reduce process efficiency and the membrane lifespan. Fouling occurs as a result of concentration polarisation, 
a phenomenon where rejected solute molecules aggregate in a concentrated layer at the membrane surface 
(Porter, 1972). This causes blockage or constriction of pores, which reduces permeate flux and overall process 
efficiency. Concentration polarisation can be overcome or reduced by a number of methods, e.g. modifying 
feed concentrations or transmembrane pressure, but a certain degree of fouling is an inevitable occurrence in 
any membrane separation process. Fouling is a common problem in the separation of bioactive phytochemicals 
from crude plant extracts because of the presence of large, non-bioactive macromolecules that readily obstruct 
membrane pores. Preliminary optimisation of the process parameters and membrane characteristics can be 
carried out with the aim of minimising fouling (Li & Chase, 2010a). 
The ultrafiltration of a crude hydro-ethanolic extract of C. genistoides was optimised by Bosman 
(2014). Centrifugal and stirred cell devices were first used to find the most suitable molecular weight cut-off 
(MWCO), membrane material and feed concentration for optimal productivity and xanthone enrichment. 
Subsequently, a tangential flow ultrafiltration (TFU) system was used to investigate 10 and 30 kDa MWCO 
regenerated cellulose membranes for the processing of 1% and 3% feed concentrations (concentration 
expressed in terms of soluble matter content). Results for both feed concentrations indicated that the 10 kDa 
membrane achieved better enrichment of mangiferin with a lower incidence of fouling than the 30 kDa 
membrane, whilst maintaining the same level of process efficiency. Two important process parameters 
(transmembrane pressure and feed flow rate) were then optimised using a 10 kDa regenerated cellulose 
membrane and a 3% feed concentration. A central composite experimental design was used and response 
surface methodology was applied to find the optimal process parameters, viz. transmembrane pressure of 2.04 
bar and feed flow rate of 444 mL/min. The optimised TFU process was validated using 12 batches of 
unfermented C. genistoides extracts, resulting in xanthone enrichment ranging between 14.2 and 26.0%. 
 
2.5.3. Macroporous adsorbent resin chromatography (MARC) 
2.5.3.1. General overview of adsorption technology 
 
Adsorption can be described as an enrichment of compounds from a liquid or gaseous phase onto the 
surface of solid state bodies (Kammerer et al., 2018), and adsorption chromatography is recognised as an 
efficient method for the separation and enrichment of plant phenolics from extracts or industrial waste streams 
containing high levels of these compounds. Various natural materials have proven useful for selective 
adsorption of phenolic compounds, e.g. activated carbon, clay and zeolites have all been used to remove 
phenolic compounds from industrial wastewaters through an irreversible adsorption process. However, these 
adsorbents require chemical regeneration at high temperatures, which limits their use in the recovery of 
thermo-labile bioactive compounds (Kammerer et al., 2018; Pérez-Larrán et al., 2018). The development of 
synthetic macroporous resins (also referred to as macroreticular resins) resulted in major advances in the field 
of adsorption technologies, owing to their larger internal surface areas compared with the aforementioned 




polymerisation using methacrylic acid, acrylic acid or styrene in combination with divinylbenzene or other 
divinyl monomers as crosslinking agents (Kammerer et al., 2011, 2018). The co-polymerisation of styrene 
with divinylbenzene (S-DVB) yields resins that can swell but not dissolve in solvents, with the degree of 
swelling adjustable by the content of divinylbenzene (Li & Chase, 2010b).  
Macroporous resins are popular industrial adsorbents because of their chemical stability, limited 
toxicity, high adsorption capacity, and ease of regeneration at low or moderate temperatures (Soto et al., 2011; 
Kelly et al., 2019). Both ion-exchange and non-ionic resins have been described for the adsorption of plant 
phenolics (Kammerer et al., 2018). Plant phenolics typically contain both non-polar and polar moieties, and 
either non-polar resins or non-ionic polar resins could be used to adsorb polyphenols, depending on the 
compounds in question (Ma et al., 2015). The same resins that are used in commercial food processing to 
remove unwanted polyphenols, which cause bitterness, astringency or browning, can be used to enrich and 
purify phenolic compounds from extracts or waste streams (Kammerer et al., 2018; Pérez-Larrán et al., 2018). 
Macroporous adsorbent resin chromatography (MARC) is a relatively low-cost method for the 
separation of plant polyphenols based on their polarity and molecular weight. MARC has been applied for the 
recovery of bioactive polyphenols or other functional compounds from plant extracts or industrial food waste 
streams (Schieber, 2017). The interactions between molecules and macroporous resins may involve 
electrostatic Van der Waals forces, hydrogen bonding, acid-base interactions, complex formation and size-
sieving actions (Li & Chase, 2010b; Pérez-Larrán et al., 2018). The reversible adsorption properties of 
macroporous resins are of great importance where recovery of the adsorbate is required, e.g. the enrichment of 
valuable bioactive compounds for further development as functional health products. 
MARC is typically applied in a series of unit operations aimed at enriching, purifying or isolating 
specific target compounds. These unit operations may include conventional or non-conventional extraction 
methods (e.g. microwave- or ultrasonic-assisted extraction), centrifugation, and membrane processing (ultra-, 
nano- or microfiltration) (Li & Chase, 2010b). Following the production of a crude extract, a column with a 
solid phase of macroporous resin can be used to separate groups of compounds in the extract with similar 
properties. Compounds belonging to the same chemical classes are likely to co-elute in the various elution 
fractions from the packed resin bed (Fig. 2.10), and analytical HPLC can be used to locate the target 
compounds. Isolation and purification of individual compounds usually require subsequent preparative HPLC 
or high-speed counter-current chromatography unit operations (Pérez-Larrán et al., 2018). 
Li and Chase (2010b) noted that direct comparison between MARC studies reported in literature was 
difficult due to a lack of consistency in the experimental conditions that were used, and that high-resolution 
separation and purification of target compounds from complex samples are often not possible due to the strong 






Figure 2.10 Schematic showing the basic operating principles of column chromatography using an adsorbent 




2.5.3.2. Effect of process parameters, scale-up and other considerations  
 
When dealing with complex solutions like plant extracts that typically contain numerous chemical 
compounds with varying properties, each case requires individual optimisation, as extrapolation from a 
different system would not necessarily be applicable. Adsorption characteristics measured in a model solution 
may also not be representative of what would occur in real extracts (Kammerer et al., 2010b). A study using 
model phenolic solutions, supplemented with amino acids and saccharides, demonstrated that these 
components could positively or negatively affect polyphenol recovery depending on the experimental 
conditions and resin type, and should not be neglected in the systematic optimisation of sorption processes 
(Kammerer et al., 2010a). 
The behaviour of a particular adsorbent-adsorbate system cannot be easily predicted, and depends on 
various factors, e.g. resin characteristics (porosity, surface area, particle size), target compound attributes 
(water solubility, ionic charge, structure, functional groups, pKa, polarity, molecular weight) and solution 
conditions (solvent type, temperature, pH, solute concentration) (Bretag et al., 2009; Kammerer et al., 2011; 
Soto et al., 2011). The adsorption process in MARC consists of a series of stages, including: mass transfer 
from the liquid phase to the external particle surface, diffusion within pores, and solute-solid interactions at 
the particle surface (Kammerer et al., 2018; Pérez-Larrán et al., 2018). Pore diameter, internal surface area 
and surface polarity are three major parameters affecting the adsorption capacity of macroporous resins. 
Generally, the pore diameter is inversely related to the surface area, and vice versa (Li & Chase, 2010b). The 




that is even more complicated for multi-compound systems, where different components interact with each 
other, as well as with the adsorbent surface (Kammerer et al., 2018). 
The implementation of MARC on an industrial scale may involve the use of bed processes with fixed-
bed reactors, agitated batch processes, or moving bed processes with a moving solid phase (Kammerer et al., 
2011). Fixed-bed processes are most frequently used due to its relatively low cost and equipment requirements. 
In batch sorption processes with agitated reactors, the adsorbent is brought into contact with the liquid 
supported by an agitated platform. Upon completion, the adsorbent and liquid are separated by sedimentation 
or filtration. In moving bed processes with moving solid phases, the adsorbent material and liquid phase move 
continuously in countercurrent flow, with recovery of loaded resin occurring at specified intervals. Higher 
implementation and running costs compared with fixed-bed processes have limited the use of this approach to 
the manufacture of high-value pharmaceutical or biotechnological products. 
While batch adsorptions processes are typically used to screen for appropriate resins and determine 
adsorption equilibrium properties, dynamic adsorption processes are used for the fractionation of complex 
solutions by passing them through columns of resin. In dynamic adsorption (also referred to as column 
loading), fresh sample is continually introduced to the top of the column as the column effluent is collected at 
the bottom. In contrast, batch adsorption systems are “static”, i.e. no fresh sample is introduced and no effluent 
is removed. Batch studies are useful for determining optimal process parameters, e.g. sample concentration 
and temperature, before commencing dynamic adsorption experiments (Ma et al., 2009; Zhao et al., 2011; 
Wang et al., 2014b; Nian et al., 2016). 
Column loading is usually stopped when the target compound content in the eluate exceeds certain 
pre-defined threshold levels, thus indicating exhaustion of the resin capacity. This has been referred to as the 
“breakthrough” or saturation point, i.e. the loading volume at which a given compound will reach a specified 
concentration in the eluate, typically a low percentage of its concentration in the initially loaded sample. This 
percentage value is user-defined and varies amongst authors, from 5% (Sandhu & Gu, 2013; Buran et al., 
2014) to 10% (Yang et al., 2012). Loading of the column should therefore be halted before the first target 
compound to elute exceeds this specified concentration. Another approach that has been reported was to set 
the saturation point as the point where the last target compound to elute reached its breakthrough concentration 
(10%) (Yang et al., 2012). In such a scenario, substantial amounts of target compounds that had eluted earlier 
would presumably be lost in the “pre-fraction” unless active efforts are made to recover them. 
The adsorption of polyphenols onto macroporous resins involves weak Van der Waals attractions and 
hydrogen bonds that may be broken (for desorption) by the introduction of an organic solvent like EtOH, 
typically in an aqueous solution so that the polarity of the desorbing medium can be adjusted to achieve 
selective desorption of specific target compounds. This is usually achieved by a stepwise increase in the 
concentration of the organic solvent, i.e. gradient elution (Nian et al., 2016). The use of aqueous solutions of 
methanol, EtOH and methanol-EtOH mixtures have all been described for the desorption of plant polyphenols 
from macroporous resins (Du et al., 2008; Ma et al., 2009; Soto et al., 2011; Sandhu & Gu, 2013; Wang et al., 
2014b). Some MARC studies include an initial desorption step using pure water to first elute hydrophilic 




organic solvent concentration in a step-wise manner for selective desorption, i.e. gradient elution, of specific 
target compounds (He & Xia, 2008; Li & Chase, 2010b; Nian et al., 2016). 
Besides the chemical and physical characteristics of the liquid and solid phases, process parameters 
like temperature and solvent flow rates may all significantly affect the efficiency of a MARC unit operation 
(Daignault et al., 1988; Buran et al., 2014). Flow rates are typically expressed in terms of resin bed volumes 
(BVs), although it should be noted that what constitutes a low or high flow rate in such experiments can vary 
depending on the study in question. Wang et al (2014b) tested flow rates of 0.5 to 2 BV/h for loading of a resin 
column (ID = 30 mm) with tea polyphenols, and considered 2 BV/h a high flow rate. Similarly, Liu et al. 
(2016) refers to 2 BV/h as a “fast flow rate”, as it was the highest level tested in their study. Yang et al. (2012) 
tested flow rates of 2 to 4 BV/h in a 12 mm ID glass column, and considered 2 BV/h a “low” flow rate. Higher 
flow rates allow for shorter processing times and higher throughput, but often at the expense of adsorption 
efficiency (Liu et al., 2011b; Yang et al., 2012; Buran et al., 2014). The final choice of flow rate should strike 
a balance between optimal performance and economic feasibility. Sandhu & Gu (2013) tested flow rates of 2, 
4 and 6 BV/h for the dynamic adsorption of anthocyanins on FPX66, and reported the best adsorption 
performance at the lowest flow rate (2 BV/h), but finally opted for 4 BV/h after considering the  processing 
times involved. Similarly, Buran et al. (2014) selected 5 BV/h as the practical optimum flow rate for loading 
of blueberry anthocyanins on macroporous resin, despite a 2 BV/h flow rate having resulted in greater 
adsorption efficiency. 
There is a considerable amount of literature focusing on the use of adsorption isotherms to describe 
and compare batch adsorption processes under equilibrium conditions at different temperatures. Several 
isotherms have been deduced and described in literature, including the Langmuir and Freundlich isotherms 
(frequently used together), Henry isotherm, Temkin isotherm, Brunauer-Emmett-Teller and Redlich-Petersen 
isotherms (Kammerer et al., 2011; Soto et al., 2011). The application of the most commonly used Langmuir 
and Freundlich isotherms is discussed in more detail in Section 2.7.6 (Methodologies). 
The majority of commercial non-ionic macroporous resins are poly-acrylic or S-DVB based, with 
pore-forming agents (porogens) introduced during the manufacturing process to create the spacious network 
of macropores. Porogens are subsequently removed by volatilisation, but resin cleaning/pre-treatment steps 
should be routinely carried out when using new resin in order to remove any residual porogens. Daignault et 
al. (1988) reviewed cleaning and regeneration procedures described for Amberlite XAD resins used for 
phytochemical enrichment. Some studies reported that resin "artifacts"—chemical by-products of the resin 
manufacturing process, including biphenyl, chlorine, naphtalenes, styrenes and benzoic acid—could be 
detected in column eluates, and these could interfere with the identification and quantification of target 
compounds. This was particularly associated with changes in the aqueous-organic solvent compositions and 
the associated temperature and pressure fluctuations, resulting in bead swelling or rupture (Daignault et al., 
1988). Resin artifacts can be reduced or eliminated by pre-treatments ranging from simple rinsing to exhaustive 
Soxhlet extraction. Probably the simplest and cheapest resin cleaning approach is to rinse it with the same 
solvents that will be used in subsequent elution procedures (Daignault et al., 1988). Resin regeneration can be 




direction, or in countercurrent flow, where column loading and regeneration flows occur in opposite directions. 
Countercurrent regeneration results in more concentrated eluates than concurrent regeneration (Kammerer et 
al., 2011). Soto et al. (2011) also reviewed various other methods of regeneration reported for adsorbents in 
literature, including thermal and microwave heating protocols. 
Physical adsorption processes like MARC are favoured for their relative simplicity, low 
implementation costs and ease of operation and scale-up. Laboratory-scale dynamic sorption experiments can 
provide useful data for the development of large-scale, industrial MARC systems (Soto et al., 2011; Wu et al., 
2012). Linear scalability of unit operations is an important consideration for the downstream development of 
industrial-scale processes (Putnik et al., 2013). If the resin column dimensional ratio (bed height to diameter) 
is maintained, laboratory-scale protocols can easily be scaled up because flow rates and loading volumes are 
described in terms of bed volumes (BVs) that easily translate to larger setups. 
 
2.5.3.3. Separation of xanthones, benzophenones and honeybush extracts by adsorption 
chromatography  
 
Some researchers have previously investigated the use of MARC to isolate and enrich mangiferin from 
plant sources. Mangiferin was amongst a number of xanthones purified from extracts of Swertia mussotii using 
MARC (Tian et al., 2014). Geerkens et al. (2015) used adsorbent resin to recover mangiferin from mango peel 
extracts. In another study, an extract of A. asphodeloides root was fractionated in a column packed with non-
polar macroporous resin (Zhou et al., 2007). After column loading, an initial desorption step using pure water 
was carried out to remove “some un-target [sic] chemicals”, after which 30% aqueous EtOH was used to desorb 
the target compounds, mangiferin and neomangiferin (7-O-β-D-glucopyranosylmangiferin). The content of 
mangiferin in the desorbed fraction was not reported, but it served as the starting material for a high-speed 
counter-current chromatography (HSCCC) method aimed at purification of the target compounds. Nian et al. 
(2016), investigating the fractionation of A. asphodeloides root extract on three different saturated polystyrene 
resins, reported higher desorption efficiency for mangiferin when using 30% aqueous EtOH instead of 40% 
aqueous EtOH. 
In a study on bitter-tasting compounds, Alexander et al. (2019) used the non-polar S-DVB co-polymer, 
Amberlite XAD 1180N, to further fractionate an EtOH-soluble fraction of a hot water C. genistoides extract 
into a polar fraction and three fractions enriched in benzophenones, xanthones, and flavanones, respectively. 
The fractionation protocol, which was not optimised, entailed the use 5–20% aqueous EtOH to obtain a 
benzophenone fraction, followed by 20–30% aqueous EtOH to desorb xanthones. The benzophenone fraction 
contained 21.9% IDG, 6.4% I3G and 12.5% I3G, as well as a small amount (< 0.04%) of mangiferin and 
isomangiferin as “impurities”. Similarly, the xanthone fraction, which contained 45.4% mangiferin and 13.3% 
isomangiferin, also contained a benzophenone “impurity” in the form of 2.5% I3G.  
A recent study (Raaths, 2016) investigated the inhibition of rat intestinal AG by crude extracts and 
benzophenone and xanthone-enriched fractions of C. genistoides, which were produced by MARC using 
Amberlite XAD 1180 resin (Table 2.6). Two crude extracts, ARC188 and ARC189, were prepared using two 




differed between the two crude extracts, but the total benzophenone and xanthone contents did not differ 
substantially. The crude extracts, which were less potent AG inhibitors than acarbose, were fractionated using 
the non-polar resin to obtain benzophenone-enriched fractions (ARC188/189 Benz) and xanthone enriched 
fractions (ARC188/189 Xanth). A sequence of aqueous methanol (10–50 % v/v) elution steps was carried out 
to desorb the target compounds from the loaded resin. Crude extract ARC189 contained more than twice the 
amount of IDG than ARC188, and a separate IDG-enriched fraction (ARC189 IDG) was prepared from this 
batch only. Consequently, the IDG content of ARC189 Benz (3%) was much lower than that of ARC188 Benz 
(23.3%), and ARC189 IDG was composed mainly of IDG (75%). Both xanthone-enriched fractions 
(ARC188/189 Xanth) contained an amount of benzophenone, specifically I3G. Both this study, and that of 
Alexander et al. (2019), indicate that it was not possible to completely separate the xanthone and benzophenone 
groups of compounds from each other using the limited resolving capabilities of this resin fractionation 
method. 
No previous studies have optimised a MARC process, using an aqueous EtOH desorption protocol, 
for the fractionation of honeybush benzophenones and xanthones. Ethanol could serve as a less hazardous and 
eco-friendlier alternative to methanol for this purpose. Based on reports on literature, aqueous solutions of 5 
to 30% EtOH should be investigated for the selective desorption of benzophenones and xanthones from resin 
columns. 
 
Table 2.6 Major phenolic (xanthone/benzophenone) contents and half-maximal inhibitory 
concentrations (IC50) of crude extracts and enriched fractions of Cyclopia genistoides tested for in vitro 
inhibitory activity against rat intestinal α-glucosidase (Raaths, 2016). 
Crude 
extract/fraction 
Content (g/100 g extract) 
IC50 
(µg/mL) 
Benzophenones  Xanthones 
IDGa M3Gb I3Gc Total  MGFd IMGFe Total 
ARC188 2.2 1.1 3.7 7.0  13.8 3.2 17.0 150±6 
ARC188 Benz 23.3 11.4 28.3 63  0 0 0 121±5 
ARC188 Xanth 0 0 5.8 5.8  54.0 14.4 68.4 59±5 
ARC189 4.9 0.3 0.8 6.0  11.6 1.7 13.3 186±6 
ARC189 IDG 75.0 2.4 0 77.4  0 0 0 173±10 
ARC189 Benz 3.0 4.4 16.6 24.0  0 0 0 186±10 
ARC189 Xanth 0 0 2.1 2.1  53.8 7.9 61.7 65±6 
a 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone; b 3-β-D-glucopyranosylmaclurin; c 3-β-D-
glucopyranosyliriflophenone; d mangiferin; e isomangiferin; acarbose (positive control) IC50 = 42 µg/mL 
 
2.6. Gastroretentive delivery systems for α-glucosidase inhibitors 
 
The effectiveness of any pharmaceutical treatment relies on the efficient delivery of the API to the site where 
its therapeutic effect must be exerted. Generally, the aim of a specialised oral pharmaceutical delivery system 
is to improve the systemic bioavailability of the API and thereby achieve and maintain therapeutic levels in 




agents repaglinide (Jain et al., 2005), gliclazide (Awasthi & Kulkarni, 2012) and metformin (Ali et al., 2007; 
Ige & Gattani, 2012), all of which have systemic targets. On the other hand, the API may be targeted towards 
a specific site within the GIT itself, i.e. outside of the systemic circulation (Fig. 2.11). A prime example is the 
targeted inhibition of intestinal AG for the prevention of postprandial hyperglycaemia in diabetes or pre-
diabetes (Van de Laar et al., 2005). 
 Poor intestinal absorption of some APIs could be attributed to various reasons, including the activity 
of permeability glycoprotein 1 (P-gp), a membrane glycoprotein responsible for the active efflux of foreign 
compounds (xeniobiotics) back into the intestinal lumen after absorption by epithelial cells (Balimane et al., 
2006; Ashford, 2013). However, a high rate of P-gp-mediated efflux for an API targeted towards intestinal 
enzyme inhibition could be an advantage, because it would effectively concentrate the bioactive compound at 
its intended site of action. The major C. genistoides phenolics (mangiferin, isomangiferin, IDG, I3G), which 
are subject to intestinal efflux as reported by Raaths (2016) (Table 2.4), would therefore be ideal candidate 
AGIs for incorporating in an oral delivery system. 
 
Figure 2.11 Types of modified-release oral pharmaceutical delivery systems (McConnell & Basit, 2013). 
 
Standard oral pharmaceutical dosage forms simply ensure that the API reaches therapeutic levels in 
the systemic circulation, whereas modified delivery systems are designed to regulate the blood plasma 
concentrations of the API over time, e.g. for a prolonged effect or to reduce dosage intervals (Streubel et al., 
2006). By combining APIs with specialised excipients, the residence time of the API in the upper small 
intestine can be significantly extended (Chaudhari et al., 2012). Jigar et al. (2013) developed a bi-layered 
sustained-release tablet for the combination therapy of metformin and pioglitazone, two oral anti-diabetic 
agents requiring a strict dosing regimen. They concluded that their formulation would achieve a reduction in 
dosage frequency and improve patient compliance to treatment. Modified-release oral delivery systems 
facilitate the release of a single dose at a controlled rate over a more-or-less predictable period of time, longer 




the in vivo efficacy of such modified-release systems, because of the natural variation between the GIT 
environments of different individuals (McConnell & Basit, 2013). 
Gastroretentive delivery systems (GRDSs) are designed to be retained in the stomach for as long as 
possible while the slow dissolution of the API into the small intestine over an extended period provides a 
prolonged and consistent therapeutic effect (Umamaheswara Rao & Pavan, 2012). These systems can be used 
for APIs with systemic targets, i.e. where maximal intestinal absorption is desired, or where the target is located 
in the GIT itself (Bardonnet et al., 2006). Retention of the GRDS in the stomach can be achieved through a 
number of designs, including floating-type systems, delaying excipients, swelling/expanding-type systems, 
muco-adhesion and high density systems (Narang, 2010). Low density floating-type GRDSs refers to those 
which have a density less than that of gastric acid, causing it to float to the surface and avoid passage through 
the pyloric valve and out of the stomach (Arora et al., 2005). Floating can be achieved in an effervescent or 
non-effervescent formulation. Non-effervescent GRDSs (e.g. colloidal gel barrier or floating bead systems) 
are typically composed of inert low density polymers such as polypropylene, whereas effervescent or gas-
generating systems achieve buoyancy by the release of gas from the matrix (Arora et al., 2005; Bardonnet et 
al., 2006). The efficacy of the floating mechanism for a GRDS will depend on the formulation, which may 
contain a number of different functional excipients (Chaudhari et al., 2012). Polystyrene co-polymers such as 
S-DVB are composed of free-flowing, orbicular particles that achieve buoyancy in non-effervescent systems 
by trapping air in the matrix (Galia et al., 1994). 
Currently, pharmaceutical-grade AGIs are available only in conventional immediate-release dosage 
forms, but the repetitive administration schedule and unfavourable side effect profile associated with higher 
doses have emphasised the need to develop novel modified-release dosage forms for these types of drugs, with 
a number of patents filed since the 1990s (Kumar & Sinha, 2012). Blumen et al. (2006) developed a sustained-
release formulation for acarbose based on a gas-forming gastroretentive mechanism that would prevent an 
immediate burst-release and allow for homogenous mixing of acarbose with the stomach contents. However, 
this type of system might contribute to the symptoms of bloating already associated with acarbose use, and 
non-gas-forming, low-density floating systems would therefore be more suitable for this application. 
Raaths (2016) developed a non-effervescent, multiple-unit pellet system (MUPS) for the sustained 
delivery of a crude honeybush extract (ARC188), containing active AGIs (refer to Section 2.5.3.3; Table 
2.6). It demonstrated satisfactory in vitro sustained release and buoyancy properties for gastroretentive 
delivery of the AGIs to the upper small intestinal section of the GIT. Physicochemical analyses of two different 
formulations of the MUPS tablets indicated that polypropylene was superior to polyvinyldibenzene co-polymer 
as a bulking agent. The formulation containing polypropylene demonstrated more favourable buoyancy 
properties and target compound dissolution profiles. Synthetic excipients like polypropylene, polyethylene, 
polystyrene, and polyvinyl chloride have been shown to contribute to the harmful effects of microplastics on 
the environment (Andrady, 2011; Wright et al., 2013; Wu et al., 2019), but microcrystalline cellulose has 
gained attention as an eco-friendlier alternative. Derived from refined wood pulp, it is valued for its dry-
binding and compactibility properties, which enables effective tableting by direct compression methods (Gohel 







This section provides an overview of some of the experimental procedures and methodologies that will be 
employed in the current project. First, in vitro testing of AG inhibition will be discussed in more detail as it 
has been the subject of some debate. The remainder will cover basic aspects of the various physicochemical 
tests to be carried out on the extracts, fractions or GRDS that will be produced in the present study. 
 
2.7.1. Source of enzyme for in vitro α-glucosidase inhibition assay 
 
Hakama et al. (2009), in developing a high-throughput screening method for AGIs based on 
enzymological information, noted that “in quite a few reports, however, α-glucosidases with different origins 
than the target α-glucosidases, have been used to evaluate inhibitory activities”. They emphasised that substrate 
specificity and susceptibility to inhibitors could vary markedly amongst enzymes in the AG category. They 
advised that the design and screening of AGIs without consideration of these differences is “not efficient”, as 
the use of an inappropriate source of AG in enzyme inhibition assays may lead to erroneous conclusions or 
misleading claims regarding the bioactivity of the sample under investigation. 
Nevertheless, an alarming number of studies aimed at developing alternative AGIs for human 
consumption have made use of non-mammalian AG for bioactivity testing. Yin et al. (2014) reviewed the 
accumulated literature on natural AGIs obtained from medicinal plants and summarised details on 411 different 
compounds with AG inhibitory activity, including  terpenes, alkaloids, quinines, phenylpropanoids, sterides 
and flavonoids. The enzyme types ranged from various mammalian AGs to yeast and bacterial AGs—even an 
enzyme preparation extracted from coffee beans. In some cases, the origin of the AG is simply not stated at all 
(e.g. Prashanth et al., 2001; Zhang et al., 2019), but it is often possible to deduce this by looking at the reported 
inhibition data for the positive control (typically acarbose). However, at times neither the enzyme source nor 
the measured inhibitory activity of acarbose is provided, despite the latter being expressly included as the 
positive control (Mathivha et al., 2019). 
 Relatively weak or moderate inhibitory activity (IC50  > 100 µM) reported for acarbose strongly 
suggests that yeast or other non-mammalian AG was used, as it is known that acarbose should exhibit a potent 
inhibitory effect (IC50 < 100 µM) against mammalian AG (Sancheti et al., 2011). There are exceptions to be 
found in literature, e.g. Lavelli et al. (2016) and Alvarado‐Díaz et al. (2019) reported acarbose IC50 values of 
154.0 µM and 195.2 µM, respectively, against rat intestinal AG. Potent inhibitors of non-mammalian AG will 
often prove to be poor inhibitors of mammalian AG under the same experimental conditions (Hakamata et al., 
2009; Jo et al., 2011; Zhang et al., 2015). For example, salmon muscle hydrolysate that had previously been 
reported to have “potent α-glucosidase inhibitory activity” (IC50 = 48.7 mg/mL) (Matsui et al., 1996) showed 
a much weaker effect (IC50 = 345 mg/mL) when the enzyme was of mammalian origin rather than yeast (Oki 




The currently available literature and data on plant-derived AGIs are quite disperse and variable 
because of the use of varying enzyme or substrate concentrations, incubation times and different sources of 
enzyme, which makes direct comparisons between studies difficult in many cases (Proença et al., 2017). Only 
occasionally will a single study investigate and compare the effect of the candidate AGI on enzymes of 
different origins. A good example of such a study is one by Oki et al. (1999), who tested the inhibitory effect 
of different types of AGIs (green tea catechin, voglibose, acarbose and glucono-1,5-lactone) against the origin 
of the enzyme (baker’s yeast and rat, rabbit and pig intestines). The AGIs under study exhibited varying 
potencies depending on the enzyme origin. Acarbose, included as positive control, inhibited all types of 
mammalian AG (IC50 < 87 µM), but did not have any effect against yeast AG. Similarly, Kim et al. (2005) 
reported that acarbose strongly inhibited porcine intestinal AG (IC50 = 54.2 µM), but was completely inactive 
against yeast AG. Tadera et al. (2006) found that a number of flavonoids (including luteolin, naringenin, 
quercetin and hesperetin) were weaker inhibitors of rat intestinal AG than of yeast AG.  
Kwon et al. (2007) compared the inhibitory activity of nine different pepper extracts (Capsicum 
annuum) against both yeast AG and rat intestinal AG for the development of an anti-hypertensive and anti-
diabetic nutraceutical. For all nine extracts, the inhibitory activities against yeast and rat AGs were directly 
proportional (Fig. 2.12), but the inhibitory effect against rat intestinal AG was weaker in all instances.  
 
Figure 2.12 Comparison of inhibitory effects of nine different aqueous extracts of pepper (Capsicum annuum) 
against α-glucosidase from rat intestine and baker’s yeast (Kwon et al., 2007). 
 
An extract of Chinese chestnut (Castanae mollissima), investigated for in vitro inhibitory activity 
(Zhang et al., 2014), showed potent inhibition of yeast AG (IC50 = 0.33 µg/mL), proclaimed to be 613-fold 
more effective than acarbose (IC50 = 200 µg/mL). This statement may technically be correct, but the authors 
did not highlight that the weak effect of acarbose was observed against the yeast AG. Mammalian (rat) AG 




of yeast AG resulted in only 16.8% inhibition of the rat enzyme, suggesting that the C. mollissima extract may 
prove to be not quite such an effective nutraceutical as the reported results may proclaim. The authors did not 
emphasise the relevance of the different sets of enzyme results (yeast vs. rat) to the express aim of their study, 
i.e. the development of an anti-diabetic nutraceutical for human consumption. In contrast, Jo et al. (2011), who 
used rat intestinal AG to investigate the anti-diabetic potential of Omija (Schizandra chinensis) extracts, did 
specifically note the relevance of having used an enzyme of mammalian origin for their study, as did Oh et al. 
(2015), who studied tea and tea pomace extracts. 
The differences in inhibitory activity based on the enzyme origin may be attributed to major 
differences between the primary molecular structures and binding sites. Chiba (1997) proposed that two broad 
categories or “families” of AG exist, i.e. type I (baker’s yeast) and type II (mammalian). It is known that 
hydrophobic interactions, Van der Waals interactions and hydrogen bonding (H-bonds) are all involved in the 
interactions between AG, its substrates and inhibitors (Di Stefano et al., 2018), and some studies have 
attempted to elucidate the structure-function relationships of AGIs in more detail. Proença et al. (2017) tested 
a panel of 44 flavonoids for AG inhibitory activity, using yeast AG, and found that the position and number 
of hydroxyl groups were important factors. Specifically, a flavonoid with 2 catechol groups in the A- and B-
rings and three hydroxyl groups in the C-ring was shown to be the most potent AG inhibitor, with an IC50 value 
“much lower than acarbose” (7.6 µM vs. 607 µM). This flavonoid was, therefore, proposed as a superior 
alternative to acarbose as pharmaceutical-grade AGI, despite the fact that acarbose is known to have a weak 
effect against yeast AG. Xiao et al. (2013a), in a review on structure-activity relationships of AGIs derived 
from food sources, also noted that hydroxylation of flavonoids improves the inhibitory activity. 
Possible reasons for the superior inhibitory effect of samples vs. acarbose have been hypothesised in 
some studies. Elya et al. (2011) found that 37 of 45 phyto-extracts under investigation were more potent than 
acarbose against yeast AG, and attributed the superior effect of the phyto-extracts to “no further fractionation” 
(sic) of their active chemical compounds, as well as a possible synergistic effect. In some instances, misleading 
results are perpetuated through subsequent citations. For instance, Shai et al. (2010) used acarbose as a positive 
control when testing the inhibition of baker’s yeast AG by six extracts of South African medicinal plants. All 
the test samples (IC50 < 2 mg/mL) outperformed acarbose (IC50 = 17 mg/mL) in this regard. This very weak 
inhibitory effect observed for acarbose was substantiated by referring to previous studies that had 
inappropriately used yeast AG for bioactivity testing (Oki et al., 1999; Anam et al., 2009). The same research 
team followed up their 2010 study by investigating the mammalian and yeast AG inhibitory activities of seven 
medicinal plant extracts (Shai et al., 2011). This time, the extracts were substantially weaker inhibitors of rat 
AG than of yeast AG, and the authors newly emphasised the importance of using mammalian rather than non-
mammalian AG for the assessment of anti-diabetic bioactivity. Different types of mammalian AG may, 
however, still respond differently to the same AGI, e.g. Pyner et al. (2017) reported that EGCG strongly 
inhibited rat intestinal maltase (IC50 = 14 µM), but was much weaker against maltase derived from human 
Caco-2 cells (IC50 = 677 µM). 
A literature review on the topic of xanthone derivatives as AGIs (Santos et al., 2018) noted that the 




nitrophenyl β-D-glucopyranoside (PNPG) as the substrate. Inhibitors are typically prepared in phosphate 
buffer, dimethyl sulfoxide (DMSO), water or water-DMSO mixtures. Enzyme activity is then determined by 
measuring the release of yellow p-nitrophenol (PNP) from PNPG at 400–405 nm. Only two previous studies 
made use of a fluorimetric enzyme inhibition assay (Ryu et al., 2012; Bosman et al., 2017). The use of a yellow 
marker compound in the enzyme assay may not be the most appropriate method when the samples are likely 
to contain yellow-coloured compounds such as mangiferin and isomangiferin (Kokotkiewicz et al., 2013) and 
M3G (Beelders et al., 2014a). Fluorescence spectroscopy assays overcome this problem by quantifying 
enzyme activity using fluorogenic substrates such as 4-methylumbelliferyl-β-D-glucopyranoside, and could 
prevent underestimation of enzyme inhibition that may occur with colourimetric methods. 
Mangiferin, the major bioactive compound of interest in the present study, has been the specific subject 
of in vitro AG inhibition testing, with the reported inhibitory activities showing considerable variation, 







Table 2.7 Details on studies reporting α-glucosidase inhibitory activity for mangiferin. 
Reference Mangiferin source Sourcea of α-glucosidase Mangiferin IC50 Method 
Dineshkumar et al. (2010) 





(Acarbose = 83.3 µg/mL) 
Spectrophotometric method with 
PNPGb as substrate 
Feng et al. (2011) Aquilaria sinensis leaves Not stated 
299.7 µM 
(Acarbose = 576.2 µM) 
Spectrophotometric method with 
PNPG as substrate 





(Acarbose = 16.3 µg/mL) 
(Norathyriol = 4.2 µg/mL) 
Spectrophotometric method with 
PNPG as substrate 
Ichiki et al. (2007) 




(Acarbose = 2.39 µg/mL)  
Spectrophotometric method with 
PNPG as substrate 
Li et al. (2004) 




(Acarbose = 53.9 µg/mL) 
Colourometric mutarorase-
glucose oxidase method 
(commercial glucose test kit) 
Nian et al. (2017) From synthesis Not stated 
85.4 µg/mL 
(Isomangiferin = 77.0 µg/mL) 
(Acarbose = 900 µg/mL) 
Spectrophotometric method with 
PNPG as substrate 
Phoboo et al. (2013) From synthesis Rat intestine 
52171.4 µM 
(Acarbose = 1824.4 µM) 
Spectrophotometric method with 
PNPG as substrate 
Sekar et al. (2019a) 
Mango pulp 
(Mangifera indica) 
S. cerevisiae 36.8 µg/mL 
Glucose oxidase-peroxidase 
(GOD-POD) colourimetric 
method with sucrose as substrate 
Shi et al. (2017) 





(Acarbose = 479.2 µM) 
(Norathyriol = 3.1 µM) 
Spectrophotometric method with 
PNPG as substrate 





(Acarbose = 199 5 mg/mL) 
Spectrophotometric method with 
PNPG as substrate 
Wan et al. (2013) 
Swertia kouitchensis 
 (whole plant) 
S. cerevisiae 
296 µM 
(Acarbose = 627 µM) 
Spectrophotometric method with 
PNPG as substrate 





2.7.2. Intestinal permeability of target compounds 
 
Transport of bioactive compounds across the intestinal epithelium can occur via transcellular pathways 
(e.g. active transport or carrier-mediated transport and passive diffusion), paracellular pathways or efflux 
transporter (e.g. P-glycoprotein 1, P-gp) (Alqahtani et al., 2013). P-gp, an efflux protein, occurs in high 
concentrations in columnar cells of the intestinal epithelial brush border, facilitating the counter-transport of 
absorbed molecules back into the intestinal lumen (Linardi & Natalini, 2006). High rates of active efflux by 
P-gp is undesirable for most APIs, because it results in low oral bioavailability, but compounds targeted 
towards intestinal enzymes like AG or amylase would effectively be concentrated at the intended site of action. 
Various methods are available for testing the intestinal permeability and predicting the oral 
bioavailability of candidate APIs. The most commonly used methods include cell-based in vitro models (e.g. 
Caco-2 cell monolayers, Mardin-Darby canine kidney cells), in vitro artificial membrane models (e.g. parallel 
artificial membrane permeability, PAMPA), excised tissue-based ex vivo models (e.g. everted sac technique, 
Ussing-type diffusion chamber) and in situ methods (e.g. single-pass perfusion studies) (Balimane et al., 2006; 
Alqahtani et al., 2013). In vitro methods are generally more cost-effective and less labour-intensive than other 
methods, but they do not account for the many variables that may affect absorption and metabolism of 
compounds in the GIT, e.g. blood supply, pH, mucus layer secretions, peristalsis and gastric emptying (Volpe, 
2010). The frequently used Caco-2 model enables high-throughput screening using small amounts of sample 
(Hubatsch et al., 2007), but consists of just one cell type and does not necessarily reflect physiological 
conditions to an accurate degree (Balimane et al., 2006; Alqahtani et al., 2013). An ex vivo method like the 
electrophysiologic or Ussing-type chamber may provide better data in this regard (Sutton et al., 1992; 
Lennernäs, 2007). Limitations in the earlier Ussing-type chamber apparatuses prompted the development of 
the Sweetana-Grass diffusion apparatus (Grass & Sweetana, 1988), which improved upon the earlier design 
by providing larger surface area for absorption, easy cleaning, assembly and disassembly, and better 
temperature control. Excised sheets of intestinal tissue are mounted between half-cells representing the apical 
and basolateral compartments, and transport between the compartments is evaluated by analysing samples 
drawn at set intervals over time. Intestinal tissue from various animal types (dogs, monkeys, pigs, hamsters, 
mice) have been used for diffusion chamber permeability studies, but Ashford (2013) recommended the use 
of rat intestinal tissue for its good correlation with human intestinal tissue. However, Nejdfors et al. (2000) 
reported that pig intestinal tissue correlated better with human tissue than that of rat in Ussing-chamber 
experiments. 
The apparent permeability coefficient (), defined as the initial flux of compound through the 
membrane, normalised by membrane surface area and donor compartment concentration, is commonly used 
as part of a general screening process in in vitro or ex vivo intestinal permeability studies (Palumbo et al., 
2008). The efflux ratio (ER) is an index of bi-directional intestinal transport that compares the adsorptive and 
secretory permeability (Hubatsch et al., 2007), and is represented by the equation:  





where   and   represent values in the basolateral to apical (BA) and apical to basolateral (AB) 
directions, respectively. The inverse of ER is referred to as the uptake ratio. Efflux ratios that are equal to unity 
(1) indicate that no efflux occurred, ER > 2 suggests active efflux mechanisms are involved, and ER between 
1 and 2 suggests that passive efflux mechanisms dominate (Skolnik et al., 2010; Lin et al., 2011).  
 
2.7.3. Oral carbohydrate tolerance testing  
 
Following the demonstration of in vitro anti-diabetic effects of candidate drugs, e.g. the stimulation of 
glucose uptake in cultured cells (Pranakhon et al., 2015; Sekar et al., 2019b) or inhibition of glycolytic enzyme 
activity (Jo et al., 2016), it is recommended that this should be followed by a controlled evaluation of in vivo 
blood glucose-lowering effects using an appropriate animal model and bioactivity assay. Acarbose has been 
included as the positive control, or as a co-administered agent in combination with a test sample, in various in 
vivo studies that investigated the anti-diabetic effects of plant extracts or purified phytochemicals (Table 2.8). 
Acarbose has been administered at doses ranging from 0.1 to 20 mg/kg BW in different experimental animal 
models. An appropriate human equivalent dose for administration of acarbose can be calculated by using dose 
translation conversion factors as reported by Reagan-Shaw et al. (2007). 
Since acarbose and other AGIs do not exert their hypoglycaemic effect by inhibiting the absorption of 
glucose from the GIT, but rather by inhibiting the enzymatic release of glucose monomers from larger 
molecules, it is recommended that the oral glucose tolerance test should be avoided when examing the in vivo 
effect of AGIs. This is highlighted by the study of Mohamed et al. (2015), who carried out oral starch, sucrose 
and glucose tolerance tests with acarbose as the positive control in all three cases. Their results showed that 
acarbose had no reducing effect on the peak blood glucose levels of streptozotocin (STZ)-induced diabetic rats 
after oral glucose administration; however, acarbose significantly reduced peak blood glucose levels (P < 0.05) 
in the oral starch and sucrose tolerance tests, in both normal and diabetic rat models. Similarly, Shi et al. (2017) 
reported that the AGIs, mangiferin and norathyriol, failed to reduce the peak blood glucose levels of diabetic 
mice in oral glucose tolerance tests, but significantly lowered peak blood glucose levels in an oral starch 
tolerance test. In another study, Li et al. (2013) administered a mixture of 1-deoxynojirimycin (a commercial 
AGI) and mulberry polysaccharides to STZ-induced diabetic mice, and found that blood glucose was 
significantly lowered compared with controls in both the oral sucrose and glucose tolerance tests. This 
indicates that the test sample was able to attenuate the spike in blood glucose levels by (1) inhibition of sucrase 
activity or (2) inhibition of glucose absorption, or (3) inhibition of both sucrase activity and glucose absorption. 






Table 2.8 Selected details of in vivo studies using rat or mouse models to evaluate the blood glucose-lowering effect of test samples and of acarbose, the 
commercial α-glucosidase inhibitor and positive control. 
Reference Animal model Test sample Test sample dose Acarbose dose Dosage regimen Assay details 
Adisakwattanna et al. 
(2011) 




30, 100 or 
300 mg/kg BW 
3 mg/kg BW 
Single dose 
 
One treatment group 
received a combination 
of 30 mg/kg C3R and 
3 mg/kg acarbose 
Oral maltose and 
sucrose loading 
 
5 min after test 
sample/acarbose 







(ethanol or water) 
100 mg/kg BW 5 mg/kg BW Single dose 











100 mg/kg BW 5 mg/kg BW Single dose 















250, 500 or 
1000 mg/kg BW 
10 mg/kg BW Single dose 
Oral starch, sucrose 
and glucose loading 
 
10 min after test 
sample/acarbose 




Camellia sinensis tea 
and tea pomace 
extracts 
0.5 mg/kg BW 5 mg/kg BW Single dose 










Reference Animal model Test sample Test sample dose Acarbose dose Dosage regimen Assay details 






Ethyl acetate fraction 
of Caralluma 
europaea 
50 mg/kg BW 10 mg/kg BW Single dose 
Oral sucrose loading 
 
30 min after test 
sample/acarbose 
Priscilla et al. (2014) 
Male Wistar rats 
(75–100g) 
 
High-fat fed and STZ-
induced diabetic  
Naringenin 25 mg/kg BW 5 mg/kg BW Single dose 






Satoh et al. (2015) 
GK rats  
 




31.3, 62.5 or 
250 mg/kg BW 
0.1, 0.3 or 3.0 






31.3 mg/kg extract + 
0.3 mg/kg acarbose 
 
250 mg/kg extract + 
3 mg/kg acarbose 












15 or 30 mg/kg BW 10 mg/kg BW Single dose 
Oral starch and 
glucose loading 
 







Reference Animal model Test sample Test sample dose Acarbose dose Dosage regimen Assay details 





induced pre-diabetic   
Oroxylum indicum 
seed extract 
50 or 200 mg/kg BW 
4 or 
20 mg/kg BW 
 
8 weeks of treatment 
 
Combinations 
4 mg/kg acarbose + 
50mg/kg extract 
 
4 mg/kg acarbose + 
200 mg/kg extract 
Oral glucose loading 









40, 80 or 240 mg/kg 
BW 






80 mg/kg baicalein and 
1 mg/kg acarbose 










2.7.4. Cytotoxicity testing 
 
Liver cell models are the logical first choice for toxicological screening studies of pharmaceuticals or 
natural supplements because of the major role of the liver in metabolism and biotransformation of xenobiotics. 
Various types of in vitro model systems, derived from liver cells (hepatocytes), have been  developed for 
toxicological screening, e.g. liver tissue slices, immortalised cell lines and primary hepatocyte suspensions and 
cultures (Mitaka, 1998). These methods present with some significant shortcomings, e.g. loss of viability, 
limited throughput, and decrease in liver-specific functionality and gene expression (Soldatow et al., 2013). 
This prompted the development of more complex cell models, which simulate in vivo conditions more closely, 
e.g. bioartificial livers, three-dimensional (3D) tissue constructs and co-cultures of hepatocytes with various 
cell types. Some of the novel cell-culture systems provide a physiological environment for hepatocytes by 
incorporating fluid flow and micro-circulation, or altering the extracellular matrix (Meng, 2010). The gold 
standard approach to evaluating chemical toxicity involves expensive, time-consuming in vivo studies in 
animal models.  
At present, there are limited data available for in vivo effects of honeybush extracts in animals, but a 
study by Marnewick et al. (2003) indicated that rats exposed to an aqueous extract of C. intermedia as the sole 
source of drinking fluid did not suffer adverse toxic effects to their liver or kidney function. A more recent 
study (Van der Merwe et al., 2017) investigated an extract of C. genistoides (8.35% mangiferin, 2.59% 
isomangiferin, 2.08% IDG, 1.79% I3G; 0.97% M3G), which was fed to male Fischer rats for 28 days (2.5 g/kg 
feed), resulting in significantly increased activity (P < 0.05) of glutathione reductase, a key antioxidant enzyme 
in the liver, without any reported liver toxicity. 
However, the predictive accuracy of extrapolation from animal studies has been disputed in recent 
years, driving toxicologists to explore non-animal alternatives (Holmes et al., 2010). The advantages of in 
vitro toxicological assays include increased throughput, reduced costs and lower sample amount requirements, 
as well as the ability to study chemical metabolism and dose-response relationships, measure enzyme kinetics 
and evaluate the mechanisms of toxicity (Le Cluyse et al., 1996). A number of studies have reported that 
immortal cells grown in 3D cultures demonstrated physiological characteristics that are more reminiscent of 
their parental organ than when the same cells are grown by classic two-dimensional (2D) culture techniques 
(Loessner et al., 2010; Daus et al., 2011; Lin et al., 2012b). This could be attributed to the more elaborate 
extracellular matrix and better intracellular communication that develops in 3D culture (Fey & Wrzesinski, 
2012), which leads to maintenance or recovery of in vivo function (Selden et al., 2000). The use of a 3D 
structure has been suggested as the missing link to provide in vitro models that most accurately simulate in 
vivo conditions (Griffith & Swartz, 2006; Pampaloni et al., 2007). The use of a 3D model would therefore be 







2.7.5. Liquid chromatography with diode array detection 
 
High-performance liquid chromatography with diode array detection (HPLC-DAD) is one of the most 
frequently used quantitative analytical tools for analysis of bioactive polyphenolic content in plant extracts. 
Previous studies on the phenolic compositions of aqueous extracts of C. maculata and C. subternata (De Beer 
et al., 2012; Schulze et al., 2014) emphasised the need for species-specific HPLC methods to accommodate 
quantitative and qualitative differences between Cyclopia species. Currently, the method optimised by 
Beelders et al. (2014b) is the most comprehensive HPLC-DAD method for the species-specific analysis of 
C. genistoides extracts. This method provides improved separation of minor compounds and reduced loss of 
highly polar constituents in the void volume as compared with an older, “generic” method for Cyclopia spp. 
(De Beer & Joubert, 2010) and the one used by Joubert et al. (2003) for quantification of mangiferin and 
hesperidin in Cyclopia spp. In all instances, ascorbic acid is added to the sample before analysis to prevent 
oxidative degradation of the target analytes. 
 
2.7.6. Langmuir and Freundlich isotherms 
 
In a previous section (2.5.3.2; p. 52), the use of experimental data from batch adsorption experiments 
was noted as a means to obtain useful data on the adsorption process under equilibrium conditions. Adsorption 
isotherms are mathematical models that describe the adsorption behaviour, at a constant temperature, of solutes 
from a liquid or gaseous phase onto the surface of a solid phase adsorbent. The Langmuir and Freundlich 
isotherms (eqs. 2.4 and 2.5, respectively) are the most frequently used models for describing adsorption 
equilibrium data of phytochemicals onto macroporous adsorbent resins: 
 
-.-/ =	 0)12.(3	0)12.)   (Eq. 2.4) 
45 =	6785/:   (Eq. 2.5) 
 
where Qe is the adsorption capacity (mg/g), which represents the mass of target compound adsorbed to 1 g of 
resin at the adsorption equilibrium, Ce is the equilibrium concentration of the target compound in solution, 
(mg/mL), Q0 is the theoretical maximum adsorption capacity (mg/g), Kad is the adsorption equilibrium constant 
(mL/mg), KF is the Freundlich constant, which indicates adsorption capacity, and n is an empirical constant in 
the Freundlich model relating to the adsorption intensity of the system. These equations were derived from the 
study of gas adsorption systems and subsequently applied to solid-liquid systems (Kammerer et al., 2011). The 
term 1/n in the Freundlich equation is an indicator of the degree of favourability of adsorption of a given 
adsorbate to an adsorbent, with 0.1 < 1/n < 1.0 indicating favourable adsorption. The more 1/n approximates 
a value of 1.0, the higher the adsorption affinity, whereas 1/n > 1.0 indicates low affinity and poor adsorption 




Apart from providing basic characterisation data for the target compounds, these model parameters 
provide valuable information for process development. Batch adsorption isotherm experiments are typically 
carried out at two or more temperatures in the range of 20–50 °C, with interpretation of the resulting model 
parameters subsequently revealing the effect of temperature variation, as well as the relative affinities of 
various compounds to the adsorbents (Kammerer et al., 2007; Bretag et al., 2009; Liu et al., 2011b, 2016; 
Zhao et al., 2011; Yang et al., 2012; Sandhu & Gu, 2013; Buran et al., 2014; Wang et al., 2014b; Ma et al., 
2015). The effects of temperature on various adsorbent-adsorbate systems for plant phenolics have been 
reviewed by Soto et al. (2011). Lower temperatures were reported to enhance adsorption in many cases, 
including the adsorption of mangiferin on HPD400 macroporous resin (Nian et al., 2016), but the opposite, 
i.e. an endothermic process, has also been described (in addition to temperature having no significant effect). 
A key advantage of exothermic adsorption is that no additional energy expenditure in the form of heating is 
required to improve the process—a distinct advantage when scaling up to an industrial level. 
 
2.7.7. Water activity and hygroscopicity 
 
Moisture content refers to the total amount of water in a material, regardless of its availability to 
partake in chemical reactions, and is expressed on a volumetric or gravimetric basis. Water activity (aw) is a 
concept commonly applied in food safety and quality assessment and refers to the amount of water available 
(at equilibrium) for hydration of the material, taking part in chemical reactions and to support microorganism 
and enzyme activity (Rockland & Nishi, 1980; Labuza & Altunakar, 2007; Sablani et al., 2007). The aw of a 
product is largely a function of its moisture content and the conditions of the surrounding air. A value of zero 
indicates the total absence of water, while the maximum value of 1 corresponds to pure water. Below a value 
of 0.5, the occurrence of microbial growth and biochemical degradation is greatly reduced, thereby ensuring 
safety and shelf-stability (Woo & Bhandari, 2013). The simple measurement of moisture content or water 
activity of dried plant extracts is limited in terms of predicting the storage stability under conditions of varying 
relative humidity or temperature. Moisture sorption isotherms (MSIs) describe the relationship between the 
equilibrium moisture content and aw of a food product at a constant temperature (Mathlouthi, 2001; Al-
Muhtaseb et al., 2002). This equilibrium relationship between moisture in the product at a given temperature 
and moisture in the atmosphere are determined experimentally for each individual type of material (Al-
Muhtaseb et al., 2002; Fitzpatrick, 2013). The relationship between aw and moisture content is complex, but 
an increase in moisture content generally corresponds with an increase in aw in a non-linear fashion. 
Determining the MSI of a product can provide useful information for optimising processing steps like drying, 
storage and packaging (Andrade et al., 2011). 
Moisture sorption data can also be used to evaluate the degree of hygroscopicity, which Newman et 
al. (2008) defined as the tendency of a material to take up moisture, at increasing levels of relative humidity 
and a constant temperature. There are three broad categories of moisture uptake, viz. (1) surface adsorption 
without penetration into the solid bulk, (2) surface liquefaction and (3) absorption into the bulk portions of the 




(Newman et al., 2008). Moisture sorption isotherms can also be useful for the selection of appropriate 
packaging material and storage conditions for a particular product, e.g. avoiding exposure to RH higher than 
that corresponding to the monolayer moisture content (M0) (Gabas et al., 2007; Sinija & Mishra, 2008). The 
molecular monolayer water value, which can be derived from the Guggenheim-Anderson-Boer (GAB) and 
Brunauer-Emmett-Teller (BET) models, indicates the amount of water that is strongly absorbed to the surface 
of the material. Above this value, the product is more prone to undergo degradation due to hydrolysis and 
microbial growth (Timmermann et al., 2001). Various semi-empirical and empirical mathematical equations 
can be used to describe moisture sorption behaviour of foods based on the degree of fitting of the experimental 
data to the model. In addition to GAB and BET models, which are the most commonly used models in the 
food industry, other available models include the Peleg, Iglesias-Chirife, Oswin, Smith, Halsey and Henderson 
models (Lomauro et al., 1985; Andrade et al., 2011). The BET model, although frequently used, has been 
shown to have limitations at higher ranges of aw, whereas the GAB model is more reliable over the entire range 
of aw (Timmermann et al., 2001; Timmermann, 2003; Blahovec & Yanniotis, 2008). 
A typical adsorption-desorption curve for a food product (Fig. 2.13) should provide insight into the 
binding mechanism of water to the sample in question. The isotherm should contain three distinct regions 
(indicated by a–c) that represent (a) strongly bound water, including hydrogen-bonded water (structural water) 
and monolayer water sorbed by hydrophilic and polar groups of the food constituents, (b) less firmly bound 
water in small capillary spaces, with an enthalpy of vaporisation slightly higher than that of pure water, and 
(c) free water held in large capillaries, crevices and void spaces. Hysteresis is indicated by a desorption curve 
that lies above the adsorption curve, resulting in a closed loop. The presence of hysteresis reflects the potential 
for structural and conformational rearrangements in food products following moisture absorption, which alters 
the accessibility of binding sites and significantly reduces shelf-life (Al-Muhtaseb et al., 2002; Andrade et al., 
2011). The MSI of a spray-dried C. subternata extract without any added excipients displayed a sigmoidal 
curve (Fig. 2.14a) characteristic of type II isotherms (Pauck et al., 2017; De Beer et al., 2018). Irreversible 
deliquescence of the sample occurred at RH = 75%. The moisture sorption data fit well to the BET model (R2 
> 0.95), particularly at aw < 0.4, which is in agreement with data reported for other low aw foods (Labuza & 
Altunakar, 2007). The calculated M0 fell within the range of 0.2–0.3 aw, and storage of the spray-dried extract 
at < 30% RH was recommended to prevent moisture uptake and physical state changes and thereby maintain 
shelf-stability. While there was some evidence of hysteresis in the MSI of pure C. subternata extract powder 
(Fig. 2.14a), a greater degree of hysteresis was seen in a spray-dried powder containing 75% inulin as an 





Figure 2.13 Moisture sorption isotherm of a typical food product showing adsorption and desorption phases 




Figure 2.14 Moisture sorption isotherms for spray-dried (a) pure Cyclopia subternata extract, as well as 
(b) C. subternata extract microencapsulated with inulin at 750 g/kg of the total solids, showing first adsorption 






Dissolution testing is considered an important tool in pharmaceutical development and quality control 
because it determines the rate and extent of API release from orally administered dosage forms, in addition to 
providing an in vitro prediction of in vivo absorption. When developing a new oral dosage form, it is important 
to ensure that the API release occurs as desired by the product specification. The in vitro drug release behaviour 
can be characterised by applying various mathematical models to represent dissolution data as a function of 
parameters related to pharmaceutical dosage (Costa & Lobo, 2001). A dissolution profile for a particular API 
is a measurement of in vitro release from a preparation in a vessel of media over a period of time. Multiple 
samples are collected at several time points for analysis of target compound content, and the resulting curve 





Typically, in studies on drug release kinetics, experimental data are fitted to a number of frequently 
used mathematical models, usually presented as nonlinear equations, e.g. zero order, first order, Higuchi, 
Weibull, Gompertz, Hixson-Crowell and Korsmeyer-Peppas models (Costa & Lobo, 2001; Singhvi & Singh, 
2011; Ramteke et al., 2014; Gouda et al., 2017). Such mathematical modelling can be used to elucidate the 
underlying release mechanisms and optimise the design of novel dosage forms (Siepmann & Siepmann, 2008). 
The freely available DDSolver add-in for Microsoft Excel allows the modelling of dissolution data 
using 40 built-in dissolution models (Zhang et al., 2010b), and can be used to compare API dissolution profile 
data and model parameters using, amongst others, univariate ANOVA, exploratory data analysis, mean 
dissolution time (MDT), difference and similarity factors and the Rescigno indices. DDSolver also provides a 
number of statistical tools for the evaluation of model goodness of fit, including the correlation coefficient, the 
coefficient of determination	(), adjusted coefficient of determination ( ), the mean square error, the 
Akaike Information Criterion (AIC) and the Model Selection Criterion (MSC).  is used to compare models 
with different numbers of parameters, with higher   indicating a better fit. The Akaike Information 
Criterion is a popular tool for selecting optimal models due to its general applicability and simplicity. It can 
be defined according to the following equation: 
 
AIC	 = 	n=>(WSS)	+ 	2B  (Eq. 2.6) 
 
where n is the number of data points, WSS is the weighted sum of squares of residuals, and p is the number of 
parameters in the model. In a comparison of models, a lower AIC value indicates a better fit (Costa & Lobo, 
2001). The MSC is a modified reciprocal form of the AIC that has also been attracting attention as a useful 
statistical tool for model selection. When comparing models, a larger MSC value indicates a better model fit, 
with a value > 2 generally indicating a good fit (Zhang et al., 2010b). 
Alternatively, nonlinear fitting of dissolution data can be performed using other statistical software 
packages such as GraphPad Prism, Micro-Math Scientist or SigmaPlot, but these applications require the user 
to provide initial values for each parameter and manually define model equations. Zuo et al. (2014) used both 
DDSolver and Excel spreadsheets to analyse experimental data from dissolution studies, and found that 
performing routine quantitative analysis proved much easier when using DDSolver due to reduced calculation 
time and less potential for calculation error. 
Raaths (2016) conducted dissolution testing on a non-effervescent floating-type GRDS, containing 
50% polypropylene (w/w) (Fig. 2.15). Mean dissolution times for the target compounds increased in the order 
IDG < I3G < mangiferin < isomangiferin. The dissolution of IDG followed a steep ascending curve, indicating 
immediate and relatively fast release (MDT = 16.3 min), which was followed by the release of I3G (MDT = 
29.8 min). Mangiferin and isomangiferin dissolved at similar, slower rates (MDT = 39.2 and 42.3 min, 
respectively), with dissolution profiles approximating straight lines, and it was suggested that they follow zero 
order kinetics, which is the ideal release profile for prolonged pharmacological action (Costa & Lobo, 2001). 






Figure 2.15 In vitro dissolution profiles of four marker molecules released from polypropylene-based 
gastroretentive delivery system in 0.1 N HCl medium at 37 °C (Raaths, 2016). IDG = 3-β-D-glucopyranosyl-
4-O-β-D-glucopyranosyliriflophenone, I3G = 3-β-D-glucopyranosyliriflophenone. 
 
 
2.8. General conclusion 
 
While some studies have investigated in vitro inhibition of mammalian α-glucosidase by C. genistoides 
extracts, phenolic fractions, xanthones and benzophenones, there are no studies that have investigated the 
potential synergistic interactions between these inhibitors, either in vitro or in vivo using a suitable oral sucrose 
tolerance test. Synergism is frequently mentioned as one of the potential mechanisms through which multi-
compound extracts may exert their various bioactivities. The present study provides an opportunity to 
investigate this aspect of the established α-glucosidase inhibitory effect of C. genistoides extracts, which 
represents a complex mixture of confirmed single-compound α-glucosidase inhibitors. Macroporous adsorbent 
resin chromatography has been used to obtain benzophenone or xanthone-enriched fractions of C. genistoides, 
but the process parameters have not been optimised by batch sorption studies and dynamic studies. 
The available literature has emphasised the importance of optimising each particular adsorbate-
adsorbent system, since parameters cannot be reliably extrapolated from different systems. No previous studies 
have investigated the particular system that will be implemented in the present study, which will make use of 
recently optimised extraction and ultrafiltration protocols to produce a starting material for resin 
chromatography. This presents a different starting material than those previously used in the most closely 
related studies. It is important to develop a new resin fractionation protocol for the ultrafiltered extract as 
ultrafiltration will significantly alter the extract matrix by removing larger molecules. The effect of temperature 
on target compounds adsorption onto the macroporous resin has also not been studied by isotherm analyses. 
This is an important consideration in terms of process efficiency and warrants an investigation. 
Despite the low degree of intestinal absorption and subsequent low bioavailability of many natural 
polyphenols, the potential liver toxicity of highly enriched extracts or fractions, as proposed for development 




for a hydro-ethanolic extract or enriched phenolic fractions of C. genistoides. This literature review has also 
emphasised the importance of considering the context of the research being undertaken when selecting 
appropriate experimental methods, to ensure that any obtained data remain as relevant as possible to the scope 
of the study. 
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Extracts of honeybush (Cyclopia genistoides) containing glycosylated xanthones and benzophenones inhibit 
α-glucosidases, a group of key glycolytic enzymes and drug targets in the treatment of type 2 diabetes mellitus. 
Ultrafiltered C. genistoides extract was used as the starting material for the development of an optimised 
protocol to produce xanthone- and benzophenone-enriched fractions (XEFs and BEFs) by macroporous 
adsorbent resin chromatography. Static sorption experiments were performed to determine resin loading 
capacity. Both the Langmuir and Freundlich models showed high goodness-of-fit (R2 > 0.97) for adsorption 
isotherm data collected at 25 °C and 40 °C. Analysis of the Freundlich model parameters indicated exothermic 
adsorption of the target compounds onto the resin (Amberlite XAD 1180N), which had higher affinity for the 
xanthones than for the benzophenones. A fractionation protocol using step-wise gradient elution with 0–30% 
aqueous ethanol was developed, based on the results of dynamic sorption experiments. All XEFs contained 3-
β-D-glucopyranosyliriflophenone due to co-elution with the xanthones, mangiferin and isomangiferin, whereas 
BEFs contained zero or trace amounts of xanthones. Phenolic variation between different batches of the raw 
material (n = 10) manifested as variation in the composition and degree of enrichment of BEFs and XEFs. This 
scalable, eco-friendly enrichment strategy should find application for the preparation of enriched fractions 




The search for plant-based inhibitors of intestinal α-glucosidases, a group of key enzymes involved in  
carbohydrate digestion, and a drug target for treatment of type 2 diabetes mellitus, has gained momentum in 
recent years because of discouraging gastrointestinal side effects associated with the commercially available 
drugs, e.g. acarbose (Rosak & Mertes, 2012). Amongst the potential alternatives from plants, several 
polyphenol-rich extracts and compounds are under investigation (Kumar et al., 2011). 
Polyhydroxybenzophenones, along with their glycosylated derivatives, have been shown to inhibit α-
glucosidase (Feng et al., 2011; Hu et al., 2011; Beelders et al., 2014a). A good source of glycosylated 
polyhydroxybenzophenones is Cyclopia genistoides, more commonly known for its consumption as the herbal 
tea, honeybush. Benzophenones identified in extracts from this plant are 3-β-D-glucopyranosyliriflophenone 
(I3G), 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone (IDG) and 3-β-D-
glucopyranosylmaclurin (M3G) (Kokotkiewicz et al., 2013; Beelders et al., 2014b,a; Malherbe et al., 2014). 
I3G and M3G have previously been extracted from mango (Mangifera indica), amongst others (Zhang et al., 
2013a), but IDG has thus far only been reported in Cyclopia (Beelders et al., 2014a). M3G is only a minor 
compound, but the total I3G and IDG content of C. genistoides extracts could amount to as much as 8.9% 
(Bosman et al., 2017).  Furthermore, extracts of C. genistoides also contain high levels of the C-glycosylated 
polyhydroxyxanthones, mangiferin and isomangiferin (>15%), both confirmed to inhibit α-glucosidase (Feng 
et al., 2011; Bosman et al., 2017; Sekar et al., 2019a). Mangiferin has been extensively reviewed in terms of 




Substantial variation has been reported in the xanthone and benzophenone content of C. genistoides, 
due to genotype (Bosman et al., 2017), origin of seeds, environmental stress and harvest time (Joubert et al., 
2014). Apart from the obvious variation in benzophenone and xanthone content of the extracts, other 
compositional differences affected process efficiency as demonstrated for tangential flow ultrafiltration 
(Bosman, 2014), the first step that was employed towards the development of a standardised nutraceutical 
containing high levels of these compounds. This inherent compositional variation of the plant material could 
also affect downstream processing steps and would have implications for the production of an efficacious and 
standardised anti-diabetic nutraceutical or functional food ingredient. This would mean that control over 
composition or activity of the final nutraceutical ingredient should be exercised. However, the complexity of 
plant extracts and the interplay between compounds preclude full control of the composition of the final 
ingredient. One approach to control batch-to-batch variation could be to identify active fractions and their main 
active compound(s), and re-engineer the extract to ensure a fixed ratio of these main active compounds, as 
opposed to a specified amount of chemical marker, which is currently standard practice. Another motivation 
for such a “fixed ratio-combination” approach is the loss of activity with bio-guided fractionation of active 
extracts (Caesar & Cech, 2019).  
 The focus of the present study was the production of fractions respectively enriched in benzophenones 
and xanthones of C. genistoides, as an intermediate processing step towards development of a standardised 
nutraceutical ingredient. Macroporous adsorbent resin chromatography (MARC) is a relatively low-cost 
method used on industrial scale for the separation of compounds, and favoured for its simplicity, scalability, 
high capacity, and avoidance of toxic chemicals (Soto et al., 2011). Plant phenolics typically contain both non-
polar and polar moieties, and either non-polar or polar resins could be used to adsorb polyphenols (Ma et al., 
2015). Previously, members of our group showed the potential of MARC, using the non-polar styrene-
divinylbenzene co-polymer, XAD 1180N, to separate benzophenones and xanthones of C. genistoides for a 
study on bitter-tasting compounds (Alexander et al., 2019). Other studies showed the use of HPD-300 and 
XAD 16HP for purification of mangiferin from extracts of Swertia mussotii (Tian et al., 2014) and mango peel 
(Geerkens et al., 2015), respectively. 
 Our aim was to develop an eco-friendly, scalable MARC protocol for the production of a 
benzophenone-enriched fraction (BEF) and a xanthone-enriched fraction (XEF) from C. genistoides for 
downstream incorporation into a sequence of unit operations ultimately to produce a standardised nutraceutical 
ingredient. The starting material for this unit operation was a C. genistoides extract, produced using previously 
optimised extraction (Bosman et al., 2017) and ultrafiltration protocols (Bosman, 2014). Static batch 
experiments were carried out to determine the basic sorption characteristics of the target compounds and their 
interaction with two resins (XAD 1180N and HP20). Dynamic experiments, using a fixed-bed resin column, 
were conducted to determine the optimal loading volume and establish an aqueous ethanol (EtOH) gradient 
elution protocol for selective desorption of benzophenones and xanthones for preparation of the fractions, BEF 
and XEF. As final evaluation of the process, the effect of batch-to-batch variation of the raw plant material 
typical in an industrial environment was quantified in terms of the phenolic composition and degree of 





3.2. Materials and methods 
3.2.1. Chemicals and macroporous resins 
 
 Authentic reference standards (purity > 95%) were obtained from Sigma-Aldrich (St. Louis, MO, 
USA; hesperidin, mangiferin) and Phytolab (Vestenbergsgreuth, Germany, I3G, vicenin-2, isomangiferin). 
IDG and M3G were previously isolated from C. genistoides (Beelders et al., 2014a). All other reagents were 
of analytical grade and supplied by Sigma-Aldrich or Merck (Darmstadt, Germany), except EtOH (Servochem, 
Cape Town, South Africa). Deionized water, prepared using an Elix Advantage 5 (Merck) water purification 
system, was further purified to HPLC grade using a Milli-Q Reference A+ (Merck) water purification system. 
Amberlite XAD 1180N macroporous resin (polystyrene divinylbenzene matrix; 0.35–0.6 mm 
diameter; 450 m2/g specific surface area; 300–400 Å average pore diameter; 61–67% moisture holding 
capacity) and Diaion HP20 macroporous resin (polystyrene divinylbenzene matrix; 0.25–0.6 mm diameter; 
590 m2/g specific surface area; 290 Å average pore diameter; 55–65% moisture holding capacity) were 
purchased from Sigma-Aldrich and pre-treated before experiments according to the manufacturer’s 
instructions. The moisture content of the resin was determined gravimetrically prior to experiments by heating 
an aliquot for 60 min at 100 °C using an HR73 Halogen Moisture Analyser (Mettler-Toledo, Greifensee, 
Switzerland).  
  
3.2.2. Plant material and extract preparation 
 
In total, eleven different batches of unfermented (green/unoxidised) C. genistoides plant material were 
used over the course of the present study, namely Batch A (8 kg), which was used for preliminary and 
optimisation experiments, and batches CG1–10 (0.8–1.6 kg), which were used to investigate the effect of batch-
to-batch variation of plant material on the enrichment process. Batch A was obtained by pooling shoots from 
randomly selected C. genistoides bushes that were harvested from two commercial plantations, established 
with seedlings from open-pollinated seeds. Batches CG1–10 were obtained from two different locations 
(34.54340°S, 19.87983°E, Toekomst Farm, Bredasdorp, South Africa; 34.144694°S, 19.901685°E, Tygerhoek 
Research farm, Riviersonderend, South Africa). 
The freshly harvested plant material was mechanically cut into small pieces (≤ 3 mm), spread on drying 
trays and dried to a moisture content ≤ 7% in a cross-flow dehydrator at 40 °C for 16 h. The dried plant material 
was mechanically sieved for 30 s using a SMC Mini-sifter (JM Quality Services, Cape Town, South Africa) 
to remove coarse pieces (> 1.68 mm) and fine dust (< 0.42 mm), prior to coarse milling (1 mm sieve; Retsch, 
GmbH, Haan, Germany).  
A hydro-ethanolic extract of each batch, intended as the starting material for ultrafiltration, was 
prepared according to the optimum extraction conditions determined by Bosman et al. (2017). Briefly, the 
milled plant material was batch extracted (40% EtOH-water, v/v; 10:1 solvent:solid ratio, v/m; extraction for 




rotary evaporation at 40 °C, and the aqueous residue was subsequently freeze-dried using a VirTis Advantage 
Plus freeze-drier (SP Scientific, Warminster, PA, USA). The freeze-dried extracts were stored under 
desiccation until required for ultrafiltration.  
 
3.2.3. Tangential flow ultrafiltration 
 
The concentration of the initial feed solution for ultrafiltration, i.e. freeze-dried extracts reconstituted 
in 40% aqueous EtOH (v/v), was set at 3% (m/v) as specified in the optimised protocol for tangential flow 
ultrafiltration (TFU) (Bosman, 2014). The basic TFU experimental setup (Fig. 3.1) consisted of a Pellicon 2 
mini-membrane cassette holder (Merck Millipore), containing an Ultracel regenerated cellulose membrane 
(surface area = 0.1 m2; pressure limit ca. 7 bar; Merck Millipore), a Watson Marlow peristaltic pump equipped 
with a 520S LoadSure element (peak operating pressure = 2 bar) (Watson Marlow Pumps, Cornwall, England), 
in-line pressure gauges to measure the inlet and outlet pressure and a retentate valve to create back pressure, 
as well as vessels for the feed solution and permeate. The temperature of the feed solution was maintained at 
30 °C by placing the feed container in a temperature-controlled bath. The ultrafiltration was carried out in 
batch concentration mode, i.e. the retentate was recycled to the feed container and not collected separately. 
The process was stopped when a volume concentration ratio (VCR) of 5 was reached, where VCR refers to 
the ratio (v/v) of the of initial feed solution to retentate remaining after ultrafiltration. 
 
Figure 3.1 Diagram of the tangential flow ultrafiltration system in batch concentration mode: (1) feed 
container; (2) feed; (3) peristaltic pump; (4) manometer; (5) Pellicon 2 Mini membrane cassette; (6) permeate; 
(7) permeate collection container; (8) balance; (9) retentate; (10) manometer; (11) retentate valve. 
 
The percentage enrichment of xanthones and benzophenones in the permeate, referred to henceforth 
as the ultrafiltered C. genistoides extract (UCGE), was calculated according to the equation: 
 





where CU and CIF represent the mass fraction of xanthones (or benzophenones) in the solids content of the 
UCGE and initial feed, respectively. The UCGE produced from plant material batch A is denoted by UCGE0, 
whereas the remaining ten UCGEs are denoted by the subscripts 1–10. 
 
3.2.4. Static adsorption and desorption 
 
UCGE0, reconstituted with deionised water to the specified concentration, served as the test sample 
for all static sorption assays. Static adsorption tests were carried out in triplicate on XAD 1180N and HP20 
resins according to the following general procedure: 250 mg resin (dry mass, d.m.) was weighed into a single 
well of a polypropylene 24-well deep-well microplate (Axygen Scientific, Union City, CA, USA), and 5 mL 
reconstituted UCGE0 solution was added to initiate the experiment. Control wells for each treatment contained 
5 mL of the UCGE0 solution, but no resin. The wells were sealed with aluminium foil strips, and the plate was 
shaken at 450 rpm for the specified time-period using an Eppendorf Mixmate (Hamburg, Germany). Upon 
completion, the supernatant was sampled and analysed by high-performance liquid chromatography with diode 
array detection (HPLC-DAD).  
 The effect of the initial sample concentration on target compound adsorption was determined by 
adding aqueous UCGE0 solutions (1, 3, 5 and 10 mg/mL) to the resin and shaking for 24 h at room temperature 
(ca. 23 °C). 
The effect of contact time on adsorption was determined by adding a calculated optimal initial loading 
of UCGE0 to the resin and shaking for 24 h at room temperature. Supernatant samples were collected at time 
intervals of 1, 2, 3, 4, 5 and 24 h, respectively. Separate wells loaded with resin and UCGE0 solution 
represented the individual time intervals.  
 Subsequently, the effect of different aqueous EtOH concentrations (0, 5, 10, 15, 20, 30, 40, 50 %; v/v) 
on static batch desorption of xanthones and benzophenones from loaded resin was investigated. Five-milliliter 
volumes of aqueous EtOH at the specified concentrations were added to separate wells containing resin (250 
mg, d. m.) loaded with UCGE0 at a predetermined optimal loading concentration after incubation for the 
optimal contact time. The supernatant of each well was sampled after 4 h of shaking at 450 rpm at room 
temperature. 
 Adsorption and desorption ratios were calculated using the following equations: 
 
45 =	U/(2/V2.)W 	 	 	 (Eq. 3.2) 
AR = U/(2/V2.)(2/U/) × 100%  (Eq. 3.3) 
DR =	 21U1U/(2/V2.)× 100% (Eq. 3.4) 
 
where Qe is the adsorption capacity (mg/g), which represents the mass of target compound adsorbed to 1 g of 
resin at the adsorption equilibrium, AR is the adsorption ratio (%) representing the percentage of the loaded 




compound in solution, respectively (mg/mL), V0 is the initial volume of solution added into the well (mL), W 
is the dry mass of the resin (g), DR is the desorption ratio (%), Cd is the equilibrium concentration of the target 
compound in the desorption solution (mg/mL), and Vd is the volume of the desorption solution (mL). Addition 
of the subscripts, X and B, refers to xanthones and benzophenones, respectively. 
 
3.2.5. Adsorption isotherms 
 
 The effect of temperature on xanthone and benzophenone adsorption onto XAD 1180N resin was 
investigated in triplicate batch sorption experiments using the following procedure: 5 mL of aqueous UCGE0 
solutions (1, 2, 3, 5, 7.5 and 10 mg/mL) were added to 250 mg of resin and shaken at 450 rpm for 2 h at 25 °C, 
whereafter the supernatant was sampled for HPLC-DAD analysis. The temperature was controlled by placing 
the shaker inside a temperature-controlled oven and controlling the ambient temperature in the room at 23 °C. 
The experiments were repeated at 40 °C. The data were fitted to the Langmuir and Freundlich models (eqs. 
3.5 and 3.6, respectively) to evaluate the adsorption behaviour between the target compounds and the resin: 
 
-.
-/ =	 0)12.(3	0)12.)   (Eq. 3.5) 
45 =	6785/:   (Eq. 3.6) 
 
where Qe and Ce are the same as defined in equation 3.2, Q0 is the theoretical maximum adsorption 
capacity (mg/g), Kad is the adsorption equilibrium constant (mL/mg), KF is the Freundlich constant, which 
indicates adsorption capacity, and n is an empirical constant in the Freundlich model relating to the adsorption 
intensity of the system. 
 
3.2.6. Small-column dynamic adsorption and desorption  
 
 Small-scale dynamic sorption experiments were performed using a glass column (25 mm ID × 700 mm 
height; Omnifit Labware, Diba Industries, Inc., Danbury, CT, USA), wet-packed with XAD 1180N resin to a 
bed height of 195 mm (bed volume, BV = 96 mL; bed height-to-diameter ratio = 7.8:1). A constant eluate flow 
rate of 2 BV/h, as prescribed by the supplier, was maintained by means of a Gilson Minipuls 3 peristaltic pump 
(Gilson International, Villiers-e-Bel, France) fitted to the bottom of the column. The top of the resin column 
was kept submerged with solvent to prevent it from drying out and trapping air in the resin column. 
 A dynamic adsorption (loading) assay was conducted first to determine the breakthrough volumes for 
the target compounds and establish the optimal loading volume. The column was loaded with 15 BVs of 
UCGE0, dissolved in water at the calculated loading concentration, and each BV (n = 15) of eluate was 
individually collected and analysed by HPLC-DAD. Following the determination of an optimal loading 
volume, a dynamic desorption assay was performed using gradient steps of 5, 10, 30 and 40% aqueous EtOH 





3.2.7. Scale-up of fractionation 
 
 The optimised MARC protocol for producing BEFs and XEFs, established on a small-scale as 
described in Section 3.2.6, was scaled up to a larger glass column (70 mm ID × 1000 mm height) wet-packed 
with resin to a bed height of 550 mm (BV = 2.1 L; bed height-to-diameter ratio = 7.8:1). Triplicate 
fractionations were carried out on the same resin column with UCGE0. The eluate flow rate (2 BV/h) was 
controlled using a Watson Marlow 5O5U peristaltic pump (Watson-Marlow Ltd., Falmouth, England) fitted 
to the bottom of the open column, while maintaining submersion of the resin column as described for the 
smaller column. BEFs were collected by eluting the column with 6 BVs of 5% EtOH followed by 3 BVs of 
10% EtOH. Subsequently, XEFs were collected by eluting the column with 4 BVs of 30% EtOH.  Regeneration 
of the resin between experimental runs entailed rinsing the column bed with 2 BVs each of 50%, 75% and 
100% EtOH at a flow rate of 2 BV/h. 
 
3.2.8. Effect of batch-to-batch variation of plant material on phenolic composition and degree of 
enrichment of fractions 
 
 To determine the effect of batch-to-batch variation of the raw material on the production of BEFs and 
XEFs by the optimised MARC protocol, the freeze-dried ultrafiltered extracts (n = 10; UCGE1–10) were 
reconstituted to 3 mg/mL with deionised water for fractionation on the small column. Each reconstituted 
UCGE was fractionated (in triplicate) according to the optimised MARC protocol using a new resin column 
for each run, i.e. the resin was not regenerated or re-used. The enrichment ratios (ERs) for xanthone and 
benzophenone contents in XEF and BEF were determined as follows: 
 
ER = 2ZS2Q    (Eq. 3.7) 
 
where CEF and CU refer to the content (g/100 g soluble solids) of the target compounds in the enriched fractions 
and their corresponding UCGE, respectively. 
 
3.2.9. High-performance liquid chromatography with diode-array detection (HPLC-DAD) 
 
 All samples (ultrafiltration initial feed preparations and end-products; static and dynamic sorption 
assays) were analysed by HPLC-DAD for quantification of the major phenolic compounds, using a validated 
method developed specifically for C. genistoides by Beelders et al. (2014b). Any residual EtOH in samples 
was evaporated in vacuo before sample analysis. Ascorbic acid was added to samples prior to analysis to 
prevent oxidation of compounds. After mixing, the samples and standard mixtures were filtered using 0.45 µm 
Millex-HV syringe filters (Merck Millipore). IDG, M3G and isomangiferin were quantified based on their 
response factor to hesperidin, vicenin-2 and mangiferin, respectively. HPLC-DAD analysis was performed on 




diode array detector, using Openlab Chemstation software (Agilent Technologies Inc., Santa Clara, CA, USA) 
for instrument control and data analysis. Separation was achieved on a Kinetex column (150 × 4.6 mm ID, 
2.6 µm dp; Phenomenex, Torrance, CA, USA) maintained at 30 °C, with the mobile phase consisting  of (A) 
1% aqueous formic acid (v/v), (B) methanol and (C) acetonitrile, at a flow rate of 1.0 mL/min. Multi-linear 
gradient elution was carried out as follows: 0 min (95.0% A, 2.5% B, 2.5% C), 5 min (95.0% A, 2.5% B, 2.5% 
C), 45 min (75% A, 12.5% B, 12.5% C), 55 min (50% A, 25.0% B, 25.0% C), 56 min (50% A, 25.0% B, 
25.0% C), 57 min (95.0% A, 2.5% B, 2.5% C), 65 min (95.0% A, 2.5% B, 2.5% C). UV-Vis spectra were 
recorded at 200–700 nm, with selective wavelength monitoring at 288 nm (benzophenones) and 320 nm 
(xanthones). The quantification of the compounds was based on six-point calibration curves, spanning 
expected concentration ranges.  
 
3.2.10. Soluble solids  
 
 The soluble solids contents of the ultrafiltration initial feed preparations and end products (UCGEs 
and retentates) were determined gravimetrically by evaporating duplicate 10 mL aliquots in pre-weighed nickel 
moisture dishes on a steam bath, followed by drying in a laboratory oven at 100 °C for 1 h. 
 
3.2.11. Data analysis 
 
 Static adsorption data (loading concentration and contact time) were subjected to ANOVA using 
XLStat (Version 7.5.2, Addinsoft, New York, NY, USA). Least significant difference of the Student’s t-test 
(P = 0.05) was calculated to compare treatment means where significant differences (P < 0.05) were found. 
Levene’s test was used to test for homogeneity of variance. In instances where variances were not equal, 
weighted analysis of variance was used for the combined analyses. The Shapiro-Wilk test was performed on 
the standardised residuals from the models to assess for normal distribution of the data. Adsorption isotherm 
data were fitted to the Langmuir and Freundlich model using Excel 2010 (Microsoft Corporation, Redmond, 
WA, USA). 
 
3.3. Results and discussion 
 
The growing interest in the health-promoting potential of green C. genistoides extracts prompted the 
optimisation of a hydro-ethanolic extraction protocol (Bosman et al., 2017) and a scalable ultrafiltration 
protocol (Bosman, 2014) for the production of enriched extracts. The optimised extraction protocol, applied 
to plant material Batch A, produced an extract that served as the initial feed (starting material) for 
ultrafiltration, which produced UCGE0 and a retentate (by-product). Xanthone enrichment of 20.7% and 
benzophenone enrichment of 25.4% was achieved by ultrafiltration (Table 3.1). This compares favourably 
with xanthone enrichment of 20–22% previously reported (Bosman, 2014). More detailed results of the 




supplementary material (Table S1). UCGE0, with total xanthone and total benzophenone contents of 15.16% 
and 3.21%, respectively, served as the starting material for fractionation by adsorbent resin. 
 
Table 3.1 Application of an optimised tangential flow ultrafiltration protocol to 
an extract of green Cyclopia genistoides. 
Compound class 
Content (g/100 g) Ultrafiltration 
enrichmentc 
(%) Initial feeda Retentate UCGE0b 
Xanthones 12.56 7.78 15.16 20.7 
Benzophenones 2.56 1.46 3.21 25.4 
a 23 L of 40% hydro-ethanolic extract of  plant material Batch A; b ultrafiltered 
Cyclopia genistoides extract (permeate); c increase in content from initial feed to 
permeate as expressed on a soluble solids basis 
 
 
3.3.1. Static adsorption and desorption 
 
Sorption studies conducted in a closed batch (static) system are useful for determining optimal process 
parameters, e.g. sample concentration and temperature, before commencing dynamic adsorption experiments 
(Ma et al., 2009; Zhao et al., 2011; Wang et al., 2014; Nian et al., 2016). The effects of the initial UCGE0 
loading concentration (1, 3, 5 and 10 mg/mL) on the adsorption of total xanthones (mangiferin + isomangiferin) 
(Fig. 3.2a) and total benzophenones (I3G + M3G + IDG) (Fig. 3.2b) onto XAD 1180N and HP20 resins, were 
evaluated at room temperature (ca. 23 °C) for 24 h. The ARX for total xanthones remained very high (> 94%) 
at all loading concentrations for both resins despite showing a general decrease with increasing loading 
concentrations. This indicates that most of the xanthones in the sample adsorbed onto the resin even when the 
initial loading concentration was increased ten-fold from 1 to 10 mg/mL. The limiting factor was the 
benzophenones, as ARB initially increased for XAD1180N when the sample concentration was increased from 
1 mg/mL to 3 mg/mL, but then decreased at higher sample concentrations. The highest ARB (93.5%) was 
achieved with XAD 1180N at 3 mg/mL, which was selected as the fixed UCGE concentration going forward 








Figure 3.2 Adsorption ratios (ARs) at room temperature (ca. 23 °C) for Cyclopia genistoides xanthones and 
benzophenones on Amberlite XAD 1180N and Diaion HP20 macroporous resins as a function of (a, b) sample 
loading concentration (mg/mL) and (c, d) contact time (h), as well as (e) ARs for individual compounds on 
XAD 1180N using 3 mg/mL loading concentration and 2 h contact time. Same letters inside bars indicate no 
significant difference (P < 0.05) (IDG = 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone; 
I3G = 3-β-D-glucopyranosyliriflophenone; M3G = 3-β-D-glucopyranosylmaclurin). Data are presented as 
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 At room temperature, more than 95% of the xanthones was adsorbed onto both resins after 1 h in the 
closed batch system. The ARX values increased to > 98% after 2 h (Fig. 3.2c). No substantial improvement in 
ARX was noted with longer contact times. A similar trend was observed for the benzophenones (Fig. 3.2d). 
ARB values increased significantly (P < 0.05) from 1 h to 2 h contact time for both resins, but mostly did not 
improve beyond that time-point to a degree that would justify longer contact times. Therefore, 2 h was selected 
as the contact time for subsequent batch adsorption experiments focussing on the effect of temperature. XAD 
1180N was ultimately selected as the resin for optimisation of the MARC protocol going forward. This was 
particularly based on better adsorption of IDG to XAD 1180N than to HP20, at the selected sample loading 
concentration of 3 mg/mL (Fig. 3.2e).  
 
3.3.1.1. Adsorption isotherms 
 
 The Langmuir and Freundlich isotherms (eqs. 3.5 and 3.6) are the most frequently used models for 
describing adsorption equilibrium data of phytochemicals on adsorbent resins. The behaviour of an adsorbent-
adsorbate system cannot easily be predicted and depends on various factors, e.g. resin characteristics (porosity, 
surface area, particle size), target compound attributes (water solubility, ionic charge, structure, functional 
groups, pKa, polarity, molecular weight) and solution conditions (solvent type, temperature, pH, solute 
concentration) (Bretag et al., 2009; Kammerer et al., 2011; Soto et al., 2011). The term 1/n in the Freundlich 
equation is an indicator of the degree of favourability of adsorption of a given adsorbate to an adsorbent, with 
0.1 < 1/n < 1.0 indicating favourable adsorption. The more 1/n approximates a value of 1.0, the higher the 
adsorption affinity, whereas 1/n > 1.0 indicates low affinity and poor adsorption capacity (Soto et al., 2011). 
 The Langmuir and Freundlich parameters for IDG, M3G, I3G, total xanthone and total benzophenone 
adsorption at 25 °C and 40 °C are summarised in Table 3.2. Higher adsorption affinity and capacity were 
observed at the lower temperature (25 °C) for all adsorbates, as represented by the respective 1/n and KF values 
of the Freundlich model. In all instances, the higher KF value at the lower temperature indicated an exothermic 
(thermo-positive) adsorption process (Zheng et al., 2013). The effects of temperature on various adsorbent-
adsorbate systems for plant phenolics have been reviewed by Soto et al. (2011). Lower temperatures were 
reported to enhance adsorption in many cases, including the adsorption of mangiferin on HPD400 macroporous 
resin (Nian et al., 2016), but the opposite, i.e. an endothermic process, has also been described (in addition to 
temperature having no significant effect). A key advantage of exothermic adsorption is that no additional 
energy expenditure in the form of heating is required to improve the process, a considerable advantage when 
the process is scaled up. Subsequent experiments were thus carried out at room temperature (ca. 23 °C). 
 The Freundlich model parameters provide further insight into the adsorption process: comparing KF 
values for the different compounds at 25 °C (Table 3.2) clearly indicates greater affinity of the resin for the 
xanthones (KF  = 195.4) than for the benzophenones (KF  = 30.5). The data for mangiferin and isomangiferin 
were similar (not shown), and are therefore represented as total xanthones (sum of mangiferin and 
isomangiferin content). Considering the individual benzophenones: the adsorption affinity at both 25 °C and 




O-glucosyl moiety) and higher molecular weight of IDG could explain the lower affinity of the non-polar resin 
for this compound. 
 
Table 3.2 Langmuir and Freundlich parameters for adsorption of Cyclopia genistoides benzophenones and 




Langmuir modela Freundlich modelb 
Equation R² Equation n R² 
IDGc 
25 Ce/Qe = 0.571Ce + 0.009 0.991 Qe = 9.824Ce0.559 1.65 0.983 
40 Ce/Qe = 0.784Ce + 0.013 0.996 Qe = 5.139Ce0.538 1.86 0.984 
M3Gd 
25 Ce/Qe = 0.889Ce + 0.005 0.986 Qe = 13.67Ce0.623 1.61 0.975 
40 Ce/Qe = 1.167Ce + 0.005 0.996 Qe = 5.707Ce0.553 1.81 0.982 
I3Ge 
25 Ce/Qe = 0.237Ce + 0.002 0.981 Qe = 37.09Ce0.621 1.61 0.982 
40 Ce/Qe = 0.289Ce + 0.003 0.991 Qe = 19.04Ce0.587 1.71 0.979 
Xf 
25 Ce/Qe = 0.027Ce + 0.001 0.975 Qe = 195.4Ce0.661 1.51 0.985 
40 Ce/Qe = 0.023Ce + 0.001 0.989 Qe = 134.6Ce0.671 1.49 0.984 
Bg 
25 Ce/Qe = 0.130Ce + 0.005 0.985 Qe = 30.52Ce0.620 1.54 0.985 
40 Ce/Qe = 0.171Ce + 0.008 0.992 Qe = 16.20Ce0.590 1.70 0.988 
a 
-.
-/ =	 0)12.(3	0)12.); b 45 =	6785/:; c 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone; d 3-β-D-
glucopyranosyliriflophenone; e 3-β-D-glucopyranosylmaclurin; f total xanthone content (mangiferin + 
isomangiferin); g total benzophenone content (IDG + I3G + M3G) 
 
3.3.1.2. Effect of ethanol concentration on static desorption of xanthones and benzophenones 
 
Desorption ratios (DRs) for the individual benzophenones (IDG, M3G and I3G), benzophenones 
(total) and xanthones (total) were plotted as a function of the EtOH concentration of the desorption solvent 
(Fig. 3.3). Mangiferin and its regio-isomer, isomangiferin, showed near identical desorption behaviour (data 
not shown), and are therefore represented by a curve for the total xanthone content (sum of mangiferin and 
isomangiferin content). The three benzophenones displayed different desorption characteristics, with IDG 
desorbed to a greater extent (DR = 20.5%) with 0% EtOH, i.e. pure water, than the other compounds. This 
implies that some of the adsorbed IDG could be washed off a loaded resin column using only water. It also 
explains why ARB < ARX for the static adsorption experiments (Fig. 3.2), since a higher proportion of IDG 
will desorb in a 100% aqueous medium, thereby lowering ARB. Amongst the target compounds, the lowest 
DR was observed for xanthones at 0% EtOH (1.37%) (Fig. 3.3), emphasising the higher affinity of the resin 
for xanthones over the other target compounds as evidenced by the Freundlich model parameters (Table 3.2). 
A desorption curve for the glycosylated flavanone, hesperidin, also present in UCGE in significant amounts 
(1.4 g/100g), was plotted as well (Fig. 3.3). This was not a compound of interest in the present study, and its 
separation from the target compounds was desirable. Desorption data for hesperidin indicated a substantially 
higher affinity for the resin compared to the target compounds. An EtOH concentration > 35% was required 




same degree of desorption for the target compounds. This suggested that effective column separation of 
hesperidin from the target compounds could be achieved by avoiding EtOH concentrations > 30% in the eluting 
agent. 
 
Figure 3.3 Effect of ethanol concentration (%, v/v) on desorption of Cyclopia genistoides xanthones and 
benzophenones from XAD 1180N resin at room temperature (ca. 23 °C) (IDG = 3-β-D-glucopyranosyl-4-O-
β-D-glucopyranosyliriflophenone; I3G = 3-β-D-glucopyranosyliriflophenone; M3G = 3-β-D-
glucopyranosylmaclurin; X = total xanthone content [mangiferin + isomangiferin]; B = total benzophenone 
content [IDG + I3G + M3G]; H = hesperidin). Data are presented as mean ± standard deviation (n = 3). 
 
 
 Acosta et al. (2016) investigated the solubility of mangiferin in water and five other commonly used 
organic solvents, including EtOH. At 30 °C, mangiferin was reported to be “slightly” soluble in EtOH 
(1.25 g/100 g EtOH), and “sparingly” soluble in water (0.20 g/100 g water), and the solubility increased with 
increasing temperature from 5 to 60 °C. There are no similar solubility data available for the target 
benzophenones in the present study, but the desorption data (Fig. 3.3) suggest that the target benzophenones 
have higher water solubility than the xanthones, and in the descending order of 
IDG > M3G > I3G > xanthones. This is similar to their separation order on reversed phase HPLC-DAD 
(Beelders et al., 2014b). Based on the results, the most likely concentration range for gradient elution with 
aqueous EtOH to achieve separation of BEFs and XEFs is 0–40% EtOH.   
 
3.3.2. Dynamic adsorption and desorption experiments 
3.3.2.1. Small-column dynamic adsorption 
 
 Laboratory-scale dynamic sorption experiments can provide useful data for the development of large-
scale, industrial MARC systems (Soto et al., 2011). Provided that the resin column dimensional ratio (bed 
height to diameter) is maintained, laboratory-scale protocols can easily be scaled up because flow rates and 


































 Dynamic adsorption and desorption experiments were carried out at room temperature (ca. 23 °C) 
using a flow rate of 2 BV/h. Adsorption to macroporous resins involves the diffusion of solutes, and 
interactions between solute molecules and the resin surface, including hydrophobic interactions, simple 
stacking and hydrogen bonding (Sandhu & Gu, 2013). As per the supplier’s recommendations, the 2 BV/h 
flow rate was chosen to ensure sufficient contact time between the resin and target compounds. The same flow 
rate has been used in previous studies on the enrichment of various phytochemicals by MARC (Wang et al., 
2012; Yang et al., 2012; Xiao et al., 2013; Nian et al., 2016). It should be noted that what constitutes a low or 
high flow rate in an open column chromatography system is very much user-defined and/or dependent on the 
dimensions and limitations of the equipment being used (refer to Chapter 2, Section 2.5.3.2; p. 52). 
 In dynamic column loading, there must be a pre-determined “breakthrough” or saturation point, i.e. 
the loading volume at which a given compound will reach a specified concentration in the eluate, typically a 
low percentage of its concentration in the initially loaded sample. This percentage value is user-defined and 
varies from 5% (Sandhu & Gu, 2013; Buran et al., 2014) to 10% (Yang et al., 2012). We chose a lower 
breakthrough percentage (3%) to minimise losses of IDG. Loading of the column should therefore be halted, 
before the first target compound to elute, exceeds this specified concentration. Another approach is to set the 
saturation point as the point where the last target compound to elute reaches its breakthrough concentration 
(10%) (Yang et al., 2012). In such a scenario, substantial amounts of target compounds would presumably be 
lost in the “pre-fraction”. 
 IDG reached its breakthrough concentration between 3 and 4 BVs of loaded sample (Fig. 3.4). This 
agrees with the adsorption isotherm data (Table 3.2), which indicated that IDG had the lowest affinity for the 
resin, and static batch desorption data (Fig. 3.3), which showed that IDG had the greatest tendency to desorb 
in pure water. Therefore, a column loading volume of 3 BVs was selected for the optimised MARC protocol 
going forward to limit the loss of IDG in the pre-fraction. Considering the other target benzophenones: the 
M3G breakthrough point occurred between 11 and 12 BVs of sample loading (Fig. 3.4), and I3G did not reach 
its breakthrough point within the experimental range (15 BVs). If collection only started after 10 BVs, 
approximately 6% of IDG would have been lost in the pre-fraction. The xanthones remained undetectable in 
the eluate up to 15 BVs of sample loading, reflecting their very high adsorption ratios (> 94%) observed under 






Figure 3.4 Dynamic breakthrough curves for Cyclopia genistoides benzophenones on XAD 1180N resin at 
room temperature (ca. 23 °C) at an eluate flow rate of 2 bed volumes per hour (IDG = 3-β-D-glucopyranosyl-
4-O-β-D-glucopyranosyliriflophenone; M3G = 3-β-D-glucopyranosylmaclurin; I3G = 3-β-D-
glucopyranosyliriflophenone). The dashed horizontal line indicates the breakthrough point of IDG. Data are 
presented as mean ± standard deviation (n = 3). 
 
 
3.3.2.2. Small-column dynamic desorption 
 
Using the calculated optimal column loading volume, selective dynamic desorption of BEF and XEF 
was attempted by step-wise gradient elution. Selective desorption of specific target compounds from a loaded 
macroporous resin column can be achieved by a step-wise increase in the concentration of the organic solvent, 
i.e. by gradient elution (Nian et al., 2016). MARC protocols may include an initial desorption step using pure 
water to first elute hydrophilic substances and high molecular weight polysaccharides from the loaded resin 
column, before increasing the organic solvent concentration for selective desorption of specific polyphenolic 
target compounds (He & Xia, 2008). A pure water rinsing step was omitted due to the tendency of IDG to 
desorb from XAD 1180N in substantial amounts in a pure water medium (Fig. 3.3). The need for a water-
rinsing step was further reduced by the upstream ultrafiltration step that already removed material > 10 kDa 
molecular weight, including water-soluble polysaccharides, from the crude extract. 
Various studies have described the use of aqueous to pure EtOH mixtures for selective desorption of 
phytochemicals from macroporous resins (Soto et al., 2011). The results of the batch desorption experiments 
(Fig. 3.3) indicated that desorption of the loaded column with an aqueous EtOH solution < 10% could result 
in the recovery of benzophenones with minimal co-elution of xanthones, whereas aqueous EtOH 
concentrations ≥ 30% would achieve xanthone recovery after elution of the benzophenones. 
A dynamic desorption protocol, consisting of 3 BVs each of 5, 10, 30 and 40% aqueous ethanol 
(2 BV/h flow rate) (Fig. 3.5) showed that 5% EtOH was effective for selective desorption of IDG and M3G, 
but less so for I3G. Desorption of I3G increased at an EtOH concentration of 10%, but this was accompanied 
by a gradual increase in co-elution of xanthones. Increasing the EtOH concentration to 30% resulted in a sharp 





























the content of the other benzophenones (IDG and M3G) in the eluate had already peaked, but I3G only peaked 
at 2 BVs of 30% EtOH (Fig. 3.5). This suggests that co-elution of I3G with the xanthones might prohibit the 
complete separation of xanthones and benzophenones when using only the limited resolving capabilities of 
open column chromatography. Furthermore, I3G, but not IDG or M3G, was also present as an “impurity” in a 
xanthone fraction of C. genistoides extract obtained by a step-wise methanol gradient fractionation on an 
Amberlite XAD 1180 resin column (Raaths, 2016). 
EtOH concentrations of 30 and 40% were investigated for selective desorption of XEF (Fig. 3.5). Co-
elution of hesperidin occurred with the xanthones at 40% EtOH, which would reduce the purity of xanthones 
in the resultant XEF. Similarly, Nian et al. (2016) reported higher desorption efficiency for mangiferin when 
using 30% aqueous EtOH vs. 40% aqueous EtOH on three different saturated polystyrene resins. Only trace 
amounts of hesperidin co-eluted with the xanthones at 30% EtOH, but hesperidin content sharply increased 
with 40% EtOH as eluent, similar to what had been observed in static batch desorption (Fig. 3.3).  
 
 
Figure 3.5 Dynamic desorption of major Cyclopia genistoides phenolic compounds from XAD 1180N resin 
at room temperature (ca. 23 °C) using 3 bed volumes (BVs) each of 5, 10, 30 and 40% (v/v) aqueous ethanol 
at a flow rate of 2 BV/h (IDG = 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone; M3G = 3-β-D-
glucopyranosylmaclurin; I3G = 3-β-D-glucopyranosyliriflophenone). 
 
 
3.3.2.3. Scale-up of fractionation 
 
The desorption protocol selected for scale-up entailed 6 BVs of 5% EtOH, followed by 3 BVs of 10% 
EtOH to elute BEF with minimal xanthone content, and 4 BVs of 30% EtOH to desorb XEF with minimal co-
eluted hesperidin. Linear scalability of unit operations is an important consideration for the downstream 
development of industrial-scale processes (Putnik et al., 2013). We investigated the linear scalability of the 
MARC protocol by using a larger column, but maintaining the same resin bed height-to-diameter ratio (7.8:1). 
The same UCGE was used as the starting material for the scaled-up fractionation. Three runs of the MARC 
protocol were carried out using the same packed resin bed (Fig. 3.6a) with a regeneration step between runs to 







































Table 3.3 shows the content of the target compounds in the triplicate BEFs and XEFs produced from 
UCGE0. HPLC-DAD chromatograms for the starting material (UCGE0, Fig. 3.6b) and its enriched fractions 
from the first experimental run (BEF A, Fig. 3.6c and XEF A, Fig. 3.6d) are provided in Fig. 3.7. The triplicate 
BEFs (A–C) were all greatly enriched in total benzophenone content (12.37–18.78%) compared with the 
UCGE0 (3.38%), and all had low xanthone content (< 0.2%). The IDG and M3G content of BEF varied little 
with successive runs on the regenerated resin, but I3G content decreased sharply with each successive run 
(8.51% > 4.89% > 1.31%). This was accompanied by a corresponding increase in the I3G content of XEF with 
each successive run (0.76% < 3.10% < 5.77%), indicating a change in the affinity of the resin toward I3G. 
Soto et al. (2011) reviewed the regeneration of macroporous adsorbents, and noted that irreversible adsorption 
of polyphenols could be the result of oxidative polymerisation or specific functional groups binding to active 
moieties on the resin surface. In general, published studies involving macroporous resin chromatography do 
not mention or provide sufficient details on the types of resin regeneration procedures that were followed. 
Further research would be necessary to identify an optimal regeneration protocol for used XAD 1180N resin, 
which would be beneficial in terms of the industrial applicability and economy of the process.  
 
Table 3.3 Content of benzophenones and xanthones in triplicate xanthone and benzophenone fractions 
produced from an ultrafiltered Cyclopia genistoides extract (UCGE0) using a scaled-up macroporous resin 
adsorption process, including resin regeneration with 50–100% EtOH between runs (A–C). 
Sample 
Content (g/100 g) 
IDGa M3Gb I3Gc Mangiferin Isomangiferin Xanthonesd Benzophenonese 
BEF A 6.57 3.70 8.51 0.08 0.04 0.12 18.78 
BEF B 6.55 3.70 4.89 0.07 0.04 0.11 14.78 
BEF C 7.22 3.34 1.31 0.06 0.03 0.09 12.37 
XEF A nd nd 0.76 29.17 8.44 37.62 0.76 
XEF B nd nd 3.10 40.09 11.60 51.69 3.10 
XEF C nd nd 5.77 37.48 12.03 49.51 5.77 
Resin was regenerated between runs A–C by eluting with 2 bed volumes each of 50, 75 and 100% EtOH at 2 BV/h. 
BEF, benzophenone-enriched fraction; XEF, xanthone-enriched fraction; nd = not detected; a 3-β-D-glucopyranosyl-
4-O-β-D-glucopyranosyliriflophenone; b 3-β-D-glucopyranosylmaclurin; c 3-β-D-glucopyranosyliriflophenone; d Sum 
of mangiferin and isomangiferin content; e Sum of IDG, M3G and I3G content  
 
3.3.2.4. Effect of batch-to-batch variation 
 
For this experiment, a new column of unused resin was packed for each experimental run to eliminate 
potential effects of decreasing resin adsorption efficiency, which could confound the effect of phenolic content 
variation on the fractionation process. In an industrial scenario, plant material batches will be of varying 
phenolic composition as many factors such as inherent genetic variation, harvesting date and post-harvest 
processing could play a role. Ten batches of unfermented C. genistoides (CG1–10) were used to prepare UCGE1–
10 with extraction (Bosman et al., 2017) and ultrafiltration (Bosman, 2014) conditions being constant. The 




mangiferin and isomangiferin content, while UCGE3 contained the most M3G and I3G. Total xanthone 
enrichment by ultrafiltration ranged between 33.4 and 49.6 (mean = 41.9%), and total benzophenone 
enrichment ranged between 37.9 and 59.9 (mean = 47.8%) (Table 3.5), emphasising how the different phenolic 
profiles of the initial feeds may affect the enrichment. Enrichment data for the individual xanthones 
(mangiferin, isomangiferin) and benzophenones (IDG, M3G and I3G) are provided as supplementary material 
(Table S2; p. 215). 
 
Table 3.4 Effect of plant material variation on content of major xanthones and benzophenones in ten 
ultrafiltered Cyclopia genistoides extracts (UCGE1–10), used as the starting materials for subsequent production 
of separate benzophenone- and xanthone-enriched fractions by macroporous adsorbent resin chromatography. 
Sample 
Content (g/100 g) 
IDGa M3Gb I3Gc Mangiferin Isomangiferin 
UCGE1 2.12 ± 0.02 0.67 ± 0.00 1.69 ± 0.01 14.07 ± 0.10 3.96 ± 0.05 
UCGE2 1.84 ± 0.08 0.76 ± 0.04 1.41 ± 0.06 11.91 ± 0.58 3.04 ± 0.15 
UCGE3 2.71 ± 0.01 0.78 ± 0.01 4.29 ± 0.03 11.38 ± 0.07 3.14 ± 0.01 
UCGE4 3.06 ± 0.02 0.65 ± 0.01 1.75 ± 0.01 14.39 ± 0.10 4.03 ± 0.03 
UCGE5 1.21 ± 0.01 0.40 ± 0.00 0.99 ± 0.01 13.02 ± 0.14 3.86 ± 0.04 
UCGE6 2.31 ± 0.04 0.36 ± 0.00 1.12 ± 0.00 9.77 ± 0.10 2.68 ± 0.01 
UCGE7 1.98 ± 0.01 0.50 ± 0.00 1.45 ± 0.02 15.10 ± 0.08 3.95 ± 0.03 
UCGE8 1.88 ± 0.05 0.73 ± 0.03 1.62 ± 0.01 10.75 ± 0.48 2.99 ± 0.11 
UCGE9 2.41 ± 0.01 0.56 ± 0.00 1.60 ± 0.01 10.33 ± 0.09 2.64 ± 0.01 
UCGE10 1.55 ± 0.01 0.68 ± 0.00 1.55 ± 0.01 11.19 ± 0.05 3.11 ± 0.02 
a 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone; b 3-β-D-glucopyranosylmaclurin; c 3-β-D-
glucopyranosyliriflophenone. Data are presented as mean ± standard deviation (n = 3). 
 
Table 3.5 Enrichment in total xanthone and total benzophenone contents achieved after tangential flow 
ultrafiltration of hydro-ethanolic extracts (n = 10) of green Cyclopia genistoides (40% ethanol-H2O, v/v) 
produced from plant material batches CG1–10. 
Batch 














CG1 13.50 19.25 42.6  3.24 4.79 47.6 
CG2 11.98 16.16 34.9  3.17 4.38 37.9 
CG3 10.49 15.20 44.9  5.40 8.19 51.9 
CG4 12.99 19.28 48.4  3.72 5.80 56.0 
CG5 12.10 18.11 49.6  1.91 3.05 59.9 
CG6 9.31 13.16 41.4  2.87 4.28 48.8 
CG7 14.49 19.93 37.6  3.18 4.41 38.7 
CG8 10.68 14.99 40.4  3.25 4.77 46.9 
CG9 9.93 14.44 45.5  3.35 5.08 51.5 
CG10 11.83 15.77 33.4  2.99 4.14 38.6 
Mean 11.73 16.63 41.9  3.31 4.89 47.8 
a content expressed as g/100 g soluble solids; b 40% aqueous ethanol extract with 3% soluble solids content; 
c ultrafiltered Cyclopia genistoides extract (permeate); d increased content in permeate compared with initial feed, 









Figure 3.6 (a) Scaled-up open glass column (70 mm internal diameter × 1000 mm height; 550 mm resin bed height); (b) ultrafiltered Cyclopia genistoides extract 
(UCGE0); (c) benzophenone-enriched fraction (BEF A); (d) xanthone-enriched fraction (XEF A). UCGE0 was used as the starting material for the production of BEF 
A and XEF A, using the open column chromatography system depicted in (a). Samples were freeze-dried after in vacuo removal of ethanol. 
a 








Figure 3.7 HPLC-DAD chromatograms of (a) ultrafiltered Cyclopia genistoides extract (UCGE0; 52.7 µg 
injected), (b) benzophenone-enriched fraction (BEF A; 18.1 µg injected) and (c) xanthone-enriched fraction 
(XEF A; 9.1 µg injected) of UCGE0 obtained by macroporous adsorbent resin chromatography (1 = 3-β-D-
glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone; 2 = 3-β-D-glucopyranosylmaclurin; 3 = 3-β-D-

















































































The effect of batch-to-batch variation was also manifested in the fractions (Table 3.6). UCGE5, 
prepared from batch CG5, had the lowest I3G content (Table 3.4), yet its corresponding BEF was one of only 
three with a higher I3G content than the corresponding XEF (Table 3.6). These results suggest that the higher 
the I3G content of the starting material, the higher the amount of co-eluted I3G that could be expected in 
subsequently produced XEFs.  Enrichment ratios for BEF1–10 and XEF1–10 are plotted in Fig. 3.8. ER > 1 
indicates that enrichment of the target compound has been achieved, with higher values denoting a greater 
degree of enrichment. ER < 1 indicates that enrichment was not successful, i.e. depletion of the target 
compound occurred, whereas ER = 1 represents no change in the target compound content. In general, mean 
enrichment ratios (ERs) for benzophenones in BEFs were higher (3.2–4.6) than for xanthones in XEFs (1.2–
3.1), i.e. benzophenones were enriched to a greater degree than xanthones using this MARC protocol. Mean 
ER values for xanthones in BEFs were all very low (< 0.02) because xanthones were either found in trace 
amounts or were undetected in the BEFs (Table 3.6). This is a reflection of the absence or virtually negligible 
co-elution of xanthones with the benzophenones when using 5–10% aqueous EtOH as an eluent.  
 
 
Figure 3.8 Enrichment of xanthone and benzophenone content in xanthone-enriched fractions (XEFs) and 
benzophenone-enriched fractions (BEFs) obtained from ten batches of Cyclopia genistoides using an optimised 
macroporous adsorbent resin chromatography protocol. An enrichment ratio value of 1 (unity) is indicated by 
the dashed horizontal line. Data are presented as mean ± standard deviation (n = 3). 
 
 
While BEFs contained only trace amounts or no xanthones, XEFs were not free of benzophenones 
because of the co-elution of I3G. No IDG or M3G was detected in any XEFs, but all XEFs contained some 
I3G (Table 3.6). Mean ERs for benzophenones in XEFs were smaller than unity, except in the case of XEF3 
(mean = 1.01 ± 0.11). Indeed, in seven out of ten XEFs, the I3G content was higher than that in the 
corresponding BEFs, indicating that significant co-elution of I3G with xanthones prohibited complete 
separation of the target benzophenones and xanthones using this system. The XEF with the highest content of 
co-eluted I3G was XEF3 (7.83%). Plant material batch CG3, and its resultant UCGE (Table 3.4), also had the 

























Table 3.6 Effect of starting material variation on composition of xanthone-enriched fractions (XEFs) and 
benzophenone-enriched fractions (BEFs) produced from ten ultrafiltered extracts of green Cyclopia 
genistoides (UCGE1–10) using an optimised macroporous adsorbent resin chromatography protocol. 
Fraction 
Content (g/100 g) 
IDGa M3Gb I3Gc Benzophenonesd Xanthones 
XEF1 nd nd 3.56±0.4 3.56±0.4 48.08±2.3 
XEF2 nd nd 3.11±0.3 3.11±0.3 43.44±1.0 
XEF3 nd nd 7.83±0.8 7.83±0.8 32.31±5.9 
XEF4 nd nd 2.66±0.6 2.66±0.6 32.06±1.6 
XEF5 nd nd 1.59±0.1 1.59±0.1 42.40±0.6 
XEF6 nd nd 2.26±0.1 2.26±0.1 38.53±5.9 
XEF7 nd nd 2.27±0.2 2.27±0.2 22.26±3.1 
XEF8 nd nd 3.09±0.4 3.09±0.4 26.91±8.0 
XEF9 nd nd 3.39±0.2 3.39±0.2 27.18±6.3 
XEF10 nd nd 3.30±0.2 3.30±0.2 40.43±0.6 
BEF1 11.83±0.1 3.46±0.1 2.33±0.5 17.62±0.5 Traces 
BEF2 10.71±1.3 3.87±0.8 2.17±0.6 16.75±2.4 Traces 
BEF3 15.52±0.2 4.04±0.0 5.56±0.3 25.12±0.2 nd 
BEF4 16.38±0.3 3.01±0.1 2.32±0.3 21.71±0.6 nd 
BEF5 7.08±0.4 2.11±0.1 2.19±0.2 11.38±0.6 Traces 
BEF6 11.45±0.6 1.69±0.1 1.76±0.3 14.91±0.7 Traces 
BEF7 11.99±0.2 3.05±0.1 3.15±0.5 18.19±0.3 Traces 
BEF8 9.30±0.3 3.50±0.2 3.23±0.8 16.03±1.2 Traces 
BEF9 13.09±0.6 2.79±0.2 2.16±0.5 18.04±1.4 Traces 
BEF10 7.85±0.6 3.11±0.3 2.18±0.3 13.14±1.0 nd 
a 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone; b 3-β-D-glucopyranosylmaclurin; c 3-β-
D-glucopyranosyliriflophenone; d Sum of IDG, M3G and I3G 
 
 
Amongst the XEFs, the lowest ERX was observed for XEF7 (Fig. 3.8), which originated from the plant 
material batch with consistently the highest xanthone content, both in its crude extract (14.5%) and ultrafiltered 
form (19.1%). Interestingly, XEF7 ultimately had the lowest xanthone content despite being produced from 
plant material batch CG7, with the highest initial xanthone content (Table 3.5). In contrast, the batch with the 
lowest initial xanthone content (CG6; 9.31%) produced XEF6, with the highest ERX (Fig. 3.8), but this did not 
translate to having the highest xanthone content. The highest xanthone content was observed for XEF1, which 
originated from the batch with the second highest initial xanthone content and had an ER of 2.67. Therefore, 
there was no clear relationship between xanthone content of the UCGE and the xanthone content in the 
corresponding XEF or ERX achieved. Other factors, like matrix effects from individual extracts, may play a 




Macroporous adsorbent resin chromatography can be used as a scalable, eco-friendly process for the 




genistoides.  Exothermic adsorption demonstrated for target compounds on Amberlite XAD 1180N resin is an 
advantage in terms of process efficiency as it eliminates the need for additional energy input. Batch-to-batch 
variation of the phenolic content of the raw material manifested in the feed solution and subsequently also the 
enriched fractions, emphasising the challenge of standardisation and the need for an effective strategy to 
minimise variation in bioactive content and/or bioactivity of the final product.  
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α-Glucosidase inhibitors of honeybush 
(Cyclopia genistoides): assessment of 
in vitro dose reduction potential in 
combination with acarbose and in vivo 


















The in vitro α-glucosidase inhibitory effects of Cyclopia genistoides extracts or phenolic fractions, combined 
with acarbose, was investigated using the combination index (CI) method of Chou-Talalay. Also included were 
combinations of major phenolics of C. genistoides, i.e. the xanthones, mangiferin and isomangiferin, and the 
benzophenones, 3-β-D-glucopyranosyliriflophenone (I3G) and 3-β-D-glucopyranosyl-4-O-β-D-
glucopyranosyliriflophenone (IDG), with acarbose. Individual testing of the candidate α-glucosidase inhibitors 
demonstrated potency in the descending order of acarbose (IC50 = 44.3 µM) > mangiferin (102.2 µM) > 
isomangiferin (119.8 µM) > I3G (237.5 µM) > IDG (299.4 µM). The inhibitory effects of the various 
C. genistoides products in the multi-step enrichment process were strongly linked to their xanthone content. 
Xanthone-enriched fractions (XEFs) and benzophenone-enriched fractions (BEFs) of C. genistoides, 
previously prepared from different batches of plant material (n = 10), were tested for α-glucosidase inhibitory 
activity at a fixed concentration (160 µg/mL) to investigate the effect inter-batch variation of the source 
material. XEFs, with xanthone contents ranging between 22.3 and 48.1%, achieved α-glucosidase inhibition 
of 63 to 72%, whereas BEFs, with benzophenone contents ranging between 11.4 and 21.7%, achieved α-
glucosidase inhibition of 26 to 34%. There was a weak linear correlation (R2 < 0.43) between the target 
compound content of the fractions and their achieved α-glucosidase inhibition. Synergistic interaction, 
indicated by CI < 0.7 at 50% and 75% effect levels, was observed for all combinations of acarbose with 
enriched fractions (XEFs, BEFs) or single phenolic compounds (mangiferin, isomangiferin, I3G, IDG). The 
greatest potential acarbose dose reductions (> six-fold) across all effect levels were achieved by combinations 
of acarbose with the xanthones, mangiferin or isomangiferin. Quantitative phenolic variation in the XEFs and 
BEFs due to inter-batch variation of the source material resulted in variable acarbose dose reduction indices. 
In general, XEFs showed greater potential for acarbose dose reduction (≈ four-fold at 50% inhibition) than 
BEFs, indicating the potential of the former as a supplement to acarbose in treatment of hyperglycaemia. In a 
subsequent in vivo oral sucrose tolerance test, the administration of a single dose of XEF0 (300 mg/kg body 
weight, BW) resulted in a slight but non-significant reduction in postprandial blood glucose levels after a 
sucrose loading in normal and diabetic Wistar rats. Acarbose (5 mg/kg BW), on the other hand, significantly 
reduced postprandial blood glucose in both normal and diabetic rats (P < 0.05). Furthermore, co-administration 
of a combination of acarbose and XEF0 at 5 and 300 mg/kg BW, respectively, did not result in an enhanced 




There is a growing interest in deriving greater health benefits from plant foods in the form of functional food 
ingredients or nutraceuticals (Egert & Rimbach, 2011), particularly in the management of chronic metabolic 
and lifestyle-related diseases like type 2 diabetes mellitus (Bahadoran et al., 2013). The strong association 
between the diet and diabetes underpins the development of nutraceuticals or functional food ingredients with 




glucose tolerance, along with the associated rise in obesity and the metabolic syndrome, have become major 
health issues across the globe. The International Diabetes Federation has estimated that, as of 2017, 
approximately 425 million adults (aged 20–79) were living with diabetes (IDF, 2017). This was projected to 
escalate to 629 million by the year 2045. Abnormally high levels of blood glucose can eventually lead to 
chronic complications of the skin, eye, heart, kidneys and the vascular and peripheral nervous systems 
(Chaturvedi, 2007; Pitocco et al., 2013).  
Pharmacological treatment with oral anti-diabetic agents is prescribed when simple lifestyle and 
dietary interventions alone do not provide adequate blood glucose control (Ghani, 2015). Amongst these, 
intestinal α-glucosidase inhibitors (AGIs) have been cited as most effective in terms of long-term blood glucose 
control and regulation of insulin homeostasis (Derosa & Maffioli, 2012). Acarbose (Glucobay®, Prandase®, 
Precose®), the most widely used commercial AGI, is sometimes associated with discouraging dose-related 
gastrointestinal side effects, related to its strong affinity for the enzyme binding site (approximately 105 times 
that of the dietary oligosaccharides), which results in an increased load of undigested carbohydrates making 
its way to the colon (Van de Laar et al., 2005).  The search for alternatives includes plant extracts or purified 
phytochemicals with α-glucosidase inhibitory activity (Kumar et al., 2011; Yin et al., 2014; Ghani, 2015; Di 
Stefano et al., 2018). Glycosylated xanthones (mangiferin and isomangiferin) and benzophenones (3-β-D-
glucopyranosyliriflophenone [I3G] and 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone [IDG]), 
found in South African honeybush (Cyclopia genistoides) in significant amounts, have also been confirmed as 
active inhibitors of mammalian α-glucosidase (Beelders et al., 2014a; Bosman et al., 2017). These findings 
laid the foundation for the development of optimised ultrafiltration (Bosman, 2014) and extraction (Bosman 
et al., 2017) protocols for the enrichment of these compounds, using unfermented C. genistoides plant material 
as starting material.  
 The reported inhibitory effects of natural AGIs are generally less potent than commercial inhibitors 
like acarbose, which often serves as the positive control in bioactivity testing  (Kumar et al., 2011). Some 
recent studies have reported synergistic α-glucosidase inhibition by combinations of acarbose and botanical 
extracts or plant phenolics (Adisakwattana et al., 2009; Akkarachiyasit et al., 2010; Boath et al., 2012; Satoh 
et al., 2015).  Of particular interest is a study showing that a combination of acarbose and Oroxylum indicum 
seed extracts not only resulted in a synergistic effect in vitro, but also resulted in enhanced efficacy of acarbose 
in vivo (Zhang et al., 2017b). 
Prompted by long-standing disparity in scientific literature regarding the definition and proper 
evaluation of synergism, Chou & Talalay (1983, 1984) introduced the concept of the combination index (CI), 
which provides a definition for synergism, antagonism and additive effects in combination therapy based on 
the law of mass action. At the most basic level, synergism/antagonism refers to a combined effect that is 
more/less than additive. The Chou-Talalay method offers an advantage over the traditional isobologram 
method of assessing synergism in that it provides numerically indexed conclusions, i.e. a quantitative measure 
of synergism, in the form of the CI (Chou, 2010). Other benefits of the CI method include its simplicity, 
flexibility (mechanism- and unit-independence) and economy (requires small number of data points) 




depending on the origin of the enzyme (Oki et al., 1999). Potent inhibitors of non-mammalian α-glucosidase 
will often prove to be poor inhibitors of mammalian α-glucosidase under the same experimental conditions 
(Hakamata et al., 2009; Jo et al., 2011). 
The present study aimed to determine whether a multi-step enrichment protocol for the development 
of xanthone-enriched fractions (XEFs) and benzophenone-enriched fractions (BEFs) of C. genistoides 
enhanced α-glucosidase inhibition. Furthermore, combinations of acarbose and respectively, the fractions and 
the four major polyphenolic compounds found in C. genistoides (mangiferin, isomangiferin, IDG and I3G), 
were investigated for in vitro synergistic inhibitory activity against α-glucosidase, using the Chou-Talalay 
method. It was also deemed imperative to delineate the effect of variable phenolic content of the fractions on 
α-glucosidase inhibitory activity and potential for acarbose dose reduction as batch-to-batch variation of the 
composition of source material is highly likely. Mammalian α-glucosidase was used instead of the frequently 
used commercial yeast α-glucosidase preparations, because of the intended anti-diabetic application of the 
enriched final product. Finally, the in vivo hypoglycaemic effect of the most effective fraction was compared 
with acarbose, as well as in combination with acarbose, in normal and diabetic Wistar rats. 
 
4.2. Materials and methods 
4.2.1. Chemicals and reagents 
 
Authentic reference standards (purity > 95%) for α-glucosidase assays and/or high performance liquid 
chromatography (HPLC) quantification were obtained from Sigma-Aldrich (St. Louis, MO, USA; MGF), and 
Phytolab (Vestenbergsreuth, Germany; I3G, IMGF). Reference standard IDG (purity > 95%) was  previously 
isolated from C. genistoides in our laboratory (Beelders et al., 2014a). Acarbose, rat intestinal acetone powder 
and 7-O-α-D-glucopyranosyl-4-methylumbelliferone (MUG) were supplied by Sigma-Aldrich. HPLC gradient 
grade ‘far UV’ acetonitrile was supplied by Merck Millipore (Darmstadt, Germany). All other reagents, except 
ethanol (Servochem, Cape Town, South Africa), were analytical grade and supplied by Sigma-Aldrich or 
Merck Millipore. Deionised water, prepared using an Elix Advantage 5 (Merck Millipore) water purification 
system, was further purified to HPLC grade using a Milli-Q Reference A+ (Merck Millipore) water purification 
system. 
 
4.2.2. Cyclopia genistoides extract, ultrafiltration products and enriched fractions 
 
The C. genistoides extract (23 L), which served as the initial feed for ultrafiltration in the previous 
chapter (Section 3.3; Table 3.1; p. 116), was used for α-glucosidase inhibition testing in the present study along 
with the resultant ultrafiltration products, the retentate and the ultrafiltered C. genistoides extract (UCGE0) 
(Fig. 4.1). 
A reference xanthone-enriched fraction (XEF0) for α-glucosidase inhibition testing was obtained by 
combining an equal mass of each of the triplicate fractions (XEF A–C), previously produced by macroporous 




benzophenone-enriched fraction for α-glucosidase inhibition testing (BEF0) was obtained by combining an 
equal mass of each of the previously produced triplicate BEFs (BEF A–C) (Table 3.3). 
In order to test the effect of quantitative phenolic variation on α-glucosidase inhibition by enriched 
C. genistoides fractions, XEF1–10 and BEF1–10 (produced in triplicate during the preceding study; Chapter 3, 
Section 3.3.2.4; p. 124), were used. 
 
 
Figure 4.1 Schematics of enrichment processes for xanthones and benzophenones in Cyclopia genistoides 
extract, serving as sources of test samples for α-glucosidase inhibition in the present study (TFU = tangential 
flow ultrafiltration; MARC = macroporous adsorbent resin chromatography). 
 
 
4.2.3. α-Glucosidase inhibition 
 
Determination of α-glucosidase inhibition was carried out according to a fluorimetric method adapted 
from Bosman et al. (2017). An extract of rat intestinal acetone powder containing α-glucosidase was prepared 
by suspending ca. 1050 mg of powder in 30 mL of cold KH2PO4 buffer (200 mM KH2PO4, pH 6.8 with KOH), 
followed by sonication on ice. The crude mixture was centrifuged at 10000 × g for 15 min and the supernatant 
was retrieved and filtered (0.45 µm, 33 mm Millex HV PVDF filter membranes, Merck Millipore). The filtered 
supernatant was used as an enzyme mixture after dilution to a standardised concentration based on activity 
testing. Activity determination of the enzyme mixture was performed daily prior to each set of experiments, 
using the same procedure as for the inhibition assays, but with H2O as sample control and varying dilutions of 
the enzyme mixture. Fluorescence measurements, performed on a BioTek SynergyHT microplate reader 
(BioTek Instruments, Winooski, VT, USA), were used to determine the correct concentration for optimal 
enzyme activity estimated as an FL-value of 50 000 (λEX: 360 nm; λEM: 460 nm), 20 min after addition of the 
substrate (MUG).  
The following test procedure was employed: 80 µL of the assay control (H2O), positive control 
(acarbose) or test sample, diluted with 200 mM KH2PO4 buffer (pH 6.8) to the selected concentration, was 
added to 65 µL of a 200 mM KH2PO4 buffer (pH 6.8) and 65 µL of the pre-determined enzyme dilution in 96-






















After pre-incubation at 37 °C for 15 min, 40 µL of a 1.2 mM MUG solution was dispensed at t = 0 min (total 
reaction volume = 250 µL). Fluorescence (λEX: 360 nm; λEM: 460 nm) was monitored over 30 min, and the net 
fluorescence (Net FL), remaining enzyme activity (%) and α-glucosidase inhibition (%) were calculated using 
the following equations: 
 
[JD	\] = \]^_ T	\]_       (Eq. 4.1) 
Remaining	enzyme	activity	(%) = 100 × ( j5k	7lmj5k	7l	n)   (Eq. 4.2) 
Enzyme	inhibition	(%) = 100 T remaining	enzyme	activity  (Eq. 4.3) 
 
FL0 and FL30 represent the fluorescence intensity measured at 0 and 30 min, respectively, and Net FLs 
and Net FLac refer to the Net FL calculated for the sample and assay control, respectively. For determination 
of IC50 values a concentration range was employed. BEFs and XEFs prepared from different batches of 
C. genistoides plant material (n = 10) were tested at a fixed reaction volume concentration of 160 µg/mL. All 
sample concentrations were analysed in triplicate. 
 
4.2.3.1. Assessment of synergistic α-glucosidase inhibition 
 
Synergistic interaction between the various AGIs  under investigation (IF, R, UCGE0, XEF0, BEF0, 
isomangiferin, mangiferin, I3G, IDG and acarbose) was evaluated according to the CI method  (Chou, 2006).  
The AGIs were combined in a 1:1 ratio based on µg/mL concentration in the reaction volume. The same test 
procedure described in Section 4.2.3 was used, except that 40 µL of each AGI in the combination was added 
to the reaction volume, i.e. 80 µL of the combination under investigation was added (total reaction 
volume = 250 µL). 
The dose-effect data of the combinations were analysed using freely available software (CompuSyn 
Version 1.0; http://www.combosyn.com/index.html) (Chou, 2006). α-Glucosidase inhibition values (%) were 
converted to Fa (effect level) values (0–1) for CompuSyn analyses by dividing by 100.  CI is represented by 
the following equation: 
 
CI = 	 ()() + ()() =	 () + ()	  (Eq. 4.4) 
  
where (D)1 and (D)2 are the doses of inhibitors that produce a specified level of inhibition in the combination 
system, and (Dx)1 and (Dx)2 are the doses of these inhibitors that would result in the same effect. CI values 
were calculated at 25, 50 and 75% inhibition, i.e. at effect levels 0.25, 0.5 and 0.75, representing moderate 
enzyme inhibition. The combined inhibition was classified as synergistic (CI < 0.9), additive (CI = 0.9−1.1), 
or antagonistic (CI > 1.1). The dose reduction indices (DRIs) for both agents in a given combination, derived 




x-fold dose reduction of each inhibitor in a synergistic combination that may be achieved at a given effect level 
relative to the same inhibitor when used alone (Chou, 2006). 
 
4.2.4. In vivo hypoglycaemic effect  
4.2.4.1. Animals 
 
Ethical approval was obtained from the Ethics Committee for Research on Animals (ECRA) of the 
South African Medical Research Council (SAMRC) (REF 04/19). Forty-eight adult male Wistar rats (Rattus 
norvegicus domestica), obtained from the Primate Unit and Delft Animal Centre (PUDAC) of the SAMRC 
(Tygerberg, South Africa), were used in the study. All animals were maintained in a temperature-controlled 
room at 22–25 °C, 45–55% relative humidity, and a 12-hour light/dark cycle. The rats were housed three in a 
cage to foster socialisation (cage size: 0.5 m × 0.8 m = 0.13 m2/rat) and supplied with both tap water and 
standard diet (formulated at SAMRC PUDAC). The cages contained wood shaving bedding material and were 
cleaned as per the SAMRC PUDAC Standard Operating Procedure (SOP #2019-R01, version #3). Nesting 
boxes and plastic gnawing cubes were provided for cage environmental enrichment. The well-being of the rats 
was monitored daily, including recording of body weight (BW), food and water consumption.  
 
4.2.4.2. Diabetes induction 
 
Male Wistar rats (150–250 g) were injected intraperitoneally with freshly prepared streptozotocin 
(STZ) (45 mg/kg BW) in 0.1 M citrate buffer (pH 4.5) to induce diabetes. Seventy-two hours after STZ 
injection, all animals were fasted for 4 h and blood glucose levels determined by tail-prick using a glucometer 
(Precision Q.I.D, Abbott Laboratories, Johannesburg, South Africa) fitted with OneTouch Ultra test strips 
(Lifescan Inc., Milipitas, CA, USA). Animals presenting with a blood glucose level > 13.9 mmol/L (25 mg/dL) 
were considered diabetic as previously reported (Mohamed Sham Shihabudeen et al., 2011). 
 
4.2.4.3. Sucrose and treatment administration 
 
Following a 16-h fast and a blood glucose measurement, the non-diabetic (n = 24), and diabetic 
(n = 24) rats were treated (orogastric) with either the vehicle control, acarbose (5 mg/kg BW; volume of 
1 mL/kg BW), XEF0 from C. genistoides (300 mg/kg BW; volume of 1 mL/kg BW), or a combination of 
acarbose plus XEF0 (n = 6/group) 10 minutes before they were orally administered with sucrose (2 g/kg BW; 
volume of 1 mL/kg BW). Acarbose and XEF0 were completely solubilised in deionised water, which was used 
as the vehicle control.  
 





At 0, 30, 60, and 120 min after sucrose administration, blood glucose levels were recorded by tail-
prick (as described above following diabetes induction) for determination of the inhibitory effect of treatment 
on intestinal α-glucosidase activity in rats. At termination (following blood glucose testing at 120 min), the 
animals were anaesthetised by placing them in a transparent plastic induction chamber with an oxygen 
flowmeter (± 0.9 L/min) and isoflurane vaporiser (± 3.5–5% for induction and ± 2% for maintenance). 
Thereafter, the rats were removed from the induction chamber and euthanised by exsanguination.  
 
4.2.5. High-performance liquid chromatography with diode-array detection (HPLC-DAD) 
 
HPLC-DAD analysis of samples was carried out using a validated method, previously developed 
specifically for unfermented C. genistoides (Beelders et al., 2014b) and described in the previous chapter 
(Section 3.2.9; p. 114). A seven-point calibration curve was set up using a mixture of standards. UV–Vis 
spectra were recorded from 200–450 nm and peak areas of mangiferin and isomangiferin at 320 nm and IDG 
and I3G at 288 nm used for quantification. IDG and isomangiferin were quantified using an I3G and mangiferin 
response factor, respectively. 
 
4.2.6. Statistical analysis 
 
Half-maximal inhibitory concentrations (IC50) were calculated by non-linear regression analysis of the 
dose-effect data using GraphPad Prism (Version 8.2.1; GraphPad Software, San Diego, CA, USA). The four-
parameter variable slope regression model was used, with the bottom and top values for the remaining α-
glucosidase activity constrained between constant values of 0 and 100, respectively. IC50 values are represented 
as means with 95% confidence intervals. Regression analysis of α-glucosidase inhibition values against 
xanthone and benzophenone contents of the enriched fractions was performed using Excel 2010 (Microsoft 
Corporation, Redmond, WA, USA). For the in vivo experiment, the statistical power was calculated at 0.95 
and an alpha level of 0.05, with the sample size of six rats per group determined to be enough for statistical 
significance. Blood glucose level data are represented as mean ± standard error of the mean (SEM), with the 
area under curve (AUC) estimated using GraphPad Prism (Baseline set at y = 0). The statistical t-test and post 
hoc Tukey HSD Test were used to analyse data, with the difference considered to be significant when P < 0.05. 
 
4.3. Results and discussion 
4.3.1. Effects of enrichment processes on α-glucosidase inhibitory activity 
 
Tangential flow ultrafiltration and MARC represent two consecutive unit operations in an eco-
friendly, scalable enrichment process for C. genistoides xanthones and benzophenones, with the ultrafiltered 
C. genistoides extract (UCGE0) serving as the starting material for the production of xanthone- and 
benzophenone enriched fractions (XEF0, BEF0) by MARC (Fig. 4.1). In the present study, these samples were 




curves (Fig. 4.2a) and their derived IC50 values (mean with 95% confidence interval) (Table 4.1) indicate that 
UCGE0 was more potent (IC50 = 95.5 µg/mL) than the starting material, IF (IC50 = 115.3 µg/mL), and R, the 
ultrafiltration by-product containing retained or “rejected” material (IC50 = 153.3 µg/mL). Ultrafiltration was 
previously shown to achieve good enrichment in xanthones and benzophenones relative to IF (refer to Chapter 
3, Section 3.3; p. 115). Despite R being the “non-enriched” fraction of the ultrafiltration process, it still 
displayed appreciable inhibitory activity. Significant amounts of mangiferin, isomangiferin, I3G and IDG, all 
reported as active AGIs (Beelders et al., 2014a; Bosman et al., 2017) were still present in R (Table 4.1), 
partially explaining its activity. 
The dose-effect curves for the compounds and acarbose are depicted in Fig. 4.2b. Mean IC50 values 
for the single phenolic compounds of interest (Table 4.1) indicate a descending order of potency (mangiferin 
≈ isomangiferin > I3G > IDG). All compounds were less potent than acarbose (IC50 = 44.3 µM). Beelders et 
al. (2014a), using fixed concentrations to compare compounds, reported that the additional O-glucopyranosyl 
moiety of IDG at C-4 could explain its weaker inhibition of mammalian α-glucosidase compared with I3G. 
Similarly, Feng et al. (2011) noted that another iriflophenone diglucoside, 3,5-β-D-
glucopyranosyliriflophenone, was also a weaker inhibitor of α-glucosidase than I3G. The relative inhibitory 
activity determined for mangiferin and isomangiferin in the present study (IC50 = 102.2 µM and 119.8 µM, 
respectively) corresponds with previous data (Bosman et al., 2017), which compared inhibitory activity of 
mangiferin and isomangiferin against mammalian α-glucosidase at fixed concentrations. Both compounds 
previously achieved roughly 50% inhibition at 100 µM, with mangiferin slightly more potent than 
isomangiferin (Bosman et al., 2017). 
Of the two reference enriched fractions of C. genistoides, XEF0 was the more potent AGI, with a mean 
IC50 = 43.3 µg/mL compared to a mean IC50 = 205.7 µg/mL for BEF0, ranking as the least potent of the products 
under investigation from the enrichment process (Fig. 4.1). Acarbose was the most effective with a mean 
IC50 = 44.3 µM (28.5 µg/mL). There was a strong inverse relationship between the xanthone contents of the 
various samples collected during the multi-step enrichment process (IF, R, UCGE0, XEF0 and BEF0) and the 
IC50 value for α-glucosidase inhibition. In contrast, the fraction with the highest benzophenone content (BEF0) 
had the highest IC50. This can be related to IC50 values for the single compounds (Table 4.1), which clearly 
demonstrate the superior inhibitory activity of the xanthones when compared to the benzophenones. As an 
additional investigation, the D-pinitol and D-glucose content was determined for each sample excepting the 
pure compounds (refer to supplementary material; p. 225). D-Pinitol is a cyclic polyol with previously reported 
insulin-like anti-diabetic effects (Bates et al., 2000; Sia, 2004). The D-pinitol content ranged between 0 (XEF0) 
and 8% (BEF0) (Table 4.1), but purified D-pinitol was completely inactive as an inhibitor of mammalian α-










Table 4.1 Half-maximal inhibitory concentrations (IC50) against rat intestinal α-glucosidase for different 
fractions of Cyclopia genistoides, and for single compounds including acarbose (positive control). 
Sample 




interval MGFb IMGFc I3Gd IDGe D-Pinitol D-glucose 
UCGE0g 11.80 3.36 1.48 1.18 6.12 0.88 95.5 µg/mL 90.5–101.1 
Initial feed (IF)h 9.82 2.74 1.19 0.93 3.95 0.54 115.3 µg/mL 109.3–121.5 
Retentate (R) 6.11 1.67 0.68 0.53 2.40 0.34 153.3 µg/mL 147.0–159.8 
XEF0i 37.05 11.06 3.33 – 0.00 0.29 43.3 µg/mL 41.1–45.6 
BEF0j 0.62 0.03 5.22 7.04 8.15 1.60 205.7 µg/mL 197.2–214.4 
MGF >95% – – – – – 43.12 µg/mLk 41.4–44.9 
IMGF – >95% – – – – 50.54 µg/mLl 48.2–53.0 
I3G – – >95% – – – 96.94 µg/mLm 93.8–100.1 
IDG – – – >95% – – 171.08 µg/mLn 167.0–175.3 
Acarbose – – – – – – 28.58 µg/mLo 25.0–31.7 
a ultrafiltration fractions (UCGE0, IF, R) previously analysed by HPLC-DAD (refer to Chapter 3; Table 3.1; p. 116); 
b mangiferin; c isomangiferin; d 3-β-D-glucopyranosyliriflophenone; e 3-β-D-glucopyranosyl-4-O-β-D-
glucopyranosyliriflophenone; f mean half-maximal inhibitory concentration;  g ultrafiltered Cyclopia genistoides extract; 
h 40% aqueous ethanol extract of green C. genistoides; i reference xanthone-enriched fraction; j reference benzophenone-
enriched fraction; k equivalent to 102.2 µM; l equivalent to 102.2 µM; m equivalent to 102.2 µM; n equivalent to 102.2 µM;  
o equivalent to 102.2 µM 
 
 
Figure 4.2 (a) Logarithmic dose-response curves for five inhibitors of rat intestinal α-glucosidase derived from 
Cyclopia genistoides extract: ultrafiltered C. genistoides extract (UCGE0), ultrafiltration retentate (R) and 
initial feed (IF), and xanthone-enriched fraction (XEF0) and benzophenone-enriched fraction (BEF0) produced 
by macroporous adsorbent resin chromatography. (b) Logarithmic dose-response curves for purified phenolic 
compounds (3-β-D-glucopyranosyliriflophenone, I3G; 3-β-D-glucopyranosyl-4-O-β-D-
glucopyranosyliriflophenone, IDG; mangiferin, MGF; isomangiferin, IMGF) tested for inhibitory activity 
against mammalian α-glucosidase with acarbose (Aca) as positive control. Data are presented as mean ± 







4.3.1.1. Effect of quantitative phenolic variation on α-glucosidase inhibition  
 
BEFs and XEFs, previously prepared from different batches (n = 10) of C. genistoides plant material 
(Chapter 3, Table 3.6; p. 129), were tested in the present study for α-glucosidase inhibitory activity at a fixed 
concentration (160 µg/mL). XEFs showed higher overall efficacy than BEFs. XEFs, with xanthone contents 
ranging from 22.3 to 48.1%, achieved α-glucosidase inhibition ranging from 63 to 72% (Fig. 4.3a). BEFs, with 
benzophenone contents ranging from 11.4 to 25.1%, achieved α-glucosidase inhibition ranging between 26 
and 34% (Fig. 4.3b). There was a weak linear correlation (R2 = 0.138) between the xanthone content of the 
XEFs and their achieved α-glucosidase inhibition (Fig. 4.4a). XEF1, with the highest mean xanthone content 
(48.1%), achieved the strongest mean α-glucosidase inhibition (72.2%), however the XEF with the lowest 
mean xanthone content (XEF7; 22.26%) achieved inhibition not far below this level (Mean = 67.5%).  There 
was a stronger linear relationship (R2 = 0.423) between the benzophenone content of the BEFs and their 
achieved α-glucosidase inhibition (Fig. 4.4b). The BEF with the highest benzophenone content (BEF3; 25.1%), 
achieved the strongest inhibition (36.1%), but—similar to the XEFs—the BEF with the lowest mean 




Figure 4.3 Percentage inhibition of mammalian α-glucosidase achieved in vitro at 160 µg/mL by (a) ten 
xanthone-enriched fractions (XEFs) and (b) ten benzophenone-enriched fractions (BEFs) of Cyclopia 




































































































Figure 4.4 Linear correlation between target compound content and in vitro mammalian α-glucosidase 
inhibition achieved at 160 µg/mL by (a) ten xanthone-enriched fractions (XEFs) and (b) ten benzophenone-
enriched fractions (BEFs) of Cyclopia genistoides, tested in triplicate (n = 30 for XEFs and BEFs). 
 
 
The generally weak correlation between the phenolic content of the enriched fractions and their 
inhibitory activity against α-glucosidase suggests that other factors are likely also contributing to the 
bioactivity. This may include matrix effects due to presence of other unidentified AGIs in the fractions or 
“impurities” that may interact with the enzyme and enhance or decrease the bioactivity. Tan et al. (2017) used 
column chromatography with macroporous adsorbent resin to remove sugars and organic acids from crude 
extracts of black legumes, and the resultant fractions of purified and semi-purified polyphenols were more 
potent inhibitors of α-glucosidase than the original crude extracts. This could have been a consequence of 
concentrating the active AGIs in the extract, or of the removal of antagonists or non-inhibitors from the sample 
matrix. Higher or lower than expected inhibitory activity could also be the result of synergistic or antagonistic 
interactions between different AGIs in the same sample.  
 
4.3.2. In vitro synergistic effects of combined α-glucosidase inhibitors 
 
CI serves as a quantitative measure of synergistic interaction between enzyme inhibitors, based on the 
principles of the law of mass action (Chou & Talalay, 1983). Broadly speaking, CI < 1 indicates synergism 
and CI > I indicates antagonism, with CI = 1 representing a purely additive effect. A more refined classification 
system (slight, moderate, strong and very strong synergism/antagonism) has been proposed by Chou (2006), 
in which a range of 0.9 to 1.1 represents a near-additive effect, and values below 0.9 indicate synergistic effects 
that increase in magnitude as CI approximates 0. A major benefit of synergistic interaction between bioactive 
compounds is the potential to reduce the dose of one or more of the compounds while maintaining the same 
effect level, which may reduce the risk of toxicity, side effects and the development of drug resistance over 
time (Bijnsdorp et al., 2011; García-Fuente et al., 2018; Zhu et al., 2019). 


















































Testing of different combinations, i.e. fraction-fraction, fraction-compound and fraction or compound 
with acarbose allowed insight into potential synergy and the effect of composition on potency. For all 
combinations of acarbose with enriched fractions (XEF0, BEF0) or single phenolic compounds (Combinations 
1–6), the calculated CI fell within the range 0.36–0.63 at 50 and 75% effect levels, which indicates synergistic 
interactions (Table 4.2). At the 25% effect level, antagonistic interaction was seen with combinations of 
acarbose with I3G, IDG and XEF0, respectively, and additive or synergistic effects were noted with 
combinations of BEF, mangiferin and isomangiferin. There was no consistent relationship between the CI 
value and the effect level, with the CI values neither showing a consistent increase nor decrease with increasing 
effect levels. For the combination of XEF0 and BEF0 (Combination 7), the CI value decreased with increasing 
effect level, from “moderate synergism” (CI = 0.863) at 25% to synergism (CI = 0.581) at the 75% effect level. 
 
Table 4.2 Chou-Talalay combination indices at 25, 50 and 75% effect levels for 13 different combinations 
of mammalian α-glucosidase inhibitors. 
No. Combinationa Concentrationsb (µg/mL) 
Combination index (CI) at 
effect level 
25% 50% 75% 
1 Acac:BEF0d 2.5, 5, 10, 20, 40, 80, 160 0.925 0.603 0.492 
2 Aca:XEF0e 12.5, 25, 50, 100, 200, 400 1.240 0.630 0.478 
3 Aca:MGFf 2.5, 5, 10, 20, 40, 80, 120 0.503 0.366 0.387 
4 Aca:IMGFg 2.5, 5, 10, 20, 40, 80, 120 0.752 0.487 0.408 
5 Aca:I3Gh 5, 10, 20, 40, 80, 120 1.177 0.563 0.437 
6 Aca:IDGi 5, 10, 20, 40, 80, 120 1.232 0.590 0.435 
7 BEF0:XEF0 12.5, 25, 50, 100, 200, 400 0.863 0.707 0.581 
8 MGF:IMGF 10, 20, 40, 80 1.109 1.016 0.940 
9 MGF:I3G 10, 20, 40, 80 0.775 0.904 1.060 
10 IMGF:I3G 10, 20, 40, 80 1.096 1.009 0.950 
11 IDG:I3G 10, 20, 40, 80 0.687 0.980 1.397 
12 IDG:MGF 10, 20, 40, 80 0.902 0.902 0.905 
13 IDG:IMGF 10, 20, 40, 80 0.948 1.017 1.109 
a 1:1 combinations (µg/mL) of α-glucosidase inhibitors; b concentrations of both inhibitors in the reaction volume 
for the indicated combination; c acarbose; d reference benzophenone-enriched fraction; e reference xanthone-enriched 




Combinations of acarbose with mangiferin and isomangiferin showed the strongest synergistic effects 
(CI < 1) in general. Interestingly, the acarbose:XEF0 combination displayed antagonism (CI = 1.240) at 25% 
effect level despite the individual xanthones (mangiferin, isomangiferin) acting synergistically with acarbose 
at the same effect level. This is a clear indication of matrix effects and that activity of pure compounds, even 
as the major constituents (48.11%; Table 4.1) of an extract do not necessarily translate into the same activity 
when the extract is used. The reason for the switch in type of activity at the higher effect levels (50 and 75%) 
is not clear. Other methods should be applied to confirm results (Caesar & Cech, 2019). The latter authors also 
proposed the use of a modified CI range to indicate the effects, e.g. CI > 4 would indicate antagonism instead 




synergistic effects were generally less pronounced than for the xanthone-acarbose combinations. This 
synergism between acarbose and the benzophenones and xanthones explains in part the observed synergism 
between acarbose and the enriched C. genistoides fractions (Combinations 1 and 2; CI < 0.630 at 50 and 75% 
effect levels). 
Cyclopia genistoides extracts or enriched fractions will typically contain more than one identified 
compound with confirmed α-glucosidase inhibitory activity, not to mention some as yet unknown compounds 
that may potentially contribute to the overall effect, including synergistic, additive or antagonistic interactions 
with other AGIs or even augmentation by “inactive” compounds. The combination of the phenolic compounds 
demonstrated mostly additive effects (Combinations 8–13; Table 4.2), indicating that manipulation of the 
composition of the more potent XEF in terms of benzophenone content, has little value. In general, near-
additive combined effects were observed (0.9 < CI < 1.1). CI values were above 0.9, with the exception of 
Combination 9 (MGF:I3G) and 11 (IDG: I3G) at 25% effect level. Interestingly, combining the 
benzophenones, I3G and IDG, resulted in possible antagonism at 75% effect level (CI = 1.394) and synergism 
at 25% effect level (CI = 0.687). Using the more conservative approach recommended by Caesar and Cech 
(2019), a CI range of 1.0–4.0 indicates an “indifferent” effect, with antagonistic effect higher than 4.0.   
 
4.3.2.1. In vitro dose reduction of acarbose 
 
One of the potential benefits of synergism in combinations of therapeutic agents is that the same 
therapeutic effect may be achieved with significantly reduced doses of both agents (Chou, 2006). This is 
particularly beneficial in cases where a particular agent is in short supply, prohibitively expensive or associated 
with dose-related side effects or toxicity. Acarbose is the most widely prescribed commercial AGI despite 
reports of gastrointestinal side effects (bloating, flatulence and diarrhoea) preventing its more widespread 
acceptance (Ghani, 2015). Reports of side effects vary widely amongst different individuals and population 
groups, since individual dietary compositions and gastrointestinal environments will affect how well 
commercial AGIs are tolerated. A typical acarbose treatment regime is normally prescribed at 3 × 50 mg per 
day (Rosak & Mertes, 2012), with a maximum of 3 × 100 mg per day, as 200 mg is associated with a higher 
incidence of adverse effects of malabsorption (DiNicolantonio et al., 2015). There is a growing interest in 
finding less potent, natural alternatives to commercial AGIs, particularly if synergistic interaction with 
acarbose would allow for dose reduction benefits in addition to other potential health benefits associated with 
its phytochemical content (Egert & Rimbach, 2011). 
Another quantitative measure of synergism provided by the Chou-Talalay method is DRI, which is 
derived from CI, and represents the theoretical x-fold reduction, at a given effect level, in the dose of a 
particular agent in a synergistic combination. In general, DRI > 1 denotes synergism and DRI < 1 denotes 
antagonism, but in some cases, DRI may be greater than 1 despite the presence of antagonism according to the 
CI value (CI < 0.9). In such instances, the CI value should take precedent in classifying the type of interaction 
(Chou, 2006). Table 4.3 lists the DRI for acarbose at 25, 50 and 75% effect levels for all combinations 




levels were achieved by combinations of acarbose with the xanthones, mangiferin or isomangiferin. A nearly 
20-fold acarbose dose reduction was calculated for combinations 3 and 4 at the 75% effect level. Of the two 
enriched fractions of C. genistoides, BEF0 showed less dose reduction potential in combination with acarbose 
(DRI = 1.15–3.57) compared with XEF0 (DRI = 1.05–10.74). The acarbose dose reduction potential of BEF0 
and XEF0 was more or less the same at the lower effect levels, but XEF demonstrated much greater dose 
reduction potential at 75% effect level. CompuSyn-generated effect level vs. log(DRI) plots and isobolograms 
for combinations 1–13 are included as supplementary material (Figs. S1–13, p. 218–222). 
 
 
Table 4.3 Acarbose dose reduction indices at 25, 50 and 75% effect levels for 
combinations of acarbose with the xanthone- and benzophenone-enriched 
fractions of Cyclopia genistoides and four major phenolic compounds 
occurring in C. genistoides extract. 
No. Combination 
Acarbose dose reduction index 
at effect level 
25% 50% 75% 
1 Acaa:BEF0b 1.15 2.03 3.57 
2 Aca:XEF0c 1.05 3.36 10.74 
3 Aca:MGFd 2.94 7.56 19.66 
4 Aca:IMGFe 2.31 6.69 19.34 
5 Aca:I3Gf 1.00 3.16 9.94 
6 Aca:IDGg 0.90 2.46 6.75 
a acarbose; b benzophenone-enriched fraction; c xanthone-enriched fraction; 




4.3.2.2. Effect of quantitative phenolic variation on acarbose dose reduction 
 
In an industrial setting, one would expect large inherent variation in the xanthone and benzophenone 
content of different batches of C. genistoides, as plant breeding has not yet progressed to a cultivar. 
Furthermore, the effects of environmental stress on the phenolic composition have not yet been investigated 
extensively  (Joubert et al., 2014). The effect of this natural variation on synergistic α-glucosidase inhibition 
with acarbose was investigated by testing combinations of acarbose with XEFs and BEFs prepared from 10 
batches of plant material (Table 4.4). Acarbose DRIs indicate that XEFs generally showed greater potential 
for acarbose dose reduction than BEFs, confirming the trend observed for XEF0 and BEF0. XEF1, with the 
highest xanthone content (48.08 ± 2.3 g/100 g), also had the highest mean acarbose DRI at all effect levels 
tested. Similarly, the BEF with the highest mean benzophenone content (BEF3; 25.12 ± 0.2 g/100 g) had the 
highest DRI amongst the BEFs at all tested levels.  
These results suggest that an enriched fraction of C. genistoides, containing >19% xanthone (w/w), 
could potentially be used to achieve at least a theoretical four-fold acarbose dose reduction at >50% effect 
levels. The evidence of in vitro ant-diabetic effects and acarbose dose reduction activity such as presented here 




model would be of great interest. In a previous study (Zhang et al., 2017a), the combination of acarbose with 
baicalein, a flavonoid found in O. indicum, showed synergistic inhibition against mammalian α-glucosidase in 
vitro (CI < 0.41). Subsequent in vivo experiments demonstrated that a combination of 1 mg/kg acarbose with 
80 mg/kg baicalein synergistically reduced blood glucose levels in Kunming mice, with a hypoglycaemic 
effect roughly equivalent to 8 mg/kg acarbose, i.e. an eight-fold acarbose dose reduction.  
 
Table 4.4 Acarbose dose reduction indices at 25, 50 and 75% effect levels for combinations of acarbose with 
xanthone-enriched fractions (XEFs) and benzophenone-enriched fractions (BEFs) of Cyclopia genistoides, 
previously produced (in triplicate) from ten batches of varying phenolic composition.  
Fraction combined 
with acarbosea 
Content in fractionb (g/100 g)  Acarbose DRIc 
Benzophenones Xanthones  25% 50% 75% 
XEF1d 3.56 ± 0.4 48.08 ± 2.3  2.25 ± 0.1 5.16 ± 0.1 11.87 ± 0.7 
XEF2 3.11 ± 0.3 43.44 ± 1.0  1.96 ± 0.1 4.18 ± 0.1 8.40 ± 0.7 
XEF3 7.83 ± 0.8 32.31 ± 5.9  2.15 ± 0.1 4.07 ± 0.2 7.73 ± 1.2 
XEF4 2.66 ± 0.6 32.06 ± 1.6  2.17 ± 0.1 4.44 ± 0.1 9.09 ± 0.7 
XEF5 1.59 ± 0.1 42.40 ± 0.6  2.15 ± 0.1 4.62 ± 0.1 9.96 ± 0.7 
XEF6 2.26 ± 0.1 38.53 ± 5.9  2.22 ± 0.2 4.69 ± 0.4 10.05 ± 2.2 
XEF7 2.27 ± 0.2 22.26 ± 3.1  2.22 ± 0.2 4.54 ± 0.1 9.30 ± 0.3 
XEF8 3.09 ± 0.4 26.91 ± 8.0  2.14 ± 0.2 4.41 ± 0.1 9.10 ± 0.9 
XEF9 3.39 ± 0.2 27.18 ± 6.3  2.08 ± 0.1 4.41 ± 0.1 9.40 ± 0.7 
XEF10 3.30 ± 0.2 40.43 ± 0.6  2.16 ± 0.2 4.61 ± 0.1 9.91 ± 0.8 
BEF1e 17.62 ± 0.5 Traces  2.53 ± 0.1 2.20 ± 0.1 1.92 ± 0.2 
BEF2 16.75 ± 2.4 Traces  2.08 ± 0.9 1.82 ± 0.3 1.98 ± 1.2 
BEF3 25.12 ± 0.2 nd  2.16 ± 0.1 2.56 ± 0.1 3.04 ± 0.4 
BEF4 21.71 ± 0.6 nd  1.72 ± 0.3 1.67 ± 0.2 1.64 ± 0.6 
BEF5 11.38 ± 0.6 Traces  1.79 ± 0.3 1.52 ± 0.2 1.35 ± 0.6 
BEF6 14.91 ± 0.7 Traces  2.07 ± 0.3 1.59 ± 0.0 1.25 ± 0.2 
BEF7 18.19 ± 0.3 Traces  2.04 ± 0.3 1.95 ± 0.1 1.92 ± 0.5 
BEF8 16.03 ± 1.2 Traces  2.57 ± 0.5 2.33 ± 0.2 2.22 ± 0.8 
BEF9 18.04 ± 1.4 Traces  1.79 ± 0.2 1.91 ± 0.3 2.10 ± 0.7 
BEF10 13.14 ± 1.0 nd  1.87 ± 0.3 1.59 ± 0.1 1.39 ± 0.3 
a triplicate 1:1 combinations in terms of µg/mL concentration in the reaction volume; b enriched fractions previously 
analysed by HPLC-DAD (Table 3.6; p. 129); c dose reduction index; d xanthone-enriched fraction; e benzophenone-
enriched fraction. Data are presented as mean ± standard deviation (n = 3). 
 
4.3.3. In vivo hypoglycaemic effect 
 
The in vivo anti-diabetic potential of XEF0 was evaluated in terms of its blood glucose-lowering effect 
in a diabetic Wistar rat model (alone and in combination with acarbose). While the selected doses of sucrose 
(2 g/kg BW) and acarbose (5 mg/kg BW) were determined to be safe during previous studies (Oh et al., 2015; 
Jo et al., 2016), the level of XEF0 (300 mg/kg BW) was chosen based on a previous study that demonstrated 
in vivo hypoglycaemic effects for a C. subternata extract in diabetic Wistar rats (Schulze et al., 2016). The 
blood glucose levels of the rats were measured following a sucrose loading challenge and various treatments 
(XEF0, acarbose or a combination of acarbose + XEF0), given as an acute (once-off) dose. In addition, the area 
under the curve (AUC) was calculated to represent the different responses to the sucrose loading. Figure 4.5a 




after sucrose loading in treated non-diabetic rats. While XEF0 did not significantly lower blood glucose (Fig. 
4.5a), and even showed a higher level after 30 min than the control, acarbose and acarbose + XEF0 had 
significant blood glucose-lowering effects as indicated by the reduced area under the curve (AUC) (P < 0.05; 




Figure 4.5 Blood glucose levels and 2-h area under curve (AUC) following oral sucrose loading in (a, b) 
normal and (c, d) diabetic Wistar rats treated with deionised water (control), acarbose (Aca; 5 mg/kg body 
weight), xanthone-enriched fraction of Cyclopia genistoides (XEF0; 300 mg/kg body weight), and a 
combination of Aca plus XEF0. Results are expressed as means ± SEM; * P < 0.05, # P < 0.12. 
 
In diabetic animals, consistent with findings reported for the non-diabetic group, acarbose lowered 
blood glucose levels due to α-glucosidase inhibition (Fig. 4.5c), as indicated by the significantly reduced AUC 
(P < 0.05). Interestingly, contrary to results obtained for non-diabetic animals, here, XEF0 tended to lower 
blood glucose (Fig. 4.5c), although the AUC for XEF0 was not significantly lower than for the control 
(Fig. 4.5d; P > 0.05). As expected, acarbose consistently lowered blood glucose and improved glucose 
tolerance due to its potent α-glucosidase inhibitory effect in both the normal and diabetic animals, while XEF0 
only showed a trend towards reducing postprandial hyperglycaemia in diabetic animals. However, the 
combination treatment did not appear to have any additive/synergistic inhibitory effect on α-glucosidase in 






should consider a cumulative daily administration of different treatments and dosages over an extended period.  
It is possible that a significant in vivo anti-diabetic effect would be more likely to manifest itself 
following longer exposure to XEF0, as previous studies have reported that 30-day administration of C. 
maculata extract to diabetic Wistar rats resulted in significantly reduced post-prandial blood glucose (Chellan 
et al., 2014). Similarly, 30-day administration of mangiferin (40 mg/kg BW/day) to diabetic Wistar rats 
resulted in significantly reduced postprandial blood glucose after oral glucose loading (Sellamuthu et al., 
2009). Despite the low oral bioavailability of mangiferin (Hou et al., 2012), some absorption does take place, 
and the long-term effects of mangiferin and its systemic metabolites (e.g. norathyriol) on regulating insulin 
homeostasis (Singh et al., 2018) and promoting glucose uptake by cells (Sekar et al., 2019) cannot be 
disregarded. Therefore, long-term supplementation with C. genistoides extracts or fractions containing high 
amounts of mangiferin could provide anti-diabetic effects at either the intestinal or systemic level. Another 
factor that cannot be ruled out is the reported prokinetic effect of mangiferin on gastric emptying (Morais et 
al., 2012). It has previously been shown that accelerated gastric emptying resulted in larger postprandial 
hyperglycaemic excursions in type 2 diabetics compared with non-diabetics (Gonlachanvit et al., 2003). This 
is another significant physiological factor that is absent in an in vitro model, as a complex interrelationship 
exists between in vivo gastric motility and postprandial blood glucose, with the gastric emptying rate having a 
major impact on the magnitude of both the glycaemic excursion and the hormonal feedback mechanism 
(Marathe et al., 2013). Acarbose, on the other hand, has been shown to delay gastric emptying (Enç et al., 
2001). These apparently counteracting mechanisms could explain the less effective blood glucose lowering 
effect observed for the acarbose-XEF0 combination treatment vs. acarbose alone (Fig. 4.5d). 
In the present study only a single treatment dose was administered, but Shi et al. (2017) reported that 
fasting blood glucose was significantly lowered in diabetic mice that received 30 mg/kg mangiferin for 15 
days. However, AUC was not significantly reduced in the same mice after an oral starch or glucose tolerance 
test. The authors speculated that the higher water solubility of acarbose as compared with mangiferin could 
explain the non-significant effect of the mangiferin treatment. 
The in vivo model represents a much more complex biological environment, including the effects of 
other cellular pathways, metabolic processes and the gastrointestinal environment (Caesar & Cech, 2019). The 
limitation of single molecular targets is that it does not account for other processes that are inevitably connected 
through complex hierarchical networks of biological systems (Medina-Franco et al., 2013). Liu et al. (2012) 
reported that the peak plasma concentration and 24-h AUC of mangiferin was 2.79-fold and 2.35-fold greater 
in STZ-induced diabetic Wistar rats, respectively, as compared with normal rats following a single oral dose 
of 400 mg/kg BW. This suggests that intestinal absorption of mangiferin could be higher in diabetic rats, which 
might explain the non-significant postprandial blood glucose-lowering effect observed presently in the diabetic 
rat model. A recent study (Vazquez-Olivo et al., 2019) demonstrated that mangiferin showed greater intestinal 
permeability (3- to 4.8-fold higher) as part of a mango bark extract than as a pure standard, suggesting that the 
absorption of mangiferin could be increased in the presence of other constituents in an multi-compound extract 
such as from Cyclopia genistoides. This might explain the non-significant hypoglycaemic effect of XEF0 (37% 




resulting in a less pronounced inhibitory effect on α-glucosidase as manifested in the 2-h AUC. Also of 
relevance to note is that Pyner et al. (2017) reported that epigallocatechin gallate, green tea extract and acarbose 
exhibited 1.4 to 4.8-fold stronger in vitro inhibition of human intestinal sucrase compared with rat intestinal 
sucrase. This suggests that the results of oral sucrose tolerance testing in rats may underestimate the in vivo 




This study has demonstrated for the first time the synergistic in vitro inhibition of mammalian intestinal α-
glucosidase by combinations of acarbose with (1) the major bioactive compounds found in C. genistoides, and 
(2) enriched phenolic fractions of C. genistoides. The degree of synergism, indicated by the combination index 
of Chou-Talalay, differed depending on the effect level. These results highlight the potential of C. genistoides 
extracts, enriched in xanthones and benzophenones, for reducing the effective dose of acarbose required to 
prevent postprandial hyperglycaemia. This could prevent or alleviate the dose-related side effects of acarbose, 
which has been reported as a significant factor resulting in the discontinuation of treatment. The presently 
observed non-significant hypoglycaemic effect of single acute dose of a xanthone-enriched fraction in normal 
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Gastroretentive tablet containing 
anti-diabetic fractions of honeybush 
(Cyclopia genistoides): 
physicochemical characterisation, in vitro 
cytotoxicity and storage stability 








Inhibition of intestinal α-glucosidase (AG) is considered an effective treatment approach for the prevention of 
postprandial hyperglycaemia in diabetes mellitus. Fractions of an ultrafiltered Cyclopia genistoides extract, 
respectively enriched in xanthones (XEFs) and benzophenones (BEFs) were previously shown to inhibit 
mammalian AG. In the present study, lack of in vitro cytotoxicity in human-derived liver (C3A) cells was 
demonstrated, confirming the feasibility of using C. genistoides fractions as natural anti-diabetic supplements. 
Ex vivo intestinal transport studies, using a Sweetana-Grass apparatus and porcine jejunal tissue, were also 
performed to determine whether the gut could be a predominant site of action. The major bioactive compounds, 
the xanthones  (mangiferin, isomangiferin) and benzophenones (3-β-D-glucopyranosyliriflophenone [I3G] and 
3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone [IDG]), were poorly absorbed by the porcine 
intestinal tissue (efflux ratio > 1), confirming their suitability as active pharmaceutical ingredients aimed at an 
intestinal target site. Storage stability testing, moisture sorption assays and thermal analyses of the ultrafiltered 
extract and enriched fractions were carried out to determine their susceptibility to chemical degradation during 
storage, prior to formulation. The XEF and BEF were subsequently incorporated (alone and in combination) 
in a non-effervescent gastroretentive tablet formulation containing low-density polymer (styrene-
divinylbenzene co-polymer) as the floating agent and manufactured by direct compression. Physicochemical 
characterisation of the tablets (friability, hardness, mass variation, thickness, diameter, bouyancy, in vitro 
dissolution) was carried out to determine the suitability of the present formulation for further development as 
a gastroretentive delivery system for AG inhibitors of C. genistoides. The tablets conformed to British 
Pharmacopeia standards for mass variation, but > 1% friability indicates that protective blister packaging 
would be required for the present tablet formulation to prevent quality deterioration due to mechanical 
abrasion. Dissolution data were fitted to various mathematical models using DDsolver. The tablets were able 
to float in an in vitro medium (0.1 N HCl) for at least 8 h and slowly released the target compounds through a 
complex mechanism involving polymer relaxation and diffusion, with the latter predominating the process. In 




The close interrelationship between the diet and metabolic diseases such as obesity and type 2 diabetes mellitus 
has created many new opportunities for the development of novel treatments, based on the use of functional 
foods or nutraceuticals as an adjunct to first-line treatments such as lifestyle modification and pharmacotherapy 
(Riccardi et al., 2005; Zhu et al., 2019). Essentially, the ultimate goal of any anti-diabetic treatment is the 
prevention or reduction of persistent hyperglycaemia, which may give rise to a host of microvascular and 
macrovascular complications as a result of glucotoxicity (Bailey, 2015). There are various classes of oral anti-
diabetic drugs available for type 2 and other non-insulin dependent diabetics, including α-glucosidase 
inhibitors (AGIs), which prevent postprandial hyperglycaemia by inhibiting the enzymatic digestion of dietary 




Acarbose, the most widely prescribed commercial AGI, has poor oral bioavailability (< 2%) (Puls et 
al., 1977; Kumar & Sinha, 2012; Williamson, 2013), similar to many bioactive polyphenols found in food or 
other plant sources (Manach et al., 2005; Williamson & Manach, 2005; D’Archivio et al., 2010; Bohn, 2014). 
Low bioavailability of an active pharmaceutical ingredient (API) is of less concern when the therapeutic target 
is located in the gastrointestinal tract (GIT) itself, as is the case with intestinal AGIs, contrary to an API for 
which it is important to maintain a therapeutic plasma concentration (Varma et al., 2004; Lopes et al., 2016). 
The residence time of poorly absorbed AGIs in the upper small intestine can be significantly extended by 
combining them with specialised excipients in modified release delivery systems (Chaudhari et al., 2012). 
Modified-release oral delivery systems can facilitate the controlled release of a single dose over a more-or-less 
predictable period, longer than what could otherwise be achieved with a standard-release dosage form. 
Gastroretentive delivery systems (GRDSs) are a specific type of modified release delivery system designed to 
be retained in the stomach for as long as possible, while the slow dissolution of the API into the small intestine 
over an extended period provides a prolonged and consistent therapeutic effect (Umamaheswara Rao & Pavan, 
2012). Gastric retention can be achieved through a number of mechanisms, including floating-type systems, 
delaying excipients, swelling/expanding-type systems, muco-adhesion or high density systems (Narang, 
2010). Low density floating-type systems are designed to be less dense than gastric acid, enabling them to float 
to the surface and avoid the passage into the small intestine (Arora et al., 2005). Floating can be achieved in 
an effervescent, i.e. gas-forming or non-effervescent formulation, but the former type of system may contribute 
to transient side effects of bloating and flatulence that are already associated with AGI use, making a non-
effervescent system, as used in the present study, the preferred choice for such applications. Other advantages 
are that floating lag time is not affected by the gastric pH and that manufacturing does not require special 
manufacturing devices (Kim et al., 2018).    
Currently, acarbose is available only as standard-release 25, 50 or 100 mg tablets (Glucobay®, 
Prandase® or Precose®), but some researchers have developed novel oral delivery systems for acarbose, e.g. 
sustained-release microspheres composed of sodium alginate and hydroxypropyl methylcellulose (Hemlata et 
al., 2013), and a bi-layer tablet designed to release a combination of acarbose and metformin at different rates 
in the GIT (Tiwari et al., 2014). Miglitol (Glyset®), the second most studied commercial AGI (Van de Laar et 
al., 2005), was incorporated in mucoadhesive nanospheres in an attempt to achieve sustained release and 
thereby reduce dosing frequency (Agilandeswari et al., 2016). However, miglitol differs majorly from acarbose 
in that it is well absorbed and highly bioavailable (Joubert et al., 1990), even though its mechanism of action 
does not rely upon this attribute.  
In the previous chapter, xanthone- and benzophenone-enriched fractions (XEFs and BEFs), produced 
from an ultrafiltered hydro-ethanolic extract of C. genistoides by macroporous resin chromatography, were 
shown to inhibit mammalian intestinal AG in vitro. These semi-purified fractions contain at least two or more 
of the major phenolic compounds in C. genistoides with demonstrated AG inhibitory activity, i.e. mangiferin, 
isomangiferin, 3-β-D-glucopyranosyliriflophenone (I3G), 3-β-D-glucopyranosyl-4-O-β-D-
glucopyranosyliriflophenone (IDG) and 3-β-D-glucopyranosylmaclurin (M3G) (Beelders et al., 2014a; 




 The aim of the present study was to evaluate the suitability of a gastroretentive tablet formulation 
containing the XEFs and BEFs of C. genistoides for slow release of the APIs. The first objective was to assess 
the feasibility of using the fractions as APIs. This entailed assessing both the in vitro cytotoxicity of the extract 
and fractions and the intestinal transport of the major bioactive compounds in the fractions. The second 
objective was to determine the storage stability of the extract and fractions, prior to formulation. The stability 
of the compounds was determined under accelerated conditions at high temperature and relative humidity and 
during long-term storage at high temperature. Thermal analyses of the extract and fractions were carried out 
to monitor any phase changes during heating, and the hygroscopic properties of the extract and fractions were 
assessed, using a moisture sorption assay. The third objective was the physicochemical characterisation of 
non-effervescent-type gastroretentive tablets, containing the fractions as APIs. Physicochemical 
characterisation of the tablets included friability, hardness, mass variation, thickness, diameter, and buoyancy 
measurements, as well as in vitro dissolution testing with subsequent mathematical modelling of the 
dissolution data to provide insight into the release mechanisms of the target compounds from the tablet matrix. 
 
5.2. Materials and methods 
5.2.1. Chemicals and reagents 
 
Rhodamine 123, Krebs-Ringer bicarbonate (KRB) buffer, Supelco® styrene-divinylbenzene co-
polymer (15–100 mesh), dimethyl sulfoxide (DMSO) and magnesium stearate were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Kollidon VA64 vinylpyrrolidon-vinyl acetate co-polymer was purchased from 
BASF (Ludwighafen, Germany), hydroxypropyl methylcellulose from Shin-Etsu Chemical Co., Ltd (Tokyo, 
Japan), and Pharmacel 101 microcrystalline cellulose from DFE Pharma (Nörten-Hardenberg, Germany). 
Foetal bovine serum and Dulbecco’s phosphate buffered saline were purchased from Thermo Fisher Scientific 
(Waltham, MA, USA), and Eagle’s modified essential medium and L-glutamine were purchased from Lonza 
(Walkersville, MD, USA).  
Authentic phenolic reference standards (purity > 95%) were obtained from Sigma-Aldrich 
(mangiferin), Phytolab (Vestenbergsgreuth, Germany; I3G; isomangiferin) or isolated (IDG and M3G) from 
C. genistoides (Beelders et al., 2014a). All other reagents were of analytical grade and supplied by Sigma-
Aldrich or Merck (Darmstadt, Germany), except ethanol (EtOH) (Servochem, Cape Town, South Africa). 
Deionised water, prepared using an Elix Advantage 5 (Merck) water purification system, was further purified 
to HPLC grade using a Milli-Q Reference A+ (Merck) water purification system.  
All analytical grade salts for the moisture sorption assay were purchased from Sigma-Aldrich, i.e. 
lithium chloride, potassium acetate, magnesium chloride, potassium carbonate, magnesium nitrate 
hexahydrate, sodium chloride, potassium chloride and potassium sulphate. Deionised water was used to 






5.2.2. Extracts and fractions 
 
In the present study, the reference xanthone-enriched fraction (XEF0) and reference benzophenone-
enriched fraction (BEF0), previously used for α-glucosidase inhibition testing (Chapter 4, Section 4.2.2; 
p. 136), served as APIs in three different gastroretentive tablet formulations and for in vitro cytotoxicity testing 
(XEF0 only). Ultrafiltered Cyclopia genistoides extract (UCGE0), previously produced by tangential flow 
ultrafiltration (Chapter 3, Section 3.2.3; p. 111), as well as XEF0 and BEF0 were characterised by thermal 
analyses and moisture sorption assays. For initial cytotoxicity testing, a 40% EtOH-water extract was prepared 
from unfermented C. genistoides according to the extraction protocol previously described in Chapter 3 
(Section 3.2.2; p. 110), except that the extraction temperature was 93 °C instead of 70 °C.  
 
5.2.3. In vitro cytotoxicity 
5.2.3.1. Cell culture 
 
The human-derived hepatocarcinoma cell line C3A (ATCC® HB8065™) was purchased from the 
American Type Culture Collection (Manassas, VA, USA). The cells were passaged and sub-cultured in 
conventional culture medium in order to create a large reserve of cryopreserved cells. Briefly, C3A cells were 
seeded at a density of 11 × 104 cells/mL in 75 cm2 tissue culture flasks in complete growth medium, i.e. Eagle’s 
modified essential medium supplemented with 10% (v/v) foetal bovine serum and 1% (v/v) L-glutamine. Cells 
were incubated in a Galaxy® R CO2 incubator (Eppendorf AG, Hamburg, Germany) in humidified air at 37 °C 
with 5% CO2, and the culture medium was replaced every 2–3 days. Cells were sub-cultured at 70–80% 
confluence. 
 
5.2.3.2. MTT assay 
 
The cytotoxic effect of the 40% EtOH-water extract and XEF0 on C3A hepatocytes were assessed 
using a (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich). C3A 
cells were seeded into a flat-bottomed 96-well cell culture plate at 11 000 cells per well in 200 µL complete 
growth medium. The cells were exposed to concentrations of the extract and fraction at 0.1, 1, 10, 100 and 
1000 µg/mL for 3 h and 72 h, representing acute and chronic exposure, respectively, each culminating 5 days 
post-seeding. The growth medium was refreshed every 24 h, as well as 3 h prior to termination of the assay. 
Aqueous DMSO at 10% (v/v) was used a positive control. 
The colourimetric MTT assay was carried out following the respective incubations. Briefly, the cells 
were incubated in pre-warmed (37 °C) 2 mg/mL MTT solution in Dulbecco's phosphate-buffered saline for 30 
min and the resultant formazan crystals were dissolved in 200 µL DMSO. The solubilised dye was stabilised 
with the addition of 25 µL Sorenson’s fixation buffer (glycine 0.1 M, NaCl 0.1 M, pH adjusted to 10.5 with 
0.1 M NaOH). Subsequently, absorbance intensity, as a measure of mitochondrial dehydrogenase activity, was 




replicates were assessed for each treatment and the percentage viability data were represented as mean ± 
standard deviation relative to the normal control. To investigate any potential interference effect from reducing 
agents in the test samples, they were combined at all concentrations with MTT solution (no cells). The resultant 
optical density was measured and compared with the cell-based preparations. 
 
5.2.4. Ex vivo intestinal transport   
5.2.4.1. Preparation of intestinal tissue for ex vivo transport studies 
 
Porcine proximal jejenum tissue was collected at Potch Abattoir (Potchefstroom, South Africa). Fresh 
tissue was obtained from Landrace pigs, part of the domestic pig family (Sus scrofa domesticus), which is bred 
on South African farms and routinely slaughtered for meat production. All the animals were designated for 
slaughter by the abattoir on behalf of independent providers. Feeder pigs aged 4 to 6 months were selected as 
far as possible for tissue sample collection, which was carried out directly after slaughtering of the animal. 
An incision was made from the apex of the ascending duodenum to obtain a 30–40 cm segment of 
proximal jejenum. The excised tissue was rinsed with and stored in chilled KRB buffer during transportation 
to the laboratory (< 20 min). The dissected section of jejunal tissue was fitted over a glass tube, which was 
turned until the mesenteric border was visible, thus enabling careful removal of the serosa by blunt dissection. 
The tissue was kept moist by continuous application of KRB buffer. An incision was made alongside the 
mesenteric border, after which it was rinsed off the glass tube onto a section of filter paper. The apical side of 
the jejunal tissue was the downward-facing side. Any section of tissue with visible Peyer’s patches was excised 
and not used for the transport study as recommended (Pietzonka et al., 2002; Legen et al., 2005; Balimane et 
al., 2006). 
 
5.2.4.2. Preparation of solutions and samples 
 
The two fractions, XEF0, BEF0, and a 1:1 XEF0:BEF0 combination were dissolved in KRB buffer at a 
concentration of 1.714 mg/mL (equivalent to 12 mg active ingredient in 7 mL reaction volume and equivalent 
to the API content of 2 tablets) and placed in a water bath at 37 °C until required for the transport experiment. 
Preparation of the KRB buffer entailed adding an entire container of KRB mixture (Sigma-Aldrich) to a 1 L 
volumetric flask, adding an additional 1.26 g sodium bicarbonate, making the solution up to volume with 
deionised water, and then stirring for 5 min to ensure complete dissolution. The pH of the KRB buffer was 
adjusted to 7.4 using 2 M KOH, whereafter the buffer was refrigerated until required for the experiments.  
 
5.2.4.3. Transport studies 
 
The intestinal tissue sections (supplementary material; Fig. S14, p. 222) were mounted on the half-




(transport surface area = 1.78 cm2). The half-cells were clamped together to form diffusion chambers that were 
inserted in the apparatus, maintained at 37 °C using a Navicyte heating block (Harvard Bioscience, Holliston, 
MA, USA). KRB buffer (7 mL) at 37 °C was added to each half-cell compartment, followed by continuously 
bubbling of a gas mixture (95% O2:5% CO2; carbogen) through the buffer in each half-cell. The KRB buffer 
was incubated on both sides of the mounted intestinal tissue for 15 min to accustom the tissue to the 
experimental conditions. Subsequently, both apical (mucosal) and basolateral (serosal) compartments were 
aspirated (Integra Vacusafe aspirator; Labotec, Midrand, South Africa) to remove the buffer and add the test 
samples for the transport experiment, which entailed the following: Transport in the absorptive (apical-to-
basolateral, AB) direction was investigated by adding 7 mL KRB buffer (37 °C) to the basolateral (serosal) 
compartment, and an equal volume of the test sample to the apical (mucosal) compartment at 0 min. Transport 
in the secretory direction (basolateral-to-apical, BA) was investigated by adding 7 mL KRB buffer (37 °C) to 
the apical compartment and an equal volume of the test sample to the basolateral compartment at 0 min. All 
the transport studies were carried out in triplicate. 
 
Figure 5.1 Sweetana-Grass apparatus (left) with six diffusion chambers for ex vivo intestinal transport testing. 
The diagram (right) shows the basic operating principle of the diffusion chamber (Ashford, 2013). 
 
The mounted tissue was incubated for a period of 2 h, during which samples (500 µL) were collected 
from the acceptor compartment at 20-min intervals and replaced with an equal volume of KRB buffer at 37 °C 
(Legen et al., 2005). All samples were freeze-dried and stored at −18 °C until quantification of the target 
compounds by HPLC-DAD. The experimental data were used to calculate the apparent permeability 
coefficient () of each target compound according to the following equation (Wang et al., 2009): 
 
 =	-k ×  }_~2/  (Eq. 5.1) 
where  is the permeability coefficient (cm/s), dQ/dt is the permeability rate (slope of % transport/min 




The efflux ratio (ER) is an index of bi-directional intestinal transport that compares the adsorptive and 
secretory permeability (Hubatsch et al., 2007), and is represented by the equation:  
 
ER = ()**+,()**,+     (Eq. 5.2) 
 
where   and   represent values in the basolateral-to-apical (BA) and apical-to-basolateral (AB) 
directions, respectively. 
Rhodamine 123, a fluorescence marker and a substrate of the P-gp efflux transporter (Takizawa et al., 
2013), served as the model compound for transport studies. It was completely dissolved in KRB to a final 
concentration of 5 mM. The samples collected during the transport study (in triplicate in AB and BA direction) 
were analysed for rhodamine 123 content using a validated fluorescence spectroscopy assay and a Spectramax 
Paradigm® multi-mode detection platform plate reader (Molecular Devices, LLC). Excitation and emission 
wavelengths were set at 480 nm and 520 nm, respectively (Gerber et al., 2018). 
Lucifer yellow was included as an exclusion marker to indicate tissue integrity over the experimental 
time period (Bhushani et al., 2016). The lucifer yellow transport study was carried out only in the AB direction 
and the lucifer yellow concentration in the samples quantified by fluorescence spectroscopy at excitation and 
emission wavelengths of 485 nm and 535 nm, respectively (Wahlang et al., 2011). A standard curve with serial 
dilutions of 0.195–50 µg/mL was used for quantification. As an additional indicator of membrane integrity, 
the trans-epithelial electrical resistance (TEER) was measured using an ECA 825A Dual Channel Epithelial 
Voltage Clamp (Warner Instruments, Hamden, CT, USA) at the start of the experiment as the sample was 
added, and at the end of the 2 h sampling period.  
 
5.2.5. Storage stability of APIs 
 
Stability testing of target compounds in UCGE0, XEF0 and BEF0 was performed in triplicate under 
accelerated storage conditions (40 °C/75% relative humidity, RH) in a darkened stability cabinet (SMC 
Scientific Manufacturing, Table View, South Africa) over a period of 96 h. Mini-hygrostats (75% RH) were 
created by inserting a glass conical insert containing 250 µL of a saturated NaCl solution (0.36 g/mL) into each 
24 mL glass vial (Wexler & Hasegawa, 1954). The glass insert was mounted in a stainless steel compression 
spring to avoid contact of the insert with the powder (ca. 30 mg; mass accurately recorded on a Precisa 
262SMA-FR 5-decimal balance; Precisa Gravimetrics AG, Dietikon, Switzerland). Once all the components 
were added, the vials were tightly sealed with polytetrafluoroethylene (PTFE) screw-caps. Samples were 
removed from storage after 6, 12, 18, 24, 36, 48, 72 and 96 h. The glass conical insert containing the saturated 
salt solution but not the spring (to avoid powder loss) was removed directly after sampling, and the increase 
in the powder mass due to moisture uptake was determined gravimetrically. After re-weighing, 15 mL aqueous 
(DMSO) (10%, v/v) was added to the vial to obtain a solution with a concentration of ca. 2 mg/mL. Aliquots 




Stability of the target compounds in UCGE0, XEF0 and BEF0 during storage under “dry” conditions 
was determined at 40 °C for 12 weeks. Approximately 50 mg of freeze-dried sample was weighed off in 24 
mL amber glass vials, which were tightly sealed with PTFE screw-caps, mimicking moisture-impermeable 
containers, and placed in a darkened stability cabinet (SMC Scientific Manufacturing) set at 40 °C. Samples 
were removed from the cabinet after 1, 2, 3, 4, 6, 8, 10 and 12 weeks of storage. The content of each vial was 
dissolved in 15 mL aqueous DMSO (10%, v/v), equalling a concentration of ca. 3.3 mg/mL. Aliquots were 
stored at −18 °C until HPLC-DAD analysis. 
 
5.2.6. Moisture sorption analysis 
 
Moisture sorption analysis  was carried out on UCGE0, XEF0 and BEF0 by exposing samples to eight 
different saturated salt solutions, resulting in a step-wise increase in percentage RH over consecutive days 
(Hassel, 2006). Saturated salt solutions were prepared by dissolving a known amount of salt (g) (Table 5.1) in 
a known volume of deionised water at room temperature (25 °C). Predetermined amounts (≈50–100 mg) of 
each sample were weighed and were dried at 40 ˚C for 1 h in a laboratory oven (Labotec, Cape Town, South 
Africa). The samples were collected from the oven and weighed using 5-decimal digital balance (Mettler-
Toledo International Inc., Columbus, OH, USA) to determine the initial mass. An uncovered glass beaker 
containing the first saturated salt solution (LiCl) was placed in the center of a desiccator and the samples were 
arranged around the salt solution. The desiccator was sealed tightly and the mass of each sample was 
determined after 24 h of exposure to the atmosphere with known RH (Table 5.1). The study was continued and 
the masses of the samples were determined up until 48 h, or until equilibrium in the sample mass was achieved. 
The experiment was continued by replacing the first salt solution with the subsequent salt solutions in the order 
shown in Table 5.1. The same equilibration protocol was followed in each instance. For each sample, the 
percentage mass increase was plotted against the increase in RH. 







at 25 ˚C (%)a 
1 Lithium chloride 150 85 11.3 
2 Potassium acetate 200 65 22.5 
3 Magnesium chloride 200 25 32.8 
4 Potassium carbonate 200 90 43.2 
5 Magnesium nitrate 200 30 52.9 
6 Sodium chloride 200 60 75.3 
7 Potassium chloride 200 80 84.3 
8 Potassium sulphate 120 1000 97.0 







5.2.7. Thermal analysis of APIs 
 
Hot-stage microscopy was carried out to analyse the transitions in the solid-state behaviour of the 
samples (UCGE0, XEF0, BEF0) as a result of heating. The microscopic observation of morphological changes 
during heating of the samples was carried out using an Olympus SZX7 polarising optical microscope (Olympus 
Corporation, Tokyo, Japan) fitted with a THMS600 heating stage (Linkam Scientific, Surrey, UK). A small 
amount of the sample was placed on the sample slide and subsequently heated from 25–300 °C at a rate of 10 
°C/min.  Changes in the morphology of the samples (melting; degradation) were recorded as a function of 
temperature. The observed melting temperature was used as reference for thermogravimetric and differential 
scanning calorimetry analysis. 
Thermogravimetric analysis of the samples (UCGE0, XEF0, BEF0) was carried out using a TGA 4000 
Thermogravimetric Analyser (PerkinElmer, Waltham, MA, USA). Approximately 1–5 mg of the test sample 
was weighed into a porcelain crucible and inserted in the furnace. The sample was heated from 25–450 °C at 
a heating rate of 10 °C/min, followed by a nitrogen purge at 40 mL/min. Melting or degradation of the samples 
was examined by differential scanning calorimetry using a PerkinElmer DSC 8000 apparatus (Waltham, MA, 
USA). Approximately 1–5 mg of each sample was weighed into an aluminium pan, which was tightly sealed 
and heated from ambient temperature to 300 °C at a heating rate of 10 °C/min, followed by a nitrogen purge 
at 40 mL/min.  
 
5.2.7. Preparation of tablets 
 
Three tablet formulations (X, B, C) containing XEF0, BEF0 and a 1:1 XEF0:BEF0 combination as APIs, 
respectively, were prepared by weighing specific quantities of the ingredients as listed in Table 5.2. The 
ingredients were thoroughly blended using a TURBULA® shaker-mixer (Glen Mills Inc., Clifton, NJ, USA) 
for 5 min before tabletting by direct compression, performed using a single-punch Korsch XP1 tablet press 
(Korsch AG, Berlin, Germany) equipped with Korsch PharmaResearch® data acquisition and analysis software 
(supplementary material; Fig. S15, p. 223). A standard convex lower and upper punch diameter of 10 mm was 
used along with a maximum filling depth of 9 mm. The upper punch insertion depth was set at 10 mm. 
 
5.2.8. Physical properties of tablets 
 
The mass variation of each batch of gastroretentive tablets was determined by weighing 20 tablets 
from each batch on a 5-decimal digital balance (Mettler-Toledo International Inc.), and calculating the 
deviation from the mean tablet mass. Mass variation limits according to the British Pharmacopeia (2013) are 
provided in Table 5.3. The hardness, thickness and diameter of 10 tablets of each formulation were measured 
using a TBH 425 semi-automatic combination tester (ERWEKA GmbH, Langen, Germany) (supplementary 





The friability of each floating tablet formulation was determined using an ERWEKA TAR 
friability/abrasion tester (Langen, Germany) as follows: 13 tablets of each formulation were dusted, weighed, 
and placed in the rotating friability drum for 4 min at 25 rpm (supplementary material; Fig. S16, p. 223). The 
tablets were again dusted and re-weighed. Friability (%) was determined according to the following equation 
(Reddy et al., 2016): 
	
Friability	(%) = 	100	 × W/VWW/ 	  (Eq. 5.3) 
 
where W0 is the initial mass of the tablets, and W is the mass of the dusted tablets after friability testing. 
Friability of tablets should ideally not exceed 1% (British Phamacopoeia Commission, 2013). 
 
5.2.9.  In vitro floating and dissolution properties 
 
The in vitro floating time (h) of the tablets of the three formulations (X, B, C) was determined, using 
an adapted version of the method described by Kumaran et al. (2010). This entailed placing a tablet in a glass 
beaker containing 800 mL of 0.1 N HCl (pH = 1.2), which was magnetically stirred at 50 rpm and noting the 
time when the tablet descended to the bottom of the beaker before concluding the experiment after 8 h. Each 
experiment was performed in triplicate. In vitro dissolution testing of the tablets was carried out using a Distek 
Model 2500 apparatus (Distek, North Brunswick, New Jersey) in a medium of 0.1 N HCl (pH = 1.2; 37 °C). 
Once the water bath reached 37 °C, the experiment commenced by dropping two tablets of each gastroretentive 
formulation into each of three dissolution vessels numbered 1–3 (time = 0 min). The rotation speed of the 
stirring paddles was fixed at 50 rpm for the basic testing period of 480 min. At the sampling time intervals 
listed in Table 5.4, aliquots were withdrawn using a syringe fitted with a 0.45-µM nylon filter (Anatech 
Analytical Technologies, Sandton, South Africa) to filter out any suspended particles. The dissolution medium 
was replenished with an equal volume of 0.1 N HCl after each sampling. Following sampling at t = 480 min, 
stirring was accelerated to 250 rpm for 15 min, followed by ultrasonication of the reaction volume at 40 kHz 
in an Emmi 55HCQ ultrasonic bath (EMAG AG, Mörfelden-Walldorf, Germany) for 10 min to achieve 
complete dissolution of the tablet, whereafter a final sample was taken. All samples were freeze-dried and later 
dissolved in 200 µL aqueous dimethyl sulfoxide (DMSO) (10%, v/v) for analysis using ultra-high-performance 





Table 5.2 Three formulations of gastroretentive tablets containing xanthone- and/or benzophenone-enriched fractions of an 
ultrafiltered Cyclopia genistoides extract. 
Ingredient Function 
Content (%, m/m)a 
Formulation 
X B C 
Styrene-divinylbenzene co-polymer Floating agent 10 10 10 
Vinylpyrrolidon-vinyl acetate co-polymer Binding agent 10 10 10 
Hydroxypropyl methylcellulose Release-modifying agent 56 56 56 
Magnesium stearate Lubricant 0.5 0.5 0.5 
Microcrystalline cellulose Binding agent 22.3 22.3 22.3 
Xanthone-enriched fraction (XEF0) Active ingredient 1.2 - 0.6 
Benzophenone-enriched fraction (BEF0) Active ingredient - 1.2 0.6 
a individual tablet mass = 500 mg 
 
 
Table 5.3 Mass variation limits for uncoated tablets (British Phamacopoeia Commission, 2013). 
Pharmaceutical form 





< 80 < 10 
80 < x < 250 < 7.5 




Table 5.4 Dissolution testing parameters for floating gastroretentive tablets containing xanthone- and benzophenone-enriched fractions of an 
ultrafiltered Cyclopia genistoides extract. 
Sampling time intervals  
(min) 
Basic test stirring speed  
(rpm) 










5.2.10. Quantification of the major phenolic compounds 
 
Quantification of the target compounds in the extract used for in vitro cytotoxicity testing, and in the 
ex vivo intestinal transport and storage stability test samples, was carried out by HPLC-DAD, using a method 
developed specifically for C. genistoides (Beelders et al., 2014b) (refer to Section 3.2.9; p. 114). Injection 
volumes ranged between 5 and 30 µL depending on the sample. Quantitative analysis of samples from the 
dissolution studies was carried out using UHPLC-DAD (Beelders, 2016) performed with an Agilent 1290 
instrument, consisting of an in-line degasser, binary pump, autosampler, column thermostat and diode-array 
detector, and running OpenLab Chemstation software (Agilent Technologies Inc., Santa Clara, CA, USA). 
The maximum system pressure was 1200 bar. Separation was carried out on an Agilent Zorbax Eclipse Plus 
C18 column (Rapid resolution HD; 1.8 µM, 2.1 × 50 mM) controlled at 23 °C, with the flow rate maintained 
at 0.7 mL/min, and the following multi-linear gradient separation with 0.1% formic acid in water (v/v) (A) 
and acetonitrile (B): 5–22% B (0–2.2 min), 22–50% B (2.2–2.6 min), 50% B (2.6–4.1 min), 50–5% B (4.1–
4.6 min). The column was then re-equilibrated for 2 min. UV-Vis spectra were recorded at an acquisition rate 
of 20 Hz at 200–500 nm, with selective wavelength monitoring at 288 nm (I3G and IDG) and 320 nm (M3G, 
mangiferin and isomangiferin). A 10-point calibration curve was used to quantify the target compounds using 
authentic standards. Ascorbic acid at a final concentration of ca. 5 mg/mL was added to all samples to prevent 
oxidative degradation of compounds during analysis. Samples were filtered using 0.45 µm Millex-HV syringe 
filters (Merck Millipore) prior to analysis. 
 
5.2.11. Data analysis 
 
Statistical analysis of in vitro cytotoxicity data was performed using GraphPad Prism (Version 8.2.1; 
GraphPad Software, San Diego, CA, USA), where P < 0.05 from a one-way analysis of variance was 
considered significant.  
 
5.2.11.1. Modelling of degradation reaction kinetics 
 
The degradation of the target compounds during the 12-week/40 °C storage stability testing period was 
modelled using the following empirical kinetic models (Van Boekel, 2008): 
 
Zero	order	model:		8 = 	8_ T     (Eq. 5.4) 
 
First	order	model:		8 = 	8_V      (Eq. 5.5) 
 





Fractional	conversion	model:	8 = 8 +	(8_ T 8)V  (Eq. 5.7) 
 
where C0 is the initial content (g/100 g), T is the time in weeks, k is the reaction rate constant (weeks−1), and 
C∞ is the stable fraction of the compound (g/100 g sample, d.b.). Estimation of kinetic parameters was 
performed by application of the four models with time as independent variable for each experimental replicate, 
using the NLIN procedure of SAS software (Version 9.4; SAS Institute Inc., Cary, NC, USA). Model 
evaluation and selection were performed by examining   values. 
 
5.2.11.2. Modelling of API release kinetics 
 
The release of target compounds from the floating tablet (FGRDS) was evaluated by fitting the 
dissolution data to various mathematical models using the DDSolver add-in for MS Excel 10 (Microsoft 
Corporation, Redmond, WA, USA). This software, which is freely available 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895453/bin/12248_2010_9185_MOESM2_ESM.zip), fits 
established dissolution models to non-transformed data by calculating parameter values that minimise the 
weighted sum of squares (WSS) through the use of non-linear least-squares curve fitting techniques: 
 
WSS =	∑  .  T *.1  (Eq. 5.8) 
 
where n is the number of observations; wi is the weighting factor; yi_obs refers to the ith observed y value and 
yi_pred refers to the ith predicted y value. Detailed descriptions of the parameters in the model equations are 
available elsewhere in literature (Zhang et al., 2010). The goodness-of-fit of the various models was evaluated 
using the adjusted coefficient of determination ( ). The specification for goodness of fit of a model was 
arbitrarily set at a minimum value of 0.95 for  . Model suitability was also assessed by making use of the 
Akaike Information Criterion (AIC) and Model Selection Criterion (MSC) values, which are included in the 
standard DDSolver data output. A Student’s t-test was used to test for statistical significance.  
 
5.3. Results and discussion 
5.3.1. In vitro cytotoxicity 
 
Development of extracts or enriched fractions of C. genistoides as APIs begs the question whether 
these fractions could have toxic effects on cells. Measuring the activity of mitochondrial and cytoplasmic 
endoplasmic reticulum dehydrogenases serves as an indicator of cell viability. In active mitochondria, the 
tetrazolium salt MTT is reduced from a soluble yellow salt to insoluble purple formazan crystals, which can 
be quantified by spectrophotometry (Mosmann, 1983). No interference from reducing agents in the test 
samples was detected based on an additional experiment, where no differences in optical density were noted 




cell morphology as viewed under a microscope. Overall, mitochondrial dehydrogenase activity was not 
sufficiently reduced by either acute (3 h) or chronic (72 h) exposure to be considered cytotoxic to C3A cells. 
Although MTT activity was reduced following acute exposure to both the 40% EtOH-water extract and XEF0 
at the indicated concentrations (Fig. 5.2a, b), cell viability remained high (> 80% of control) in all cases, 
indicating no that no cytotoxic effects were observed (Hung et al., 2005).  
 
  
Figure 5.2 Mitochondrial dehydrogenase activity of C3A cells as a measure of cell viability following 3 h 
acute exposure and 72 h chronic exposure to (a) 40% ethanol-water extract of Cyclopia genistoides and (b) a 
xanthone-enriched fraction (XEF0) of C. genistoides at a range of concentrations. Data is represented as the 
mean of one experiment ± the standard deviation (n = 8). * P < 0.05, ** P < 0.01, *** P < 0.001, 
**** P < 0.0001 compared to the acute control. #### P < 0.0001 compared with the chronic control. 
DMSO = aqueous dimethyl sulfoxide (10%, v/v; positive control). 
 
 
While little is known about the potential toxic effects of isomangiferin or the benzophenones under 
investigation, previous studies reported no toxic effects for Vimang®, a commercial Mangifera indica extract 
(mangiferin content 10–20%) (Rodeiro et al., 2006; González et al., 2007; Garrido et al., 2009), purified 
mangiferin (> 90%) from Anemarrhena asphodeloides (Hou et al., 2012) or synthesised mangiferin 
(Matsushima et al., 1985). Reddeman et al. (2019) conducted toxicological studies on Zynamite®, a 
commercial mango leaf extract containing 60% mangiferin and 5% isomangiferin. Data from an in vitro 
bacterial reverse mutation test revealed no evidence of genotoxicity for Zynamite®, and there was also no 
evidence of in vivo mutagenicity in mice (as measured by micronucleus testing) following administration in 
two doses, 24 hours apart, at 500, 1000 or 2000 mg/kg BW. Similarly, no mortality or toxic effects were 
observed in normal rats treated with Zynamite® at doses of 500, 1000 or 2000 mg/kg BW per day for 90 days. 
Van der Merwe et al. (2017) reported that an hydro-ethanolic extract of C. genistoides (8.4% 
mangiferin, 2.6% isomangiferin, 2.1% IDG, 1.8% I3G; 1.0% M3G) caused no liver toxicity when fed to male 
Fischer rats for 28 days (2.5 g/kg feed). Dietary intake of the extract did not significantly affect body weight 
gain or relative liver and kidney mass of the rats. However, modulation of the expression of some antioxidant 





effects, based on the modulation of oxidative stress pathways, have been reported for mangiferin (Das et al., 
2012; Jain et al., 2013; Chowdhury et al., 2019). 
Mchunu (2019) studied the interaction of a hydro-ethanolic C. genistoides extract with cytochrome 
P450 (CYP) enzymes and drug transporter proteins in C3A liver cells to assess potential phytochemical-drug 
interactions. They also tested a xanthone-enriched fraction and a benzophenone-enriched fraction of the same 
extract, as well as the major phenolics in the extract, namely mangiferin, isomangiferin, IDG and I3G. The 
extract (13.8% mangiferin, 3.2% isomangiferin, 2.2% IDG, 1.1% M3G, 3.9% I3G) was a moderate inhibitor 
of all the major CYP enzymes tested. The xanthone-enriched fraction (54.0% mangiferin, 14.4% 
isomangiferin, 5.8% I3G) and mangiferin showed the most potential for herb-drug interactions based on their 
inhibitory effects on CYP enzymes, P-glycoprotein, breast cancer resistant protein (ABCG2) and solute carrier 
organic anion transporter family member 1B3 (SLCO1B3). Isomangiferin did not exhibit any of the effects 
reported for mangiferin. The benzophenone-enriched fraction and its two major compounds, I3G and IDG, did 
not have any significant inhibitory effect on the CYP enzymes. However, the low bioavailability of the 
xanthones and benzophenones were noted, and it was recommended that future toxicity testing should make 
use of lower in vitro sample concentrations to reflect the lower concentrations that are more likely to be reached 
in the systemic circulation (Mchunu, 2019).  
 
5.3.2. Ex vivo intestinal transport 
 
The low systemic bioavailability of dietary polyphenols underpins their potential as AGIs, as their 
confinement to the GIT due to poor intestinal absorption places them at the intended site of action (Bernardi 
et al., 2019). Membrane permeability and aqueous solubility are two major factors that determine the 
bioavailability of a bioactive compound, and forms the basis of the Biopharmaceutics Classification System, 
which allows broad predictions of the rate-limiting step in intestinal absorption following oral administration 
(Amidon et al., 1995; Dahan et al., 2009). Various methods are available for testing the intestinal permeability 
and predicting the oral bioavailability of candidate APIs. In vitro methods, e.g. Caco-2 cell monolayer or 
parallel artificial membrane permeability (PAMPA) assays, are generally less labour-intensive and more cost-
effective (Volpe, 2010), but they may not accurately reflect physiological conditions as well as excised tissue-
based ex vivo models (e.g. everted sac technique, Ussing-type diffusion chamber) or in situ methods (e.g. 
single-pass perfusion studies) (Balimane et al., 2006; Alqahtani et al., 2013; Sjöberg et al., 2013). For the 
present study, an ex vivo assay using a Sweetana-Grass diffusion apparatus was carried out to assess the 
potential of the major phenolic compounds of C. genistoides compounds to target intestinal enzymes. 
Intestinal transport studies were conducted using the fractions, XEF0 and BEF0, equivalent to the 
amount in two fully dissolved gastroretentive tablets (mass = 500 mg each, containing 6 mg API per tablet; 
Table 5.2) in the donor compartment (volume = 7 mL). The intestinal permeability of the target compounds 
was investigated twice, i.e. as a constituent of its parent fraction (XEF0 or BEF0) tested individually, or as a 
constituent of its parent fraction tested in combination with the other fraction. This represents the three different 




and 11.1%, respectively, whereas the IDG and I3G content of BEF0 were 7.0% and 5.2%, respectively (refer 
to Chapter 4, Table 4.1; p. 142).  
Use of the modified Ussing-type device (Grass & Sweetana, 1988) involved the mounting of sections 
of freshly excised porcine intestinal tissue (< 20 min post-slaughter). Transport of the marker compound, 
Lucifer yellow, an indicator of tissue integrity (Bhushani et al., 2016), amounted to < 5% over the experimental 
period, indicating that tissue integrity was maintained. TEER was measured directly after application of the 
test solutions to the apical chamber and again at t = 120 min (data included in supplementary material, Table 
S3; p. 216). TEER is indicative of the tight junction integrity of epithelial layers, i.e. it can be used as an 
indication of paracellular permeability, with opening of tight junctions resulting in decreased TEER (Hsu et 
al., 2012; Lemmer & Hamman, 2013). TEER > 30 Ω.cm2 observed in the present study, is considered 
acceptable for intact excised intestinal tissue (Sjöberg et al., 2013; Da Silva et al., 2015) and confirms epithelial 
integrity.  
The , defined as the initial flux of compound through the membrane, normalised by membrane 
surface area and donor compartment concentration, is commonly used as part of a general screening process 
in in vitro or ex vivo intestinal permeability studies (Palumbo et al., 2008). The efflux ratio (ER), representing 
the ratio of the value for the secretory (BA) direction vs. the absorptive (AB) direction, is indicative of 
the degree of efflux of a given compound, i.e. ER = 1 indicates that no efflux occurred, ER > 2 suggests active 
efflux mechanisms are involved, and 1 < ER < 2 suggests that passive efflux mechanisms dominate (Skolnik 
et al., 2010; Lin et al., 2011).  
For transport in the AB direction, I3G was not detected in the receiver compartment over the 
experimental period, precluding the calculation of  	and ER values for this compound when tested as a 
constituent of BEF0 (Table 5.5). Calculation of   was also not possible for I3G when tested as part of the 
combined fractions, due to too low transport rates across the membrane in either the AB or BA direction. 
Although this cannot provide further insight into the degree of efflux of I3G, it does confirm that I3G is unlikely 
to cross the intestinal membrane in substantial amounts, emphasising its likelihood to be confined to the target 
site in the small intestine. The calculated ER values for mangiferin and isomangiferin were between 1 and 2 
(1.53–1.81), whereas ER values > 2 were obtained for IDG. The ER of IDG, tested as part of the single fraction 
(3.05) was similar to that of rhodamine 123, a known substrate for the intestinal glycoprotein efflux transporter, 
P-glycoprotein 1 (P-gp) (Takizawa et al., 2013). A previous study showed that mangiferin, isomangiferin, IDG 
and I3G up-regulated the P-gp efflux drug transporter encoded by the ABCB1 gene, which suggests the 
potential for increased efflux of these compounds by enterocytes (Mchunu, 2019).  
The dominance of efflux mechanisms in the transport of the target compounds may be explained by 
their violation of two or more of Lipinski’s “rule of five” criteria (refer to Literature Review, Section 2.3.1.2; 
p. 33), which enables the prediction of the oral bioavailability of compounds on the basis of specific molecular 
properties (Lipinski et al., 1997; Veber et al., 2002). Seelig (1998) noted that (i) substrates for P-gp typically 
require specific recognition elements, viz.  two or more electron donor groups with fixed spatial separation of 
the compounds, and (ii) binding to P-gp increases with the strength and number of electron donor or hydrogen 




the multiple Lipinski “rule of five” violations that predicts their low oral bioavailability. The higher ER of IDG 
compared with the xanthones could be related to its additional glucose moiety, resulting in molar mass > 500 
g/mol, larger polar surface area and greater number of hydrogen bond acceptor groups and “rule of five” 
violations (3) as compared with the other compounds (2), suggesting its stronger affinity to P-gp. 
 
Table 5.5 Apparent permeability coefficients and efflux ratios for the two major xanthones, mangiferin 
and isomangiferin, and the two major benzophenones, IDG and I3G, in Cyclopia genistoides fractions, 
tested individually or in combination, for ex vivo intestinal permeability. 
Compound 
Single fractions 




 !""#$  
(× 10−7 cm/s) 
 !""$#  




 !""#$  
(× 10−7 cm/s) 
 !""$#  
(× 10−7 cm/s) 
Efflux 
ratio 
IDG 1.29 ± 0.1 3.93 ± 0.1 3.05  0.96 ± 0.3 2.05 ± 1.3 2.14 
I3G nd 10.1 ± 1.6 –  – traces – 
Mangiferin 0.93 ± 0.3 1.60 ± 0.1 1.71  1.43 ± 0.1 2.41 ± 0.5 1.68 
Isomangiferin 1.06 ± 0.4 1.91 ± 0.1 1.81  1.78 ± 0.2 2.73 ± 0.7 1.53 
Rhodamine 123  1.38 ± 0.4 4.12 ± 1.8 2.99  – – – 
AB, apical-to-basolateral direction (absorption); BA, basolateral-to-apical direction (efflux); BEF, benzophenone-
enriched fraction; IDG, 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone; I3G, 3-β-D-
glucopyranosyliriflophenone; nd, not detected; , apparent permeability coefficient; XEF, xanthone-enriched 
fraction. Data are presented as mean ± standard deviation (n = 3). 
 
These results confirm the validity of developing an anti-diabetic nutraceutical, containing these 
compounds as active ingredients, targeted towards the inhibition of intestinal α-glucosidase. Low rates of 
transport across the apical membrane, coupled with efflux mechanisms (likely mediated by P-gp transporters), 
would effectively concentrate the active ingredient at the intended site of action. These compounds could serve 
as a natural alternative or supplement to acarbose, the most widely used commercial α-glucosidase inhibitor, 
which is also poorly absorbed from the GIT (< 2% oral bioavailability) (Puls et al., 1977; Kumar & Sinha, 
2012; Williamson, 2013). With this confirmation that the target compounds would most likely be available to 
exert an effect in the GIT, the next steps were elucidation of their stability during storage of the APIs, and the 
physicochemical properties of the APIs prior to and during their incorporation into a floating gastroretentive 
tablet as potential delivery system.  
 
5.3.3. Storage stability 
5.3.3.1. Mini-hygrostat storage experiments 
 
The moisture sorption characteristics of dried plant extracts, intended for commercialisation as 
functional products or ingredients, is an important quality parameter with regard to selecting appropriate 
packaging material and specifying storage and handling conditions (Sinija & Mishra, 2008). Highly 
hygroscopic products require appropriate packaging and environmental conditions to minimise moisture 




deliquescence at > 25 °C and > 55% RH (De Beer et al., 2018). In the present study, a basic controlled moisture 
uptake study at 40 °C/75% RH was carried out by making use of a hygrostat, i.e. a saturated NaCl solution in 
a closed vessel. 
The greatest decrease in the target compound content over 96 h was observed for M3G in BEF0 
(15.4%) (Table 5.6). A greater decrease in M3G content occurred in BEF0 than in UCGE0, which suggests that 
the matrix of the ultrafiltered extract (pre-resin fractionation) may provide a degree of protection against 
chemical degradation. During the first 18 h of storage, the highest rate of moisture uptake was observed in 
BEF0, followed by UCGE0 and finally XEF0 (Fig. 5.3). The same order was observed for the total moisture 
uptake, with BEF0 having undergone a mass increase > 20% after 96 h, compared with a mass increase < 11% 
for XEF0. The moisture uptake of UCGE0, which represents the starting material from which XEF0 and BEF0 
were produced, fell between these two extremes. 
 
Table 5.6 Change in target compound content of ultrafiltered Cyclopia genistoides extract and its xanthone- and 
benzophenone-enriched fractions after 96 h of storage with mini-hygrostat (40 °C/75% RH). 
Compound 
UCGE0a  XEF0b  BEF0c 
Initiald 96 he 
Δ 
(%)f 
 Initial 96 h 
Δ 
(%) 
 Initial 96 h 
Δ 
(%) 
Mangiferin 11.80±0.08 11.51±0.34 -2.8  37.05±0.24 36.86±0.30 -0.5  – – – 
Isomangiferin 3.36±0.02 3.32±0.10 -1.1  11.06±0.07 10.55±0.18 -4.5  – – – 
IDGg 1.18±0.01 1.12±0.03 -4.8  – – –  7.04±0.02 6.99±0.09 -0.7 
M3Gh 0.55±0.01 0.50±0.01 -9.5  – – –  4.07±0.07 3.44±0.13 -15.4 
I3Gi 1.48±0.00 1.35±0.03 -8.8  3.33±0.03 3.11±0.02 -6.5  5.22±0.13 4.74±0.05 -9.2 
a ultrafiltered Cyclopia genistoides extract; b xanthone-enriched fraction; c benzophenone-enriched fraction; d initial content 
(g/100 g d.b.) and e content (g/100 g d.b.) after 96 hours; f percentage change in content after 96 h; g 3-β-D-glucopyranosyl-
4-O-β-D-glucopyranosyliriflophenone; h 3-β-D-glucopyranosylmaclurin; g 3-β-D-glucopyranosyliriflophenone. Data are 
presented as mean ± standard deviation (n = 3). 
 
 
 Visual inspection of the samples further emphasises this point, as visible liquefaction of UCGE0 and 
BEF0 could be observed after 96 h of storage (Fig. 5.4b, f), whereas XEF0 retained the superficial appearance 
of a dry product (Fig. 5.4d). The data indicate that the content of individual benzophenones (IDG, M3G and 
I3G), or other compounds present in the BEF0 in substantial amounts, are major contributors to hygroscopicity. 
BEF0 was produced by desorption of a UCGE0-loaded resin column with dilute aqueous solutions of ethanol 
(5–10% v/v). Therefore, it could be expected that the majority of hydrophilic constituents in UCGE0 would 
have desorbed along with the target benzophenones in BEF0. The greater degree of moisture uptake in BEF0 
could also be attributed to the additional glucosyl moiety in IDG, its major benzophenone (7.04%), which was 
not present in XEF0. This could also be related to the relatively high content of hygroscopic D-pinitol (8.2%) 
and D-glucose (1.6%) in BEF0 (refer to Chapter 4; Table 4.1; p. 142), as compared with XEF0 (D-pinitol = 








Figure 5.3 Remaining content of the target compounds (%) and degree of moisture uptake (expressed as % 
mass increase) in freeze-dried (a) ultrafiltered Cyclopia genistoides extract (UCGE0), (b) xanthone-enriched 
fraction (XEF0) and (c) benzophenone-enriched fraction (BEF0) as a function of time during storage at 
40 °C/75% RH for 96 h in sealed glass vials containing saturated NaCl mini-hygrostats. (I3G = 3-β-D-
glucopyranosyliriflophenone; IDG = 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone; M3G = 3-

















































































































































































Figure 5.4 Freeze-dried powders of (a, b) ultrafiltered Cyclopia genistoides extract (UCGE0), (c, d) xanthone-
enriched fraction (XEF0) and (e, f) benzophenone-enriched fraction (BEF0), pictured before (a, c, e) and after 














Based on an adapted European Pharmacopeia classification system for hygroscopicity of 
pharmaceutical ingredients (Murikipudi et al., 2013), UCGE0 and XEF0 can be described as “hygroscopic” and 
BEF0 as “very hygroscopic” , emphasising the importance of preventing exposure to high environmental 
humidity. According to ICH guidelines, a greater than 5% decrease in API content during accelerated stability 
testing is considered a “significant change” (Huynh-Ba & Zahn, 2009).  Prolonged exposure to RH > 75% 
should be avoided as far as possible by the storing and distributing the dried extracts or fractions in packaging 
with appropriate barrier properties. Normally, water- and UV light-impermeable containers are used (Newman 
et al., 2008; Hiatt et al., 2011). In the present study, the effect of UV light was not investigated, but the results 
emphasise that control of temperature and atmospheric humidity is imperative in order to prevent moisture 
uptake and target compound degradation in dried extract and fractions of C. genistoides, intended as anti-
diabetic functional ingredients. This is not only relevant in a formulated product, but also during bulk storage 
of the extract and fractions prior to production of the tablets. 
 
5.3.3.2. Moisture sorption analysis 
 
Moisture sorption analysis of freeze-dried samples at 25 °C showed that BEF0 was substantially more 
hygroscopic than XEF, with mass increases of 72.5% and 21.3%, respectively, measured at 97% RH (Fig. 5.5). 
Also included in the analysis was D-pinitol, which is present in UCGE0 (6.1%) and BEF0 (8.2%), to relate the 
relative moisture sorption attributes of the samples to their D-pinitol content. The higher moisture uptake by 
UCGE0 and BEF0 at RH > 75% can clearly be related to their content of D-pinitol, which underwent a sharp 
increase in mass due to higher moisture uptake at RH > 75%, ultimately showing the greatest mass increase 
(90.9%). As expected based on previous results, XEF0 was the least hygroscopic, with < 22% mass increase at 




Figure 5.5 Increase in mass of freeze-dried ultrafiltered Cyclopia genistoides extract (UCGE0), xanthone-
enriched fraction (XEF0), benzophenone-enriched fraction (BEF0) and D-pinitol due to moisture absorption as 



























5.3.3.3. Chemical stability and kinetic modelling of target compound degradation 
 
The degradation of chemical compounds in a solid state is usually a very gradual process, especially 
if the structure is crystalline, but this process can be accelerated by exposing the substances to elevated 
temperature and/or RH levels (Waterman & Adami, 2005). In the food and pharmaceutical industries, products 
are designed to undergo minimal changes under normal distribution and storage conditions, and the use of 
accelerated storage conditions enables producers to predict shelf-life or adapt processes to improve shelf-life 
(Corradini & Peleg, 2007). 
 Given the rapid increase in moisture content of UCGE0, XEF0 and BEF0, accompanied by target 
compound degradation, as demonstrated in the previous experiment (Fig. 5.3), further investigation of their 
chemical stability was merited in the absence of high RH. The samples were again subjected to ‘high’ 
temperature storage (40 °C) at 75% RH, but they were placed in moisture-impermeable containers. For 
countries such as South Africa with a subtropic/Mediterranean climate, the International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 
recommends 40 °C/75% RH for accelerated (6 months) storage testing (ICH, 2003). For the present study an 
abbreviated storage period of 12 weeks was employed and a moisture-impermeable container mimicked the 
type of packaging proposed for storage and distribution, given the results of the previous experiment. Weighing 
of the vials before and after storage (data not shown) indicated the no mass increase of samples occurred during 
storage, and thus confirmed that any degradation of the compounds would be the result of the temperature 
effect, and that the PTFE caps and glass barrier prevented moisture uptake even at 75% RH. 
The decrease in the xanthone (mangiferin and isomangiferin) and benzophenone (I3G and M3G) 
content of the different samples (UCGE0, XEF0, BEF0) was modelled using the zero order, first order, second 
order and fractional conversion models. Degradation data for mangiferin, isomangiferin, M3G and I3G were 
significantly explained by first-order reaction kinetics (P < 0.001) (Fig. 5.6). The benzophenone, M3G, was 
most susceptible to thermal degradation over the storage period of 12 weeks. This is in accordance with 
Beelders et al. (2017), who reported that the chemical stability of major phenolic compounds of C. genistoides 
in an aqueous model solution (pH 5) increased in the order M3G < mangiferin < I3G < isomangiferin < IDG. 
In the present study, IDG was the most stable compound, with < 13% degradation observed over 12 weeks of 
storage. Therefore, the degradation data for IDG were not fitted to the kinetic models. In general, the relatively 
low percentage of xanthone degradation after 12 weeks of storage (13.35–15.59%) resulted in a weaker fit of 
the data to the various models (0.531 <   < 0.791) compared with the benzophenones (0.633 <   < 
0.894). 
Despite the slightly higher   for the fractional conversion model (Table 5.7), the predicted 
equilibrium content of M3G < 0 was obtained, which is practically impossible, and therefore the degradation 
rate constants were derived by fitting the data to the first order model (Fig. 5.6). The first order reaction kinetics 
model has previously been used to describe the thermal degradation of the xanthones (mangiferin and 
isomangiferin) and benzophenones (I3G and IDG) in C. genistoides plant material (Beelders et al., 2015). The 




(R2 = 0.111), due to an insignificant decrease in the contents over 24 h. The first order degradation rate 
constants (k) and percentage degradation at 6 weeks and 12 weeks of storage are presented in Table 5.8 
(xanthones) and Table 5.9 (benzophenones). The highest k values were observed for the most heat-labile 
compound, M3G, which degraded at a higher rate in BEF0 (k = 0.0503) than UCGE0 (k = 0.0347). Indeed, 
almost half of the M3G content in BEF0 had degraded after 12 weeks of storage. 
 
Table 5.7 Adjusted coefficient of determination ( ) between mean observed content and 




Adjusted coefficient of determination (! ) 




UCGE0e 0.676 0.678 0.680 0.668 
XEF0f 0.531 0.538 0.544 0.747 
      
Isomangiferin 
UCGE0 0.722 0.725 0.727 0.716 
XEF0 0.749 0.757 0.765 0.791 
      
I3Gg 
UCGE0 0.824 0.833 0.835 0.829 
BEF0h 0.633 0.663 0.691 0.774 
      
M3Gi 
UCGE0 0.816 0.815 0.808 0.808 
BEF0 0.818 0.854 0.882 0.894 
a zero order model: C = C0 – kT; b first order model: C = C0−kT; c second order model: C = C0/(1 + kTC0); 
d fractional conversional model: C = C∞ + (C0 − C∞)−kT, where C0 is the initial content (g/100 g sample, 
d.b.), T is the time in weeks, k is the reaction rate constant (weeks−1), and C∞ is the stable fraction of the 
compound (g/100 g sample, d.b.); e ultrafiltered Cyclopia genistoides extract used as starting material for 
production of fractions; f xanthone-enriched fraction; g 3-β-D-glucopyranosyliriflophenone; 









Figure 5.6 First order model predicted values (indicated by (F), solid and broken lines) and experimental data (markers only) for degradation of 
(a) mangiferin, (b) isomangiferin, (c) 3-β-D-glucopyranosyliriflophenone (I3G) and (d) 3-β-D-glucopyranosylmaclurin (M3G) in different freeze-dried 
samples (UCGE0, ultrafiltered Cyclopia genistoides extract; XEF0, xanthone-enriched fraction; BEF0, benzophenone-enriched fraction) as a function of 
















































































































Table 5.8 Degradation (%) and first ordera degradation rate constants (k) for Cyclopia genistoides xanthones in powdered samples stored at 




Mangiferin   Isomangiferin 
Decrease after 
6 weeks (%) 
Decrease after 





6 weeks (%) 
Decrease after 
12 weeks (%) 
k (weeks−1) 
UCGE0b 8.11 ± 0.9* 15.59 ± 1.3 0.0125 ± 0.0017   7.15 ± 0.1* 13.35 ± 1.0 0.0153 ± 0.0019 
XEF0c 10.12 ± 1.2 14.55 ± 0.4 0.00872 ± 0.0016   9.61 ± 0.8 13.89 ± 0.5 0.0135 ± 0.0015 
a first order model: C = C0−kT where C0 is the initial content (g/100 g sample, d.b.), T is the time in weeks and k is the reaction rate constant (weeks−1); b ultrafiltered Cyclopia 
genistoides extract; c xanthone-enriched fraction; percentage decrease values are given as mean ± standard deviation (n = 3 except *n = 2 due to omission of outlier). k values 
given as mean ± standard error. 
 
 
Table 5.9 Degradation (%) and first ordera degradation rate constants (k) for Cyclopia genistoides benzophenones in powdered samples stored 




3-β-D-glucopyranosyliriflophenone (I3G)  3-β-D-glucopyranosylmaclurin (M3G) 
Decrease after 
6 weeks (%) 
Decrease after 
12 weeks (%) 
k (weeks−1)  
Decrease after 
6 weeks (%) 
Decrease after 
12 weeks (%) 
k (weeks−1) 
UCGE0 21.86 ± 5.7 28.81 ± 8.4 0.0326 ± 0.0029  20.19 ± 5.7 32.43 ± 10.5 0.0347 ± 0.0033 
BEF0c 29.72 ± 4.7 37.39 ± 8.9 0.0318 ± 0.0044  31.79 ± 3.9 46.28 ± 6.1 0.0503 ± 0.0042 
a first order model: C = C0−kT where C0 is the initial content (g/100 g sample, d.b.), T is the time in weeks and k is the reaction rate constant (weeks−1); b ultrafiltered 






5.3.3.4. Thermal analyses 
 
Hot-stage micrographs, obtained for UCGE0, XEF0 and BEF0 during heating from ambient temperature 
to 450 °C, are presented in Table 5.10. Initial liquefaction and discolouration of UCGE0 occurred at 177.5 °C 
with complete charring documented at 283.6 °C. For XEF0, the first morphological change occurred at 216.4 
°C when the sample became more liquid-like with some discoloration. Degradation was already completed at 
245.3 °C. For BEF0, a transition from a solid to a more liquid-like consistency was observed at 163.4 °C with 
simultaneous discoloration of the sample. Complete charring of the sample was noted at 276.3 °C. 
 
Table 5.10 Hot-stage micrographs of freeze-dried samples of ultrafiltered Cyclopia genistoides extract 
(UCGE0), xanthone-enriched fraction (XEF0) and benzophenone-enriched fraction (BEF0) of C. genistoides 
obtained during heating from ambient temperature up to 450 °C. 
UCGE0 
24.6 °C 177.5 °C 259.3 °C 283.6 °C 
XEF0 
23.7 °C 216.4 °C 245.3 °C 291.6 °C 
BEF0 
24.6 °C 163.4 °C  196.4 °C  276.3 °C  
 
 
The TGA thermogram obtained for UCGE0 (Fig. 5.7a) indicated an initial mass decrease of 5.8% from 
30 °C to 95 °C. An initial mass decrease of 2.9% was also observed for XEF0 between 30 °C and 162 °C (Fig. 
5.7b). This may be attributed to some adsorbed surface moisture. A second mass decrease step of 47.7% 
(UCGE0) and 39.3% (XEF0) was observed from ≈150–160 °C up to the end of the heating cycle at 450 °C. A 
single mass decrease step (58.1%) was noted for BEF0 (Fig. 5.7c). DSC thermograms obtained for UCGE0 and 
XEF0 (Fig. 5.8a, b) displayed no obvious thermal events, which correlates well with the hot-stage micrographs 




liquefaction followed by gradual discolouration of the samples. The DSC thermogram for BEF0 (Fig. 5.8c) 
showed a clear glass transition step at 132.4 °C, which correlates with the clear transition from a solid to a 
liquid-like state observed during hot-stage microscopy.  
 
 
Figure 5.7 Thermogravimetric analyses of (a) ultrafiltered Cyclopia genistoides extract (UCGE0), 
(b) xanthone-enriched fraction (XEF0) and (c) benzophenone-enriched fraction (BEF0) of C. genistoides during 














Figure 5.8 Differential scanning calorimetry thermograms for (a) ultrafiltered Cyclopia genistoides extract 
(UCGE0), (b) xanthone-enriched fraction (XEF0) and (c) benzophenone-enriched fraction (BEF0) of 












5.3.4. Physicochemical properties of gastroretentive tablets 
 
Tabletting of the different formulations (X, B, C) by direct compression produced off-white, flat tablets 
with concave bevelled edges (Fig. 5.9). The formulations differed only in their API composition, which 
represented 1.2% (m/m) of the total formulation (Table 5.2). Tablets with different formulations were not 
visually distinguishable from one another. The International Conference on Harmonisation (ICH) Harmonised 
Tripartite Guideline on Pharmaceutical Development (ICH, 2009) notes that the physicochemical and 
biological properties relevant to the performance, safety or manufacturability of the product should be 
identified and characterised. The appearance, mass and size of tablets should be consistent, with sufficient 
mechanical strength to withstand mechanical erosion and fracture during manufacture and handling. According 
to the British Pharmacopoeia (BP) (2013), the maximum allowable mass deviation for uncoated tablets with 
an average mass > 250 mg is 5%. For all three gastroretentive tablet formulations, mass deviation of the tablets 
(specified mass = 500 mg) were less than 5% indicating adherence to the BP guideline. Detailed mass deviation 
data for all individual tablets are provided in the appendix; (supplementary material; Table S4, p. 217). 
Hardness refers to the resistance of a material to indentation, abrasion, scratching or cutting, whereas 
friability, which is related to hardness, refers to the tendency of tablets to chip or fragment by mechanical 
abrasion (Bolhuis & De Waard, 2011). This can negatively affect the appearance and increase mass variation 
within batches (Gordon, 1994). The ICH guidelines suggest using these parameters as in-process controls that 
do not need to be included in product specifications unless they impact on the product quality and its ability to 
release the prescribed amount of active ingredient per dose (Acosta, 2008). All the tablet formulations 
exceeded the recommended BP limit for friability < 1% (Table 5.11). This indicates that blister packaging 
would be suitable for these tablets to avoid disintegration by abrasion, although friability and hardness 
attributes could be improved by reformulation (e.g. adding less magnesium stearate) or optimisation of the 
direct compression process parameters (Gordon, 1994). Shlieout et al. (2002) found that increasing the degree 
of polymerisation of MCC resulted in greater hardness of tablets. The lowest friability (1.31%) was observed 
for tablet formulation B, which had the highest hardness (60.60 N). Formulations X and C, which had similar 
hardness values but lower than that of B, were the most friable (> 2%).  
Floating-type GRDSs achieve buoyancy in the stomach due to a bulk density lower than that of the 
gastric contents, and rely on the presence of food in the stomach to delay gastric emptying and provide a 
sufficient liquid volume to achieve buoyancy (Singh & Kim, 2000; Bardonnet et al., 2006). Low-density 
polymers such as the floating agent used in the present formulations achieve buoyancy by the entrapment of 
air in the matrix (Gautam & Deva, 2012). All tablets were able to float for the full eight hours of the testing 
period. This duration was chosen because of the typical three times a day dosing regimen for commercial AGIs 
(Kumar & Sinha, 2012). This assumes that three substantial meals are taken daily, since AGIs are most 
effective when taken with meals. The composition of excipients used in the present floating tablet formulations 
was able to achieve the required buoyancy properties for 8-hourly dosing intervals. Specifically, Kollidon VA 
64 and hydroxypropyl methylcellulose are important excipients for maintaining integrity of the tablets in the 






Figure 5.9 Gastroretentive tablets of formulations X, B and C, containing xanthone-enriched fraction (XEF0), 
benzophenone (BEF0) and 1:1 combination of XEF0:BEF0 as active pharmaceutical ingredients, respectively. 
 
Table 5.11 Physical properties of gastroretentive tablets containing phenolic-enriched 
fractions of Cyclopia genistoides. 
Physical attribute 
Formulationa 
X B C 
Mass (mg) 492.82 ± 3.8 500.60 ± 5.0 490.30 ± 3.1 
Hardness (N) 52.80 ± 3.6 60.60 ± 4.3 51.10 ± 3.0 
Thickness (mm) 5.04 ± 0.0 5.03 ± 0.0  5.05 ± 0.0 
Diameter (mm) 11.94 ± 0.0 12.04 ± 0.0 12.04 ± 0.0 
Friability (%) 2.14 1.31 2.06 
Total floating time (h) > 8 > 8 > 8 
a formulations X, B and C differ only in terms of active pharmaceutical ingredient (refer to Table 
5.2): X = xanthone-enriched fraction, B = benzophenone-enriched fraction; C = 1:1 combination 
of the xanthone-enriched and benzophenone-enriched fractions. Mass and size data are 
presented as mean ± standard deviation (n = 20). 
 
 
5.3.5. In vitro dissolution 
 
In vitro dissolution data, collected over 8 h (Fig. 5.10), were fitted to seven frequently used 
mathematical models included in the DDSolver database, which allows for reduced calculation time in 
quantitative analysis of dissolution data and less potential for calculation error (Zuo et al., 2014). Mathematical 
modelling of  the release kinetics of APIs describes the dependence of release as a function of time, and is an 
important tool in the design of pharmaceutical formulations and delivery systems, and for in vitro and in vivo 
evaluation of release processes (Peppas & Narasimhan, 2014). The use of multiple mathematical models can 
aid in providing a more comprehensive characterisation of the release kinetics through the evaluation of various 
parameters unique to specific models (Gouda et al., 2017). 




The Akaike Information Criterion (AIC) is a popular tool for selecting optimal models due to its 
general applicability and simplicity. In a comparison of models, a lower AIC value indicates a better fit (Costa 
& Lobo, 2001). The MSC is a modified reciprocal form of the AIC that has also been attracting attention as a 
useful statistical tool for model selection. When comparing models, a larger MSC value indicates a better 
model fit, with a value > 2 generally indicating a good fit (Zhang et al., 2010). 
Mangiferin and isomangiferin dissolution data were obtained by dissolving formulation X tablets, 
whereas I3G and IDG data were obtained from the dissolution of formulation B tablets. Model parameters for 
these phenolic compounds are presented in Table 5.12. All the models fitted well to the data ( 	> 0.90; 
MSC > 2), but evaluation of   showed that the zero order and Higuchi models (0.90 <  	< 0.95) did not 
fit the data as well as the other models ( 	> 0.95). The zero order and Higuchi models also had the highest 
AIC and lowest MSC values, emphasising their relatively weak fit to the data. Typically, zero order models 
are used to describe non-disintegrating delivery systems (e.g. transdermal release patches or osmotic systems) 
where API release is only a function of time and is independent of the API concentration (Bruschi, 2015). The 
current system under investigation does involve a degree of polymer disintegration, and accordingly the data 
were better explained by first order reaction kinetics (  > 0.98) than zero order kinetics (  < 0.95). 
Pharmaceutical dosage forms following first order reaction kinetics release the APIs proportional to the 
remaining amount in its interior, with the rate of release diminishing over time (Costa & Lobo, 2001). The 
Higuchi model describes API release as a square root time-dependent diffusion process, based on Fick’s Law 
(Costa & Lobo, 2001), and assumes no change in the matrix structure during dissolution (Bruschi, 2015). This 
could explain why this model did not fit the data as well as others, since dissolution did involve erosion of the 
polymer matrix.  
The overall best fit was observed for the Weibull model (  > 0.998; lowest AIC values; highest 
MSC values), which is useful for describing release mechanism from matrix systems (Kosmidis et al., 2003; 







Figure 5.10 In vitro dissolution profiles (8 h) of major phenolic compounds in gastroretentive tablets, 
formulated using different active pharmaceutical ingredients: (a) Formulation C tablets containing 1:1 
combination of xanthone-enriched fraction (XEF0) and benzophenone-enriched fraction (BEF0) of Cyclopia 
genistoides, (b) Formulation X tablets containing XEF0 only and (c) Formulation B tablets containing BEF0 
only. MGF = mangiferin; IMGF = isomangiferin; IDG = 3-β-D-glucopyranosyl-4-O-β-D-












































































Table 5.12 Model-fitting data for in vitro dissolution of target compounds from gastroretentive tablets 
containing phenolic-enriched fractions of Cyclopia genistoides. 
Modela Parameter 
Target compounds 
Mangiferin Isomangiferin I3G IDG 
Zero Order 
 \ = _D 
k0 0.221 0.220 0.197 0.217   0.927 0.925 0.949 0.921 
AIC 45.44 45.60 41.62 45.76 
MSC 2.337 2.303 2.688 2.254 
First Order 
 \ = 100 ∙ 1 T JVk 
k1 0.004 0.004 0.003 0.004   0.987 0.987 0.991 0.988 
AIC 33.50 33.04 29.53 32.60 
MSC 4.043 4.098 4.415 4.134 
Higuchi 
 \ = D_. 
kH 3.915 3.887 3.458 3.836   0.920 0.919 0.906 0.917 
AIC 46.09 46.15 45.89 46.13 
MSC 2.245 2.225 2.079 2.200 
Weibull 
 
\ = 100 ∙ 1 T JVk  ¡ 
α 726.5 729.0 717.7 718.5 
β 1.212 1.211 1.165 1.204 
Td 229.03 231.3 282.7 235.9   0.998 0.999 0.999 0.999 
AIC 19.61 15.74 13.43 16.87 
MSC 6.027 6.569 6.715 6.380 
Korsmeyer-Peppas 
 
\ = ¢£ ∙ D T ¤¥: 
kKP 1.742 1.753 1.199 1.702 
n 0.653 0.651 0.697 0.653 
Tlag 12.31 12.53 11.70 12.04   0.989 0.987 0.989 0.982 
AIC 33.42 34.65 31.74 36.70 
MSC 4.052 3.868 4.099 3.548 
Hixson-Crowell 
 \ = 100 ∙ ¦1 T (1 T §D)^¨ 
kHC 0.001 0.001 0.001 0.001   0.987 0.999 0.999 0.998 
AIC 33.50 16.29 16.81 20.20 
MSC 4.043 6.491 6.233 5.905 
Peppas-Sahlin 
 \ = 	 ∙ D_. + © ∙ D 
kd 1.937 1.931 1.417 1.921 
kr 0.116 0.115 0.120 0.113   0.976 0.973 0.980 0.970 
AIC 38.44 39.12 35.89 39.77 
MSC 3.338 3.230 3.506 3.109 
a F is the fraction of the compound released at time t; α and β are scale & shape parameters in the Weibull model; 
k0, zero order release constant;  k1, first order release constant; kd, diffusion constant; kr, polymer relaxation 
constant; kH, Higuchi release constant; kHC, Hixson-Crowell release constant; I3G, 3-β-D-
glucopyranosyliriflophenone; IDG, 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone; kKP, 
Korsmeyer-Peppas release constant; n, release exponent; Td, mean dissolution time at 63.2% dissolution (min) 
Tlag, lag time prior to compound release (min);  , adjusted coefficient of determination; AIC, Akaike 
information criterion; MSC, model selection criterion. 
 
 
To elucidate the mechanisms involved in API release from the tablets, dissolution data were fitted to 
three semi-empirical models, viz. the Weibull, Peppas-Sahlin and Korsmeyer-Peppas models. The time 
exponent (β) of the Weibull model can serve as an indicator of release mechanism of an API through a polymer 




Table 5.13 Release mechanisms of active pharmaceutical ingredients as interpreted 
using the Weibull model time exponent β (Papadopoulou et al., 2006). 
Release mechanism Value of time exponent (β) 
Fickian diffusion in fractal or Euclidian spaces < 0.75 
Combined release mechanism 0.75 ≤ β ≤ 1 
Complex release mechanism > 1.0 
 
 
Table 5.14 Interpretation of Korsmeyer-Peppas model release exponent (n) 
according to geometry of solid dosage form (Bruschi, 2015). 
Release mechanism  Geometry Release exponent (n) 
Fickian diffusion 




Planar (thin film) 0.50 < n < 1.0 
Cylindrical 0.45 < n < 0.89 
Spherical 0.43 < n < 0.85 
Case-II transport 
Planar (thin film) 1.0 
Cylindrical 0.89 
Spherical 0.85 
Super Case-II transport 
Planar (thin film) > 1.0 
Cylindrical > 0.89 
Spherical > 0.85 
 
 
The β or shape parameter in the Weibull model describes the dissolution curve as either exponential 
(β = 1), parabolic (β < 1) or sigmoid with a turning point (β >1) (Bruschi, 2015), with the latter being the case 
for all the target compounds presently under study (Table 5.12). β > 1 indicates that complex release 
mechanisms are involved in the release of mangiferin, isomangiferin, IDG and I3G, with the release rate 
initially increasing in non-linear fashion up to an inflection point and thereafter decreasing asymptotically 
(Papadopoulou et al., 2006). The Td parameter of the Weibull model indicates the time required (min) to release 
63.2% of the total amount of compound present in the dosage form (Ramteke et al., 2014). Mangiferin, 
isomangiferin and IDG had similar Td values (ca. 229–235 min), but I3G had the highest (282.7 min), indicating 
a more gradual dissolution process. The Weibull model has a limitation in that it is an empirical model with 
no fundamental kinetics, and it is therefore not possible to fully characterise the dissolution behaviour of the 
API using this model alone (Costa & Lobo, 2001). 
In the Peppas-Sahlin model, the parameters kd and kr represent release rate constants for polymer 
diffusion and relaxation, respectively (Peppas & Sahlin, 1989). When kd > kr, API release occurs more through 




than kr, the relaxation constant, for all compounds, indicating the predominance of diffusion mechanisms over 
polymer relaxation in the dissolution process (Peppas & Sahlin, 1989). 
The semi-empirical Korsmeyer-Peppas model includes the n parameter, which is used to classify 
different release mechanisms depending on the geometry of the dosage form (Table 5.14). This model is often 
used to analyse dissolution behaviour where the mechanism is not well known or where more than one 
mechanism could be involved (Bruschi, 2015). A modified version of the model was used, which incorporates 
the lag time (Tlag) at the start of the dissolution process (Costa & Lobo, 2001). The observed n values for the 
target compounds (0.653–0.697) indicate anomalous transport, i.e. an intermediate state between Fickian 
(Case-I) diffusion and Case-II transport marked by a mixture of swelling-controlled mechanisms and diffusion 
(Ritger & Peppas, 1987; Arora et al., 2011; Zuo et al., 2014; Bruschi, 2015; Danyuo et al., 2019). Tlag for the 
target compounds were approximately 12 min, with no major differences between individual compounds or 
between the compound classes. Interpretation of the n values indicates non-Fickian or anomalous transport of 
the API, with the API release mechanism governed by diffusion and polymer swelling. The time-dependent 
release effect is caused by the simultaneous diffusion coupled with slow rearrangement of polymeric chains 
(Bruschi, 2015). 
The rate of solvent diffusion is the main distinguishing feature between different non-Fickian diffusion 
mechanisms, which typically occur in vitreous polymers when the environmental temperature is less than the 
glass transition temperature (Bruschi, 2015), and can be subcategorised as i) Case-II transport, in which the 
velocity of solvent diffusion is much lower than the polymeric relaxation, ii) anomalous transport, where 
diffusion and relaxation mechanisms are of similar magnitude, and iii) Super Case-II transport, which is 
characterised by much higher solvent diffusion rates and accelerated solvent penetration (Klech & Simonelli, 
1989). When n = 1, the model is classified as Case II (non-Fickian), in which the API release rate corresponds 
to zero order kinetics, and API release is driven overwhelmingly by polymer relaxation rather than diffusion 
(Bruschi, 2015). This confirms the relatively poor fit observed for the zero order model in the present study as 
compared with other models that allow for mixed release mechanisms, e.g. the Weibull or Korsmeyer-Peppas 
models. The Hixson-Crowell model also showed good fit to the dissolution data. This model typically applies 
to dosage forms such as tablets, in which the dissolution occurs in proportional parallel planes in such a way 
that the initial geometrical form remains constant throughout (Costa & Lobo, 2001). This model assumes that 
the release rate of an API is limited by its dissolution rate and not by any diffusion that might occur through 




Toxicological investigation confirmed the low risk of hepatic cytotoxicity associated with extracts or fractions 
of C. genistoides, enriched in xanthone and benzophenone content. Poor intestinal absorption of the major 
bioactive compounds in the fractions confirmed their potential to act as intestinal α-glucosidase inhibitors. A 
floating-type gastroretentive tablet formulation containing the enriched fractions achieved buoyancy of the 




involving polymer swelling, erosion and diffusion. The hygroscopicity of dried C. genistoides extracts and 
fractions, particularly benzophenone-enriched fractions, and the susceptibility of some target compounds to 
degrade at 40 °C and in humid environmental conditions (75% RH), emphasises the need to provide adequate 
barrier packaging for the active ingredients. Blister packaging may be necessary to avoid abrasion of the 
tablets, as friability measurements exceeded British Pharmacopeia limits. These findings serve as a stepping-
stone towards the development of a gastroretentive dosage form for delivery of C. genistoides AGIs to the 
small intestine, for optimisation of their blood glucose-lowering effects.   
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6.1. General overview 
 
The growing pandemic of diet- and lifestyle-related metabolic diseases, including obesity and type 2 diabetes 
(T2D) (Hruby & Hu, 2015; IDF, 2017), makes the development of a nutraceutical or functional food ingredient 
with protective effects against these disorders a meaningful undertaking. Given the close link between T2D 
and obesity, and their common co-occurrence, some have suggested the portmanteau word diabesity to 
describe this phenomenon (Farag & Gaballa, 2011). The rise in diabesity has led to greater interest in the 
gastrointestinal tract (GIT) as a potential target for pharmacological or diet-based interventions in blood 
glucose and weight management. Condition-specific products have a greater chance of commercial viability, 
given the many nutraceutical products that appear on the market every year. Manufacturers have moved on 
from antioxidant plant extracts and are seeking either novel ingredients or extracts that can be marketed 
towards specific health conditions (Hilton, 2016). Various types of phytochemicals have shown great 
therapeutic potential specifically for the treatment of diabetes, including alkaloids, terpenoids and polyphenols 
(Bahadoran et al., 2013; Teoh & Das, 2018). More specifically, a number of studies have demonstrated that 
various plant extracts and purified phytochemicals are able to inhibit intestinal α-glucosidase (AG) (Kumar et 
al., 2011; Yin et al., 2014; Ghani, 2015; Di Stefano et al., 2018), a digestive enzyme that catalyses the release 
of glucose from complex dietary carbohydrates for absorption into the bloodstream (Borges de Melo et al., 
2006). 
Pharmaceutical-grade AG inhibitors (AGIs) such as acarbose (Glucobay®, Precose®, Prandase®) and 
miglitol (Glyset®) are usually prescribed by a physician for the treatment of T2D when physical exercise and 
dietary modifications do not provide adequate control of postprandial hyperglycaemia (Kumar & Sinha, 2012). 
Although lifestyle changes should always be emphasised as an important element to successful treatment, 
pharmacological intervention is almost invariably required (Nathan et al., 2009). Before overt T2D is 
diagnosed, a patient will usually present with a period of impaired glucose tolerance or pre-diabetes. If prompt 
treatment is introduced at this stage, the progression towards full-blown diabetes could be significantly delayed 
or averted altogether (Hostalek, 2019). Although highly effective, acarbose has been associated with dose-
related side effects, specifically flatulence and abdominal bloating, which could represent a significant barrier 
to treatment for some individuals (Fischer et al., 1998; Rosak & Mertes, 2012). These side effects could be 
ameliorated by the use of modified-release formulations or combinations of different AGIs with synergistic 
effects, which allows for dose reduction whilst maintaining treatment efficacy (Chou, 2010). 
The anti-diabetic potential of honeybush (Cyclopia spp.) extracts (Muller et al., 2011; Chellan et al., 
2014; Schulze et al., 2016), and in particular extracts of C.  genistoides, containing high amounts of the 
polyphenol subclasses, the xanthones (mangiferin, isomangiferin) and benzophenones (3-β-D-glucopyranosyl-
4-O-β-D-glucopyranosyliriflophenone [IDG], 3-β-D-glucopyranosyliriflophenone [I3G], 3-β-D-
glucopyranosylmaclurin [M3G]) (Beelders et al., 2014a; Raaths, 2016; Bosman et al., 2017), motivated the 
current research on the development of a nutraceutical or functional food ingredient based on the inhibition of 
mammalian intestinal AG by these compounds. Results presented in Chapter 3 indicated that macroporous 




production of xanthone-enriched fractions (XEFs) and benzophenone-enriched fractions (BEFs) from 
ultrafiltered extracts of C. genistoides. Exothermic adsorption of the target compounds on Amberlite XAD 
1180N resin is an advantage in terms of process efficiency as it eliminates the need for additional energy 
expenditure. Batch-to-batch variation (n = 10) of the phenolic content of the raw material was apparent in the 
feed solution (xanthone content = 9.3–14.5%; benzophenone content = 1.9–5.4%) and subsequently also 
downstream in the variable enrichment ratios (ERs) achieved for the target compounds in XEFs (xanthone ER 
= 1.2–3.1) and BEFs (benzophenone ER = 3.2–4.6). At the pre-harvest level, the enrichment of xanthone and 
benzophenone content in C. genistoides can start with specific farming practices, e.g. summer harvesting or 
the cultivation of selected genotypes containing higher levels of these compounds (Joubert et al., 2014; 
Bosman et al., 2017). In an industrial setting, one would expect large inherent variation in the xanthone and 
benzophenone content of different batches of C. genistoides, as plant breeding has not yet progressed to a 
cultivar. This emphasises the challenge of standardisation and the need for an effective strategy to minimise 
variation in the final product. 
In Chapter 4, synergistic in vitro inhibition of mammalian intestinal AG was demonstrated for 
combinations of acarbose with (1) the major bioactive compounds (mangiferin, isomangiferin, IDG and I3G) 
found in C. genistoides and (2) XEFs and BEFs of C. genistoides. In preliminary enzyme inhibition assays 
using single compounds, mean IC50 values obtained for the target compounds indicated the following 
descending order of potency: mangiferin (102.2 µM) > isomangiferin (119.8 µM) > I3G (237.5 µM) > IDG 
(299.4 µM). All the xanthones and benzophenones were less potent AGIs than acarbose (IC50 = 44.3 µM), but 
the XEFs were more potent AGIs than the BEFs. The degree of synergism in AGI combinations, indicated by 
the combination index (Chou & Talalay, 1984), varied depending on the effect level and the phenolic 
composition of the fraction. Combinations of acarbose with mangiferin or isomangiferin showed the strongest 
synergistic effects and potential for acarbose dose reduction in general. The results indicated that an XEF of 
C. genistoides, containing > 19% xanthones (w/w), could potentially achieve a theoretical four-fold or higher 
in vitro acarbose dose reduction at > 50% effect levels. Despite the demonstration of potent in vitro AG 
inhibition by XEF0 (IC50 = 43 µg/mL) in a cell-free fluorimetric assay, as well as the aforementioned synergism, 
the administration of a single dose of XEF0 (300 mg/kg body weight, BW) resulted in a slight but non-
significant reduction in postprandial blood glucose after an oral sucrose loading in normal and diabetic Wistar 
rats. Acarbose (5 mg/kg BW), on the other hand, significantly reduced postprandial blood glucose in both 
normal and diabetic rats (P < 0.05). Furthermore, co-administration of a combination of acarbose and XEF0 at 
5 and 300 mg/kg BW, respectively, did not result in an enhanced blood glucose-lowering effect when 
compared with acarbose alone. 
Chapter 5 described the incorporation of the ultrafiltered C. genistoides extract and the enriched 
fractions, XEF0 and BEF0, in a gastroretentive delivery system (directly compressed tablets) aimed at extended 
delivery of the active pharmaceutical ingredient to the upper GIT region. In vitro cytotoxicity testing using 
indicated a low risk of systemic cytotoxic effects. This was emphasised by ex vivo intestinal transport studies, 
which indicated that the major phenolic compounds are subject to active efflux after intestinal absorption. The 




compounds through a complex mechanism involving polymer relaxation and diffusion, with the latter 
predominating the process. In vitro dissolution data fit well to the Weibull model ( 	> 0.99). The tablets 
conformed to British Pharmacopeia standards for mass variation, but friability > 1% indicates that protective 
blister packaging would be required for the present tablet formulation to prevent quality deterioration due to 
mechanical abrasion. 
 
6.2. Limitations, challenges and future recommendations 
 
It is recommended that further in vivo experiments should be carried out to investigate the effect of XEF0 on 
postprandial blood glucose in a diabetic animal model. Only one treatment level (300 mg/kg BW), 
administered as a single oral dose, was investigated in the present study, which showed a non-significant 
reduction in postprandial blood glucose compared with the control (P > 0.05). Future experiments should 
investigate higher doses of XEF0, as well as the effect of long-term administration. It is also possible that 
different effects could be observed when administering different types of oral carbohydrate loading, e.g. 
sucrose, maltose or starch. The present study did not investigate specific α-glucosidase inhibitory activities, 
i.e. sucrase vs. maltase, but it has been shown that AGIs may differ in their potency against these different sub-
categories of the enzyme class (Jones et al., 2011; Yasuda et al., 2014; Zhang et al., 2017). It is possible that 
a significant in vivo anti-diabetic effect would be more likely to manifest itself following longer exposure to 
XEF0, as previous studies have reported that 30-day administration of C. maculata extract to diabetic Wistar 
rats resulted in significantly reduced post-prandial blood glucose (Chellan et al., 2014). Similarly, 30-day 
administration of mangiferin (40 mg/kg BW/day) to diabetic Wistar rats resulted in significantly reduced 
postprandial blood glucose after oral glucose loading (Sellamuthu et al., 2009). Long-term administration of 
mangiferin may also provide anti-diabetic benefits through another mechanism, as  it is broken down by 
colonic microbiota to norathyriol (Sanugul et al., 2005), which is absorbed and subsequently accumulated in 
the plasma (Tian et al., 2016) with the potential to exert a number of reported anti-diabetic effects (Ding et al., 
2014; Wang et al., 2014; Shi et al., 2017; Gu et al., 2019). Polyphenols that reach the colon may also exert a 
prebiotic effect by supressing the growth of pathogenic bacteria and stimulating the growth of beneficial 
species (Laparra & Sanz, 2010). The anaerobic fermentation of polyphenols by intestinal flora produces short-
chain fatty acids (SCFAs) e.g. butyrate and acetate, as well as phenolic acids e.g. protochatecuic acid that 
sustain the microbiome (Ozdal et al., 2016) and may also play a beneficial role in energy homeostasis in type 
2 diabetes (Hartstra et al., 2015). 
The literature review highlighted the need to develop alternatives to the few currently available 
immediate-release commercial preparations of oral AGIs. Ideally, AGIs could be incorporated in a modified-
release delivery system—designed to release bioactive compounds in specified amounts at specific sites in the 
GIT—to optimise the therapeutic effect and modulate the neurohormonal sensing mechanism of the ileal brake 
(Cuche et al., 2000). A Swedish patent application (Alderborn et al., 2016) proposed a dosage form for a 
combination of acarbose and orlistat (a lipase inhibitor), contained in four different subunits with individually 




to specific parts of the GIT. Earlier, Devane (2006) filed a patent application proposing a delayed-release 
delivery system for acarbose (25 mg/tablet), aimed at the treatment of constipation and inflammatory bowel 
disease (IBD), which would deliver the API to the distal small intestine (ileum) and colon. Mangiferin reduced 
markers of colonic damage and oxidative stress in a murine model of colitis (Somani et al., 2016), suggesting 
that combinations of acarbose and mangiferin-rich XEF in such a delayed-release delivery system could also 
provide therapeutic effects against symptoms of IBD.  
One of the clear limitations of the tablet formulation used in the present study is that the API only 
comprised 1.2% of the total tablet mass. Therefore, each 500 mg tablet would only deliver 6 mg of API. If this 
formulation were to be used for the delivery of acarbose, with a typical dose of 50 mg per meal, more than 
eight tablets would be required to deliver this dose. An even greater number of tablets would be required to 
deliver an equally effective dose of less potent AGIs such as the XEFs or BEFs of C. genistoides produced 
during this study. Therefore, different floating tablet formulations allowing for higher API content should be 
investigated. Kumar et al. (2009) produced tablets, containing 150 mg acarbose each (43% of total mass), 
which included either hydroxypropyl methylcellulose (HPMC) or guar gum as release-modifying agents and 
displayed excellent sustained release properties over 12 h. An earlier US patent application for a controlled-
release acarbose delivery system  proposed different HPMC-based tablet formulations allowing for up to 300 
mg of acarbose per tablet (Morrison, 2005). 
Alternatively, XEFs or BEFs of Cyclopia genistoides may be better suited to delivery in a standard 
pharmaceutical capsule, which could contain a higher amount of powdered formulation (between 200 and 1000 
mg) than a directly compressed tablet (Anonymous, 2019). Even when allowing for the inclusion of functional 
ingredients or excipients, this would allow for much higher API content. It would also allow the consumer to 
dissolve the contents of the capsule in a glass of water for consumption as a liquid preparation with meals. In 
much the same way that in vitro enzyme inhibition assays requires thorough mixing of the substrate, enzyme 
and enzyme inhibitor to achieve reliable results, AGIs should be taken with/after the first bite of a meal, and 
not on a relatively empty stomach, when emptying of liquids occurs at a faster rate because of the so-called 
“Magenstrasse” (stomach road) phenomenon (Pal et al., 2007). This refers to a wave of muscular contractions 
at the pyloric end of the stomach that clears the postprandial stomach of ingested fluids much faster than it 
clears the stomach of solid food particles. Consequently, if digestive enzyme inhibitors are taken in liquid form 
with not enough time allowed for thorough mixing with the stomach contents, they may prove less effective. 
For optimal efficacy, digestive enzyme inhibitors should be fully incorporated into the chyme, the 
acidic mass of partly digested food that passes from the stomach to the small intestine. Only a few years after 
the development of acarbose, O’Dea and Turton (1985) reported that swallowing an intact acarbose tablet with 
water at the start of a meal was markedly less effective than ingesting it in powdered form, uniformly mixed 
in with a meal of brown rice. They suggested that patients should be advised to crush acarbose tablets between 
spoons themselves, as powdered formulations of acarbose were not available at the time and remain 
unavailable today. 
The variable intraluminal pH in the GIT affects the dissolution, solubility and efficacy of APIs as well. 




et al., 2005). Although acarbose is not currently commercially available in a gastroretentive dosage form, the 
chemical stability of acarbose and other AGIs in the typical gastric environment should be considered in the 
development of a suitable formulation. Alderborn et al. (2016) reported that prolonged exposure of acarbose 
to 0.1 N HCl at pH = 1.2 and 37 °C resulted in time-dependent degradation, with < 40% of the starting amount 
of acarbose remaining after 2 h, suggesting that a prolonged residence time in the stomach could result in 
decreased efficacy. The metabolites of acarbose, produced by bacterial fermentation or enzymatic degradation, 
have limited AG inhibitory activity (Kumar & Sinha, 2012). Therefore, a multi-unit delivery system was 
proposed, from which a portion of acarbose is released in the stomach in a prolonged manner after a delay of 
30–60 min, and the other portion of acarbose is contained in an enteric-coated subunit, which is protected from 
gastric acid and rapidly dissolves only at pH > 4 (Alderborn et al., 2016). This type of formulation, comprising 
different sub-units with time- and site-dependent release profiles, could be applied to different dosage forms, 
e.g. multiple-unit tablets (coated or uncoated), multiple-unit capsules or oral powders. The latter may be an 
especially attractive dosage form for a combination of acarbose and C. genistoides XEFs/BEFs, which could 
be packaged in single-unit sachets filled with powder for oral administration, either blended with meals or 
dissolved in water and ingested as a drink. The APIs would be combined with compatible excipients and 
blended to a homogenous mixture that is filled into single-unit sachets using standard filling operations. 
Mangiferin may withstand low gastric pH better than acarbose, as it was shown to be remarkably stable 
at pH 3 over a temperature range of 60–140 °C, with susceptibility to thermal degradation increasing with 
increasing pH (Beelders et al., 2018). The latter study also noted the possible protective effects of the extract 
matrix on mangiferin, and identified possible precursor compounds in C. genistoides extract that could 
potentially convert to mangiferin. Future research should include simulated in vitro digestion studies (Gil-
Izquierdo et al., 2002; Minekus et al., 2014) to investigate the effects of the typical gastrointestinal 
environment on the chemical stability of the bioactive compounds in the XEFs and BEFs. 
XEFs or BEFs from C. genistoides could also be combined with other natural extracts with AG 
inhibitory activity. An extract of rooibos (Aspalathus linearis), the most popular South African herbal tea, 
containing high levels of the dihydrochalcone, aspalathin, also inhibited AG in a dose-dependent manner 
(Miller et al., 2018). Blends of rooibos and honeybush are already available on the market as herbal tea 
preparations (Joubert et al., 2019), but a blend of aspalathin-enriched rooibos extract and fractions of 
C. genistoides, enriched in xanthones or benzophenones, could offer even greater anti-diabetic benefits through 
potential synergistic interactions. Such multi-compound treatment approaches are the basis of many traditional 
medicine practices, as opposed to the “one disease – one target – one drug” approach of much of modern 
medicine (Wagner & Ulrich-Merzenich, 2009; Leonti & Casu, 2013). Advances in the field of nutrition science 
since the 1980s have highlighted the impact of complex food matrices on sustaining health, as opposed to the 
mid-20th century reductionist approach to nutrition that emphasised single compounds (Mozaffarian, 2019). 
An important factor to consider when developing new anti-diabetic treatment approaches is that pill count has 
been shown to affect patient adherence to treatment regimens, and any dosage form that simplifies the dosing 




metformin and glibenclamide, scored higher adherence rates than those who received a combination of 
metformin and glibenclamide as separate doses (Melikian et al., 2002).  
A potential challenge related to the use of C. genistoides extracts or mangiferin-rich fractions as 
functional food ingredients is that mangiferin has been confirmed as a bitter-tasting compound (Alexander et 
al., 2019). In fact, its bitter taste could actually be implicated in its health-promoting effects, as a recent ethno-
pharmacological database of traditional Ayurvedic medicinal plants noted a strong association between the 
bitter taste of phyto-extracts and their reported anti-inflammatory activity (Dragos & Gilca, 2018). Similarly, 
traditional Chinese medicinal practices also consider many bitter foods to be effective anti-inflammatory 
agents (Lin & Lin, 2011). Molecular geometry is an important factor in the ligand-receptor interactions that 
determine the biological activity and taste of chemical compounds (Kortagere et al., 2009). Dragos and Gilca 
(2018) have suggested that taste, i.e. molecular geometry, could be a more relevant predictor of the 
pharmacodynamic effects of phyto-compounds than their particular chemical affiliations. The relatively recent 
discovery of a diffuse chemosensory system of extra-oral taste receptors in the respiratory system, brain, 
pancreas, kidneys, heart and adipose tissue (Dehkordi et al., 2012; Henquin, 2012; Laffitte et al., 2014; Manson 
et al., 2014), as well as the stomach and intestines (Gilca & Dragos, 2017), has prompted more extensive 
research into these ligand-receptor interactions. The purported benefits of bitter compounds notwithstanding, 
the use of bitter-masking technologies might be necessary to achieve acceptable sensory attributes in a 
mangiferin-enriched functional food ingredient or nutraceutical (Ley, 2008).  
There is also a need to develop an efficient regeneration protocol for XAD 1180N resin, which was 
used in the present study for the production of XEFs and BEFs by macroporous adsorbent resin 
chromatography (MARC), as there were clear differences in the enrichment achieved for some target 
compounds (particular I3G) in successive experimental runs using regenerated resin. The resin column was 
rinsed with 2 bed volumes each of a 50%, 75% and 100% (v/v) aqueous ethanol solution between runs, but 
different regeneration protocols could be investigated to maintain sufficient adsorption capacity (Daignault et 
al., 1988; Kammerer et al., 2011; Soto et al., 2011). Macroporous resins typically have poor heat transfer 
characteristics, making it difficult to dissipate any heat generated during an exothermic adsorption process 
such as the one observed between the target compounds and resin in the present study. An increase in the resin 
column temperature,  as a result of the aforementioned exothermic adsorption, could explain the decreasing 
adsorption capacity that was observed for subsequent adsorbates over time (Li & Chase, 2010). 
Novel applications of AGIs, involving non-intestinal targets, have also been investigated in recent 
years (Kumar & Sinha, 2012). Dermatological preparations of acarbose aimed at the treatment of eczema and 
other inflammatory skin disorders have been patented, based on a similar mechanism of action as its 
hypoglycaemic effect, i.e. prevention of glucose generation, which inhibits the formation of harmful glycation 
end-products on the surface of inflamed skin (Mummert et al., 2003; Maes et al., 2009). This has also been 
suggested as a mechanism of action underlying the skin-care benefits of mangiferin (Telang et al., 2013). 
Petrova et al. (2011) reported that mangiferin protected the skin of mice against UV-induced oxidative damage, 
inflammation and cell proliferation, but the effects were less potent than those of fermented and unfermented 




XEFs, produced by the multi-step enrichment process as presented in this study, could be used, alone or in 
combination with other AGIs such as acarbose, as an active ingredient in skin-care preparations. 
The present research resulted in the development of a potential gastroretentive delivery system for an 
anti-diabetic nutraceutical incorporating fractions enriched in xanthones and benzophenones from 
C. genistoides, hopefully paving the way for future research and development endeavours that would result in 
value-added products and a contribution to the management of diabesity. 
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Table S1 Application of an optimised tangential flow ultrafiltration process to a large volume (Batch A; 23 L) of a 40% ethanol-H2O 
(v/v) extracta of green Cyclopia genistoides (data additional to Table 3.1; p. 116). 
Parameterb 
Ultrafiltration fraction 
Initial feed Permeate (UCGE0)c Retentate 
Mangiferin 9.82 11.80 6.11 
Isomangiferin 2.74 3.36 1.67 
Xanthones (mangiferin + isomangiferin) 12.56 15.16 7.78 
3-β-D-glucopyranosyliriflophenone (I3G) 1.19 1.48 0.68 
3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone (IDG) 0.93 1.18 0.53 
3-β-D-glucopyranosylmaclurin (M3G) 0.44 0.55 0.25 
Benzophenones (I3G + IDG + M3G) 2.56 3.21 1.46 
Vicenin-2 0.25 0.30 0.16 
Eriodictyol-O-hexose-O-deoxyhexose isomer 0.29 0.35 0.17 
(2R)-5-[α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranosyloxy]naringenind 0.11 0.13 0.07 
(2S)-5-[α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranosyloxy]naringenind 1.17 1.40 0.73 
Hesperidin 1.21 1.46 0.78 
Volume (L) 23 18.4 4.6 
Soluble solids (g/L) 29.57 22.83 57.38 
Yield (g) 680 399 258 
a plant material: solvent ratio = 1:10 (m/v), 30 min, 70 °C; b compound content expressed as g/100 g freeze-dried solids, as determined using high-
performance liquid chromatography with diode array detection method described by Beelders et al. (2014); c ultrafiltered Cyclopia genistoides 
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Table S2 Enrichment in contents of major xanthones and benzophenones after tangential flow ultrafiltration of hydro-ethanolic extracts of 
green Cyclopia genistoides produced from ten plant material batches, CG1–10 (expanded version of Table 3.5; p. 125). 
Batch 
Benzophenone contenta  Xanthone contenta 



































CG1 1.55 2.12 37.2  1.23 1.69 38.2  0.47 0.67 42.9  10.57 14.07 33.1  2.93 3.96 35.3 
CG2 1.47 1.84 24.7  1.11 1.41 26.5  0.59 0.76 29.9  9.58 11.91 24.3  2.39 3.04 27.1 
CG3 1.93 2.71 40.8  2.95 4.29 45.4  0.52 0.78 51.2  8.25 11.38 37.9  2.24 3.14 40.3 
CG4 2.12 3.06 44.2  1.18 1.75 49.2  0.42 0.65 53.1  10.19 14.39 41.2  2.80 4.03 44.0 
CG5 0.89 1.21 35.4  0.73 0.99 35.5  0.28 0.40 41.3  9.39 13.02 38.7  2.71 3.86 42.5 
CG6 1.72 2.31 34.6  0.88 1.12 27.3  0.28 0.36 28.8  7.37 9.77 32.6  1.94 2.68 37.8 
CG7 1.55 1.98 27.6  1.21 1.45 19.8  0.42 0.50 21.1  11.48 15.10 31.5  3.01 3.95 31.6 
CG8 1.46 1.88 28.9  1.26 1.62 29.1  0.53 0.73 38.6  8.42 10.75 27.7  2.26 2.99 32.3 
CG9 1.77 2.41 35.6  1.20 1.60 32.9  0.38 0.56 48.8  7.96 10.33 29.8  1.97 2.64 34.1 
CG10 1.25 1.55 24.4  1.26 1.55 23.6  0.48 0.68 40.6  9.28 11.19 20.6  2.55 3.11 22.2 
Mean 1.57 2.11 33.3  1.30 1.75 32.7  0.44 0.61 39.6  9.25 12.19 31.7  2.48 3.34 34.7 
a Content expressed as g/100 g soluble solids; b 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone;  c 3-β-D-glucopyranosyliriflophenone; d 3-
β-D-glucopyranosylmaclurin; e initial feed of ultrafiltration process i.e. 40% aqueous ethanol extract; f ultrafiltered Cyclopia genistoides extract 


















Table S3 Trans-epithelial electrical resistance (TEER) values for three ex vivo intestinal transport 
studies using Sweetana-Grass diffusion apparatus. 
Cell 
Test sample 
XEF0a  BEF0b  Combined fractionsc 
0 min 120 min  0 min 120 min  0 min 120 min 
A-B 1 50 43  43 35  51 41 
A-B 2 44 40  48 41  46 41 
A-B 3 48 43  51 40  44 37 
A-B 4 49 40  46 39  48 39 
A-B 5 47 44  46 42  49 37 
A-B 6 41 34  53 41  52 46 










Table S4 Mass and mass deviation data for three different formulations of gastroretentive tablets produced by direct compression. 
No. 
Tablet formulation X 
 Xanthone-enriched fraction (XEF0) 
 
Tablet formulation B 
Benzophenone-enriched fraction (BEF0) 
 


























from mean  
(%) 
1 492.70 0.12 0.0  504.00 3.43 0.7  493.27 2.97 0.6 
2 492.23 0.59 0.1  492.81 7.76 1.6  494.03 3.73 0.7 
3 491.15 1.67 0.3  502.29 1.72 0.3  492.00 1.70 0.3 
4 487.54 5.28 1.1  493.19 7.38 1.5  487.63 2.67 0.5 
5 488.50 4.32 0.9  498.06 2.51 0.5  490.25 0.05 0.0 
6 492.65 0.17 0.0  497.91 2.66 0.5  490.94 0.64 0.1 
7 492.38 0.44 0.1  508.13 7.56 1.5  488.12 2.18 0.4 
8 489.18 3.64 0.7  496.33 4.24 0.9  482.52 7.78 1.6 
9 491.67 1.15 0.2  498.12 2.45 0.5  489.92 0.38 0.1 
10 490.70 2.12 0.4  505.86 5.29 1.1  490.36 0.06 0.0 
11 495.26 2.44 0.5  492.85 7.72 1.5  496.22 5.92 1.2 
12 498.76 5.94 1.2  502.80 2.23 0.4  489.82 0.48 0.1 
13 497.00 4.18 0.8  502.44 1.87 0.4  490.69 0.39 0.1 
14 497.82 5.00 1.0  510.26 9.69 1.9  491.58 1.28 0.3 
15 493.66 0.84 0.2  501.69 1.12 0.2  494.95 4.65 0.9 
16 487.75 5.07 1.0  503.06 2.49 0.5  485.16 5.14 1.0 
17 496.24 3.42 0.7  501.40 0.83 0.2  489.70 0.60 0.1 
18 500.75 7.93 1.6  503.88 3.31 0.7  488.44 1.86 0.4 
19 490.78 2.04 0.4  494.41 6.16 1.2  489.90 0.40 0.1 
20 489.65 3.17 0.6  501.98 1.41 0.3  490.41 0.11 0.0 







Fig. S1 (a) Effect level (Fa) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at Fa = 
0.25, 0.50 and 0.75 for combination 1: acarbose (Aca) with benzophenone-enriched fraction (BEF0) (generated 
by CompuSyn Version 1.0). 
 
 
Fig. S2 (a) Effect level (Fa) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at Fa = 
0.25, 0.50 and 0.75 for combination 2: acarbose (Aca) with xanthone-enriched fraction (XEF0) (generated by 
CompuSyn Version 1.0). 
 
  
Fig. S3 (a) Effect level (Fa) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at Fa = 









Fig. S4 (a) Effect level (Fa) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at Fa = 




Fig. S5 (a) Effect level (Fa) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at Fa = 
0.25, 0.50 and 0.75 for combination 5: acarbose (Aca) with 3-β-D-glucopyranosyliriflophenone (I3G) 
(generated by CompuSyn Version 1.0). 
 
 
Fig. S6 (a) Effect level (Fa) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at Fa = 
0.25, 0.50 and 0.75 for combination 6: acarbose (Aca) with 3-β-D-glucopyranosyl-4-O-β-D-









Fig. S7 (a) Effect level (Fa) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at Fa = 
0.25, 0.50 and 0.75 for combination 7: benzophenone-enriched fraction (BEF0) with xanthone-enriched 
fraction (XEF0) (generated by CompuSyn Version 1.0). 
 
 
Fig. S8 (a) Effect level (Fa) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at Fa = 
0.25, 0.50 and 0.75 for combination 8: mangiferin (MGF) with isomangiferin (IMGF) (generated by 
CompuSyn Version 1.0). 
 
 
Fig. S9 (a) Effect level (Fa) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at Fa = 
0.25, 0.50 and 0.75 for combination 9: mangiferin (MGF) with 3-β-D-glucopyranosyliriflophenone (I3G) 









Fig. S10 (a) Effect level (Fa) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at 
Fa = 0.25, 0.50 and 0.75 for combination 10: isomangiferin (IMGF) with 3-β-D-glucopyranosyliriflophenone 
(I3G) (generated by CompuSyn Version 1.0). 
 
 
Fig. S11 (a) Effect level (Fa) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at 
Fa = 0.25, 0.50 and 0.75 for combination 11: 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone 
(IDG) with 3-β-D-glucopyranosyliriflophenone (I3G) (generated by CompuSyn Version 1.0). 
 
 
Fig. S12 (a) Effect level (Fa) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at 
Fa = 0.25, 0.50 and 0.75 for combination 12: 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone 









Fig. S13 (a) Effect level (Fa) vs. logarithmic dose reduction index [log (DRI)] plots and (b) isobolograms at 
Fa = 0.25, 0.50 and 0.75 for combination 13: 3-β-D-glucopyranosyl-4-O-β-D-glucopyranosyliriflophenone 








Figure S14 Preparation of porcine jejunal tissue sections (< 20 min post-slaughter) (left) for mounting in 
Sweetana-Grass diffusion chamber (right) (Centre of Excellence for Pharmaceutical Sciences, North-West 







Figure S15 Korsch XP1 tablet press used for production of gastroretentive tablets by direct compression 
(Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, South Africa). 
 
 
Figure S16 TBH 425 semi-automatic combination tester (left) used for hardness, thickness and diameter 
measurements of tablets and ERWEKA TAR friability/abrasion tester (right) with tablets in situ (Centre of 







Figure S17 (a) Absorptive apparent permeability coefficients (Papp in apical-to-basolateral direction; triplicate 
chambers plus mean) for lucifer yellow, an indicator of membrane integrity; (b) Transport of lucifer yellow 




































Quantification of D-pinitol and D-glucose content by gas chromatography-mass spectrometry (GC-MS) 
 
Approximately 10 mg of the sample was extracted with 1 mL 60% methanol. 100 µL of ribitol at a final 
concentration of 10 ppm was added as internal standard. The mixture was briefly vortexed and subsequently 
incubated for 120 min at 70 °C. The sample was vortexed and 250 µL was then dried by vacuum concentration. 
The dry samples were reconstituted with 100 µL 2.5% methoxyamine in pyridine.  The mixture was vortexed 
and then derivatised by incubating for 2 h in an oven maintained at 40°C.  Subsequently, 100 µL of N,O-
Bis(trimethylsilyl)trifluoroacetamide (BSTFA) was added, the mixture was vortexed and then derivatised by 
incubating for 30 min in an oven maintained at 60 °C. After incubation, the mixture was again vortexed and 
then transferred into a GC vial with an insert. Chromatographic separation of the compounds was performed 
on a gas chromatograph where 1 µL of the sample was injected on an Agilent 6890 N (Agilent, Palo Alto, CA) 
coupled to a Agilent 5975 MS mass spectrometer detector, using a Zebron AB-MultiResidue (30 m, 0.25 mm 
ID, 0.25 µm film thickness) column (Part No. 7HG-G016-11). The oven temperature program was maintained 
at 80 °C for 1 min and ramped at 7 °C/min to 250 °C, where it was maintained for 2 min.  The total run time 
was 28 min. The carrier gas was helium at a flow rate of 1.2 mL/min and the injector temperature was 
maintained at 200 °C and operated in a splitless mode. The mass spectral data was recorded on a MSD operated 
in full scan mode (35–600 m/z), with both the ion source and quadrupole temperatures maintained at 240 °C 
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